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The goal of this dissertation was to examine the pathogenic potential of 
microglia in globoid cell leukodystrophy (GLD). We determined that psychosine, 
the pathogenic lipid toxin that accumulates in GLD, induced microglial 
transformation to globoid cells in vitro. Psychosine also induced matrix 
metalloproteinase (MMP)-3 in cultured glia. This mirrored the elevated expression 
of MMP-3 in the central nervous system (CNS) of twitcher mice, a murine model 
of GLD. Pharmacological inhibition or genetic ablation of MMP-3 blocked 
psychosine-induced globoid cell formation in vitro. These findings indicate that 
MMP-3 mediated psychosine-induced globoid cell formation. These findings were 
the first to relate the putative functions of MMPs in the CNS pathogenesis of a 
leukodystrophy. 
 We next determined the effects of the extracellular matrix (ECM) in GLD 
pathology. We determined that tenascin-c (TnC), an ECM molecule, was 
aberrantly expressed in the brain of murine and human GLD. We determined that 
TnC enhances both psychosine-induced MMP-3 expression and globoid cell 
formation in microglia. Additionally, TnC altered the phenotype of microglia and 
globoid cells from a protective toward a harmful phenotype toward 
oligodendrocytes in co-cultures. These findings suggest that TnC modulates 
cellular behaviors that may contribute to the GLD pathogenesis.  
 Overall, results of this thesis determined that microglial responses to 
psychosine are a primary event of the pathogenesis in GLD. Overall, the findings 
of this dissertation have provided a new level to our understanding of GLD 
pathogenesis and provided new potential therapeutic targets to treat GLD. 
 Glial Pathology in Globoid Cell Leukodystrophy  
 
 
 
Kumiko Ijichi 
 
B.A., University of Saint Thomas, 2005 
M.S, University of Hartford, 2008 
 
 
 
 
 
 
 
 
 
 
A Dissertation  
Submitted in Partial Fulfillment of the  
Requirements for the Degree of Doctor of Philosophy 
at the 
University of Connecticut 
 
 
 
2013 
 
  
Copyright by 
 
 
Kumiko Ijichi  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013 
 
 
 i 
APPROVAL PAGE 
 
Doctor of Philosophy Dissertation 
 
Glial Pathology in Globoid Cell Leukodystrophy 
 
 
Presented by  
Kumiko Ijichi, B.A., M.S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
University of Connecticut 
2013 
 ii 
PREFACE 
Portions of this dissertation have been previously published in the forms of 
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General Overview 
 Globoid cell leukodystrophy (GLD) is a fatal demyelinating disease resulting 
from mutations in the galactosylceramindase (GALC) gene. It is most prevalent among 
infants. Due to the rapid nature of this disease’s progression, there are presently no 
effective long-term therapies for GLD. The precise mechanisms underlying GLD 
pathogenesis are not completely understood. This dissertation focused on the molecular 
mechanisms of GLD pathogenesis with a particular focus on another poorly characterized 
glial pathology of this disease. This dissertation explored how glial pathology arises in 
GLD and provided a novel model for study of GLD-associated glial pathology, and 
generated a novel hypothesis on the overall pathogenic mechanism of GLD. 
 Chapter 1 focuses on describing clinical aspects of GLD. The first case of GLD 
is discussed, followed by a description of epidemiology, symptoms, and diagnosis of GLD. 
The cause of GLD is also briefly discussed, though the detailed information of biological 
key players is provided in the following chapter. Then, current therapies for GLD are 
discussed, as well as the limitations and need for new therapeutic approaches. 
 The second chapter centers on pathophysiological aspects of GLD. This 
chapter includes spontaneous animal models of GLD, cellular pathologies, psychosine 
(the lipid toxin that accumulates in GLD) and a detailed description on the GALC gene 
mutations causing GLD. The traditional pathophysiological hypothesis of GLD is 
described, followed by emphasis on the emerging need for revision based on new 
findings. I, thus, highlight the importance of microglia, and then the rationales of this 
dissertation with its focus on microglia and astrocytes. Lastly, the specific aims of this 
dissertation are laid out. 
 Chapter 3 focuses on the first part of specific aims: the involvement of matrix 
metalloproteinase (MMP)-3 in GLD. First, changes in MMP-3 levels in GLD are shown. 
Also, pathological glial responses to psychosine are described. This chapter ends with 
the conclusion that glial responses to psychosine are mediated by MMP-3.  
 xviii 
 The main focus of chapter 4 illustrates the effects of the extracellular 
microenvironment of glia with respect to the GLD pathogenesis. Elevated expression of 
tenascin-c (TnC), an extracellular matrix (ECM) protein, in GLD brains is described. Next, 
the effect of TnC on glial responses to psychosine is demonstrated. This chapter 
concludes that localized changes in ECM molecules during the disease alter important 
cellular behaviors, which likely contributes to GLD pathogenesis.  
 Chapter 5 begins with a summary of overall findings in this dissertation. Primary 
findings include: the MMP-3 involvement in glial responses to psychosine and the 
changes in glial functions by local TnC in the context of GLD pathology. A more detailed 
discussion on the putative mechanisms by which MMP-3 and TnC regulate glial 
responses in GLD, and future directions for research stemming from this work are 
discussed. This chapter ends with a discussion on the therapeutic potentials of the results 
of this dissertation and the applications of these findings to treat GLD. 
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CHAPTER ONE 
 
Introduction to Globoid Cell Leukodystrophy 
 
 
2 
I-1 Globoid Cell Leukodystrophy (GLD) 
 
I-1.1 History of GLD  
Globoid cell leukodystrophy (GLD) was first described by a Danish physician, 
Knud Krabbe, in 1916 (Krabbe, 1916). In his seminal report, he described five infants, 
four of which were from two families in Copenhagen, that presented with violent crying 
and extreme irritability starting at an age of four to six months (Krabbe, 1916). These 
patients developed progressive muscular rigidity, tonic spasms evoked by auditory, tactile, 
or visual stimuli, and an opisthotonic (hypertonic) posture (Krabbe, 1916). In addition, 
these children experienced poor feeding, frequent episodes of fever of unknown cause, 
and seizures (Krabbe, 1916). These patients became progressively fatigued and 
unresponsive by the end stage of their condition. These patients eventually died by 11 
months to 1.5 years of age (Krabbe, 1916).  
Krabbe and his colleagues performed post-mortem analyses on these five 
infant patients, and reported that all cases had hard and rubbery brain matter, unusual for 
children of this age (Krabbe, 1916). Microscopic examination revealed that each case 
had almost a complete loss of myelin, accompanied by extensive fibrous glial scarring, 
which had replaced the damaged tissues (Krabbe, 1916). As well, prominent, large 
“scavenger” cells, now referred to as “globoid cells”, were also observed in the brain 
tissues of these patients (Krabbe, 1916, Matsuda, 2007). These globoid cells were 
described as containing multiple nuclei, with granules, and in some cases had fatty debris 
(Krabbe, 1916, Matsuda, 2007). Krabbe described these cases as “familial early infantile 
diffuse brain sclerosis” (Krabbe, 1916), which represented a novel category of childhood 
neurological disease. On account of this first description, this condition has been named 
after him (Matsuda, 2007); thus, GLD is also called “Krabbe disease”.   
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I-1.2 Epidemiology 
GLD is a rare disease with a worldwide prevalence. For example, GLD has 
been identified in the United States of America (USA; 1/100,000 live births), Netherlands 
(1.35/100,000), and Czech Republic (0.4/100,000) (Duffner et al., 2009, Poupetova et al., 
2010). GLD can occur more frequently in certain populations, such as the Druze tribe in 
Israel, a religious minority community, where its incidence is 1/170 (Rafi et al., 1996, 
Zlotogora et al., 1991, Zlotogora et al., 1985). Interestingly, no cases have been reported 
in the Jewish population (Zlotogora, 2010, Zlotogora et al., 1991). In the United States, 
GLD has garnered awareness on account of Hunter Kelly, son of Jim Kelly, the former 
quarterback of the Buffalo Bills (1986-1996). Hunter was diagnosed with GLD soon after 
his birth in 1997. Jim Kelly and his wife established a non-profit organization for GLD, 
called "Hunter’s Hope", which has become the world’s largest non-profit center for GLD 
research. Hunter's Hope now supports an Institute for GLD research at the Buffalo 
Niagara Medical Campus. In 2006, New York State initiated a newborn screening of GLD 
for all live birth cases with an expected incidence rate of 1/100,000 (Duffner et al., 2009). 
Interestingly, this 4-year screening study, led by Patricia Duffner, a pediatric neurologist 
specializing GLD, revealed the incidence of one in 250,000, which was lower than 
expected (Duffner et al., 2011). There are no significant differences in the incidence of 
GLD between males and females, indicating that the etiology and pathogenesis of GLD is 
not gender-specific (Duffner et al., 2009).  
 
I-1.3 Classification and Symptomatology of GLD  
There are four forms of GLD classified on the basis of age of onset: infantile 
(0-6 months old), late-infantile (7 months to 3 years old), juvenile (4-8 years old), and 
adult (over 9 years old) forms (Table 1-1) (Kolodny et al., 1991, Matsuda, 2007, Wenger, 
2001). The infantile form is the most common type of GLD representing over 90% of GLD 
cases (Duffner et al., 2009, Wenger, 2001).  
4 
Table 1-1 Clinical Manifestations in four types of GLD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
The disease course of infantile GLD can be categorized into three clinical phases (I, II, 
and III) (Duffner et al., 2009, Hagberg et al., 1963). Phase I includes irritability, 
hyperesthesia, episodic idiopathic fever, limb stiffness, seizure, vomiting, and poor 
feeding (Duffner et al., 2009, Wenger, 2001). In phase II, rapid and severe motor and 
mental retardation become prominent along with hypertonic posture, including extended 
and crossed legs, flexed arms, and head bent backward (Wenger, 2001). Optic atrophy 
and abnormal pupillary reflex can be also observed (Harris et al., 1996, Wenger, 2001). 
The final stage, phase III of infantile GLD, also known as the “burnt-out” stage, can be 
reached within only a few months of onset (Wenger, 2001). Patients at this stage of the 
disease are blind and deaf, and exhibit no responsiveness to their surroundings. Most 
infantile GLD patients die within two years of clinical disease onset (Duffner et al., 2009, 
Hagberg et al., 1963).  
In late-onset GLD, including late-infant, juvenile, and adult forms, the clinical 
symptoms are similar to those seen in infantile GLD (Duffner et al., 2012). However, the 
disease course and severity vary greatly among patients compared to infantile forms of 
GLD (Duffner et al., 2012, Phelps et al., 1991). For example, one 12-year-old girl 
diagnosed with adult-onset GLD developed a progressive hemiplegia with fixed posture 
and became intellectually deteriorated over a few years after onset (Phelps et al., 1991). 
On the other hand, her 16-year-old brother, who was also diagnosed with an adult variant 
of GLD, showed minor difficulty in walking with impaired visual acuity, but remained 
intellectually intact and was able to perform social activities for over three year after his 
diagnosis (Phelps et al., 1991). Overall, the progression of the disease and the degree of 
severity in late-onset GLD are generally milder than in early-onset infantile GLD (Duffner 
et al., 2012). 
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I-1.4 Causes 
 For over 50 years after Krabbe’s first report, the pathophysiology and the cause 
of GLD were unknown. In 1970, Suzuki and colleagues identified a deficiency in a 
lysosomal enzyme, called galactosylceramidase (GALC), in brain, liver, and spleen 
samples from GLD patients (Suzuki and Suzuki, 1970). GALC enzymatic activity in all 
GLD patients was either non-detectable or significantly lowered by over 90% from normal 
(Duffner et al., 2009). Suzuki et al. also demonstrated that the central nervous system 
(CNS) of patients with GLD had a significant accumulation of the sphingolipid 
intermediate, galactosylsphingosine, a substrate for GALC also known as ‘psychosine’ 
(Miyatake and Suzuki, 1972). This metabolic association with GLD has lead to a focus on 
the study of psychosine as the causal agent in GLD. Psychosine accumulates in multiple 
organs in GLD, including the brain, spinal cord, and kidney, without exception (Suzuki, 
1998, Wenger, 2000). Additionally, psychosine has been shown to have cytotoxic effects 
on multiple cell types from both the CNS and peripheral organs (Castelvetri et al., 2011, 
Cho et al., 1997, Galbiati et al., 2007, Taketomi and Nishimura, 1964, Whitfield et al., 
2001, Zaka and Wenger, 2004, Zhang et al., 2013, Zhu et al., 2012). Thus, GLD is 
currently thought to arise from the deficiency of GALC leading to a significant 
accumulation of psychosine, resulting in the pathology. This notion is now referred to as 
the “psychosine hypothesis”, described in more detail in Chapter Two.  
In 1993, the complementary deoxyribonucleic acid (cDNA) sequence of GALC 
was successfully cloned from human brain and urine samples (Chen et al., 1993, Sakai et 
al., 1994). Since then, multiple studies have reported genetic mutations within the coding 
region of the GALC gene in GLD patients (Kleijer et al., 1997, Kukita et al., 1997, Luzi et 
al., 1995, Luzi et al., 1996, Rafi et al., 1995, Rafi et al., 1996, Selleri et al., 2000). Prior to 
the discovery of GALC mutations, it had been speculated that GLD was an inherited 
disorder mediated by a genomic defect (Krabbe, 1916, Miyatake and Suzuki, 1972, 
Suzuki and Suzuki, 1970).  
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Indeed, GLD is now defined as a genetic disorder resulting from GALC mutations that 
have an autosomal recessive pattern of inheritance. 
 
I-1.5 Diagnosis  
The most definitive diagnostic test for GLD is a genetic mutation analysis, 
followed by an enzymatic activity test for GALC. As described above, GALC is a 
lysosomal enzyme deficient in GLD patients due to GALC gene mutations (Duffner et al., 
2009). If GALC activity is less than 0.5nmol/h/mg protein in a blood sample, the patient is 
considered “at risk” (Duffner et al., 2009). The diagnostic procedure usually requires 
multiple neurological and non-neurological diagnostic tests prior to the definitive tests for 
GLD. Protein levels in the cerebrospinal fluid (CFS) collected via lumbar puncture are 
usually higher in symptomatic patients with GLD (25mg/dL above normal) (Duffner et al., 
2011), suggesting that an abnormal process, such as a tumor, bleeding, or inflammation, 
exists within the CNS. Neuroimaging is also a powerful resource, which can be used to 
analyze anatomical abnormalities and inflammation in GLD. Neuroimaging examinations 
of GLD cases have identified white matter abnormalities in areas such as pyramidal tracts, 
cerebellar white matter, and the corpus callosum in magnetic resonance image (MRI; 
76.2% of GLD cases) and computer tomography (CT; 66.7% of GLD cases) (Duffner et 
al., 2011). Indeed, over half of GLD patients have T2 MRI hyperintensities in the white 
matter of periventricular, cerebellar white matter, and/or the corpus callosum (Duffner et 
al., 2011). Some exhibit an enlargement of the optic nerve or optic chiasm, atrophy, 
and/or delayed myelination (Duffner et al., 2011). Interestingly, scans of some GLD 
patients with infantile GLD have been reported not to show any abnormalities (Duffner et 
al., 2011); neuroimaging may, therefore, be unreliable for diagnosis of this disease. 
Additionally, in pre-symptomatic individuals with GLD, MRI can show non-specific 
hyperintensities, which are not definitive for a diagnosis of GLD (Duffner et al., 2009). 
These diagnostic results indicate that some neurological exams, including neuroimaging, 
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may be more useful for a differential diagnosis rather than an initial diagnosis of GLD 
(Wenger, 2001). Importantly, almost all infantile cases exhibit neurophysiologic 
aberrations, most notably in their nerve conduction velocity and brainstem auditory 
evoked responses, even among pre-symptomatic patients (Duffner et al., 2011, Duffner 
et al., 2009). Overall, low GALC activity, identification of GALC mutations, along with 
neurological exam abnormalities, are the current standard for establishing a diagnosis of 
GLD (Duffner et al., 2009, Wenger, 2001). 
 
I-2 Anatomical Pathology of GLD 
Postmortem histological analyses of GLD CNS tissues have provided insights 
on tissue and cellular findings. One prominent and remarkable finding is the almost 
complete loss of myelin throughout the CNS in GLD, which is almost always 
accompanied by extensive fibrillary gliosis around damaged areas. Macrophage 
infiltration and the presence of large multinucleated phagocytes referred to as “globoid 
cells” are also hallmarks of GLD pathology (Krabbe, 1916, Percy et al., 1994, Sakai, 
2009). The demyelinated white matter areas in GLD are frequently replaced with hard, 
rubbery, and translucent tissues (Itoh et al., 2002). Most GLD cases present with brain 
atrophy and enlargement of the lateral ventricles (Itoh et al., 2002, Krabbe, 1916). 
Profound demyelinated lesions are found in the primary white matter tracts of the CNS, 
including the corona radiata, corpus callosum, and cerebellar peduncles (Itoh et al., 
2002). Frequently, severe demyelinating loci contain spongy-like microcystic cavitation, 
which can also be observed in other leukodystrophies (Cheon et al., 2002, Itoh et al., 
2002). However, the origin and indication of these microcysts in GLD are unknown. 
Fibrillary astrogliosis is also evident in both white and grey matter, including cerebral 
white matter, the globus pallidus, thalamus, cerebellum, and brain stem (Itoh et al., 2002). 
Severe neuronal damage with overt neuronal loss has been reported in the thalamus, 
cerebellum, dentate nucleus, and inferior olivary nuclei, whereas cerebral neurons are 
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relatively spared (Itoh et al., 2002). Optic nerves are often atrophic, and in some cases 
are grossly enlarged due to profound gliosis (Brownstein et al., 1978).  
In the peripheral nervous system (PNS), peripheral neuropathy is evident in 
both human and murine models of GLD (Hogan et al., 1969, Jacobs et al., 1982). 
Histological analyses have revealed that sciatic nerves are enlarged and hardened from 
endoneurial fibrosis (Jesionek-Kupnicka et al., 1997, Jones et al., 1999). Cross sections 
of peripheral axons exhibit an ‘onion-ring bulb’ morphology, which is suggestive of 
repeated de- and remyelination by Schwann cells (Matsuda, 2007, Matsumoto et al., 
1996). Peripheral macrophages are also present in these lesions, with a similar pattern of 
association as globoid cells with myelin lesions within the CNS (Bernal and Lenn, 2000). 
No structural abnormalities have been reported for other organs; thus, GLD is considered 
a neurological disease (Hagberg et al., 1963, Krabbe, 1916, Sakai, 2009, Suzuki, 2002, 
Wenger, 2001). 
Interestingly, recent studies have indicated potential pathologic abnormalities in 
other organs, suggesting that GALC deficiency may impact physiological functioning of 
other organ systems in conjunction with the CNS. For example, it has been reported that 
in twitcher mice, an authentic murine model of GLD, there is abnormal development of 
femurs (Contreras et al., 2010). This study also reported alterations in hepatic function of 
twitcher mice (Contreras et al., 2010). Another study reported atrophy of the thymus with 
reduced numbers of immature T cells and mature lymphocytes in twitcher mice (Galbiati 
et al., 2007). These findings, although they have not been confirmed in human GLD 
cases, suggest that GLD may impact multiple organ systems. 
 
I-3 Current Treatments for GLD 
Our current understanding on the etiology and pathogenesis of GLD is based 
upon the function of genetic mutations in the GALC gene, all of which result in a loss of 
GALC function. This loss of GALC function leads to psychosine accumulation that is 
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credited for the cellular damage, including oligodendrocyte death and demyelination. 
Thus, the primary focus of therapies for GLD has been administering functional GALC. 
Early studies using twitcher mice reported that intravenous or intraperitoneal 
administration of GALC, or liposomes containing GALC, was unsuccessful; this was due 
to failure of the administered GALC to reach or become incorporated into the CNS 
(Kobayashi and Suzuki, 1982, Umezawa et al., 1985). However, Hoogerbrugge and 
colleagues demonstrated that bone marrow transplantation (BMT), which increased 
GALC activity by 7-8 fold, effectively reduced psychosine accumulation, lowered the 
prevalence of globoid cells, and yielded some evidence of remyelination in the CNS of 
twitcher mice (Hoogerbrugge et al., 1988). In addition, BMT increased lifespan by over 60 
days in twitcher mice (Hoogerbrugge et al., 1988). BMT has also been shown to have 
beneficial effects in patients with other lysosomal storage diseases, including 
mocopolysaccharidosis and Gaucher’s disease, in which the pathology resembles 
aspects of GLD (Gasper et al., 1984, Rappeport and Ginns, 1984). Thus, enzyme 
replacement therapy via cell transplantation has become a major therapeutic strategy for 
treating GLD. 
Currently, the only effective treatment available for GLD patients is 
hematopoietic stem cell transplantation (HSCT). This transplant approach can include 
BMT or umbilical cord stem cell transplantation. The first HSCT for a GLD patient was 
performed in 1989 at the University of Minnesota (Krivit et al., 1998). This first patient 
showed a moderate to significant improvement, including reduced ataxia, hyperextended 
limbs, and increased head control, with improvement in gait, language development, 
cognition, and school performance (Krivit et al., 1998). After this report, HSCT became a 
primary therapy for GLD patients. 
The stem cells used for HSCT can be obtained from either bone marrow or 
umbilical cord blood donation, where human leukocyte antigens (HLAs) match those of 
the recipient (Escolar et al., 2005). After immuno-suppression of the recipient by 
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chemotherapy or radiation, donor stem cells are then transplanted to a host intravenously 
(Escolar et al., 2005, Yagasaki et al. , 2011). Chimerism of bone marrow cells is usually 
confirmed about one month after HSCT (Yagasaki et al., 2011). To prevent 
graft-versus-host disease, immunosuppressant agents, such as cyclosporin A, must be 
administered for the life of the patient (Escolar et al., 2005). 
 As mentioned above, a primary objective of transplantation of hematopoietic 
stem cells in GLD is for enzyme replacement therapy; that is to restore functional GALC 
in GLD individuals. Donor stem cells, which reconstitute the bone marrow of the recipient, 
are capable of producing functional GALC. When these cells proliferate and infiltrate into 
the host CNS, they function to degrade the accumulated psychosine, thereby decreasing 
the tissue damage and potentially promoting regeneration of myelin (Hoogerbrugge et al., 
1988). After one year of HSCT, hyperintensity signals by MRI have been reported to 
decrease in the CNS white matter of some GLD patients (Krivit et al., 1998). Additionally, 
protein levels in CSF have been reported to decline, and nerve conductive velocity 
increases in some cases (Krivit et al., 1998). After several years of HSCT, some patients 
have also shown improvement in cognition, gait, motor coordination, verbal learning, and 
overall academic performance in school (Krivit et al., 1998). HSCT can also extend a 
patient’s lifespan by decades (Duffner et al., 2012). Thus, currently HSCT is the primary 
treatment option for GLD, although it may only provide limited benefit to some patients 
and it is not readily available to all GLD patients. GLD patients who are not candidates for 
HSCT may only receive symptom management and palliative care, such as 
administration of anti-convulsion agents for seizures, rigorous physical therapy, and 
assisted ventilation; however, these generally do not increase the lifespan of GLD 
patients (Duffner et al., 2009). 
Although the effectiveness of HSCT after diagnosis of GLD is usually greater in 
patients with the late-onset variant than infantile GLD (Duffner et al., 2012, Krivit et al., 
1998), HSCT can be effective in both forms, when administered during the 
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pre-symptomatic period (Escolar et al., 2005, Yagasaki et al., 2011). Disease onset of 
infants is typically early in life, when HSCT would need to be implemented. Newborn 
screening for GLD is not widespread and not mandatory in many locales; thus, it is rare 
that HSCT can be provided to infantile GLD patients within the effective therapeutic 
window (Duffner et al., 2011). Additionally, due to the need for sustained 
immuno-suppression following HSCT, this therapy comes with a high risk for those prone 
to infections (Escolar et al., 2005), making it common for family members to refuse HSCT 
for their pre-symptomatic children (Duffner et al., 2011). Therefore, HSCT may be a 
therapeutic option for some, but there is a need for safer long-term therapies for GLD 
patients. 
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Pathophysiology of GLD 
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II-1 Animal Models of GLD 
 
II-1.1 The Twitcher Mouse 
 In 1976, at the Jackson Laboratories, several mice of the inbred CE/J strain 
presented with generalized tremor, low body weight, progressive weakness in limbs 
around postnatal day (P)20, and then succumbed to premature death by P45 (Duchen et 
al., 1980, Matsuda, 2007) (Table 2-1). Duchen and colleagues reported these cases and 
named them, the “twitcher mouse” line (Duchen et al., 1980). Detailed analyses of 
twitcher mice revealed a severe demyelination both in the CNS and PNS, extensive 
gliosis, and the presence of multinucleated globoid cells with periodic acid Schiff (PAS)- 
positive material inclusions (Duchen et al., 1980). All of these pathological findings are 
comparable to human GLD pathology. When the GALC gene was cloned from the 
twitcher mouse liver, a genetic analysis was performed and determined that the basis for 
this murine form of GLD was a missense mutation of guanine (G)1017 adenine(A) in the 
GALC gene (Sakai et al., 1996) (Table 2-1). Now, the twitcher mouse line is recognized 
as an authentic mouse model of GLD resulting from a spontaneous mutation in the GALC 
gene (Sakai et al., 1996, Suzuki and Taniike, 1995). Since the report by Duchen et al., 
numerous studies have used these twitcher mice to study the pathogenesis of GLD 
(Hoogerbrugge et al., 1988, Kobayashi et al., 1980, Matthieu and Omlin, 1984, Scaravilli 
and Suzuki, 1983, Suzuki, 1995, Suzuki, 1998, Suzuki et al., 2003). Although pathology 
of the nervous systems in twitcher mice is similar to that of humans with GLD, several 
additional defects observed in these mice are yet to be corroborated with the human 
condition of GLD; these include retarded femur growth and atrophy of lymphoid organs 
(Contreras et al., 2010, Galbiati et al., 2007). Overall, the twitcher mouse is a very useful 
and valuable animal model to study GLD. 
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Table 2-1 Animal models of GLD 
 Table adapted from (Wenger, 2000). 
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II-1.2 Other Animals with GLD 
 The first animal case of GLD was described by Fankhauser and colleagues in 
1963, before the discovery of the twitcher mouse model (Fankhauser R., 1963, Wenger, 
2000). Cairn and West Highland terriers presented with a lack of movement coordination, 
muscle weakness, and tremor between 1-3 months of age (Fankhauser R., 1963, 
Wenger, 2000) (Table 2-1). Although the disease course and severity varied between 
individual animals, all died prematurely (Wenger, 2000). Terriers are the most reported 
canine strain to develop GLD-like illness (Fletcher et al., 1966, Victoria et al., 1996, 
Wenger et al., 1999, Zaal et al., 1997). Other canine strains have also been reported to 
develop spontaneous GLD, including miniature poodles, hound dogs, beagles, Irish 
setters, and Australian Kelpies (Boysen et al., 1974, Fletcher et al., 2010, Johnson et al., 
1975, McGraw and Carmichael, 2006, Zaki and Kay, 1973). In all canine cases, 
symptoms are comparable to those seen in murine GLD; these include low weight gain, 
hind leg weakness, and tremor (Wenger, 2000) (Table 2-1).  
Among these animal models, spontaneous genetic mutations in GALC 
dramatically reduce enzymatic activity (<10% of normal) (Wenger, 2000) (Table 2-1). 
Analyses of GALC mutations have been performed on several strains and all have 
determined that terriers carry an A473 cytosine (C) mutation, and Irish setters have a 78- 
nucleotide insertion between positions 790 and 791 (McGraw and Carmichael, 2006, 
Wenger, 2000). 
 GLD has also been observed in other animals, including rhesus monkeys, 
domestic longhaired cats, and Pulled Dorset sheep (Johnson, 1970, Luzi et al., 1997, 
Pritchard et al., 1980, Sigurdson et al., 2002). All of these animals present with low weight 
gain, lack of coordinated movement, tremor, hindlimb weakness, and succumb to 
premature death. GALC activity in these GLD animals, except cats, was measured and 
revealed that it was only 2% (rhesus monkey) and 6% (sheep) of GALC activity of healthy 
cohorts (Luzi et al., 1997, Pritchard et al., 1980). Mutation analyses of GALC were only 
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available in rhesus monkey cases, but this determined that there was a deletion of A387 
and C388, which caused a frame shift resulting in a premature stop codon (Luzi et al., 
1997) (Table 2-1).  
Postmortem analyses in all animal cases revealed similar pathological findings 
to human and the murine model of GLD. Key findings include severe demyelination, 
widespread astrogliosis, and the presence of globoid cells (Johnson, 1970, Luzi et al., 
1997, Pritchard et al., 1980, Sigurdson et al., 2002). Animals without GALC activity tests 
or mutation analyses were diagnosed with GLD largely based on their observable 
symptoms and an identification of globoid cells within the CNS in postmortem analyses 
(Wenger, 2000). Overall, GLD is not a human-specific disease, but is a phylogenetically 
conserved disorder in mammals. Although many animal cases with GLD have been 
reported, the twitcher mouse is the most useful and practical animal model for the study 
of GLD pathogenesis, as it is an available means for study of genetic alteration with lower 
maintenance costs and shorter cycles of breeding with larger litter sizes (Wenger, 2000). 
 
II-2 Cellular Abnormalities of GLD 
 
II-2.1 Cellular Pathology  
 Cytological analyses and in vitro studies have revealed that accumulated 
psychosine can impact multiple cell types in GLD. For example, at the end stage of GLD 
in twitcher mice, there are no oligodendrocytes and/or oligodendrocyte progenitor cells 
(OPCs) present in the CNS parenchyma (Itoh et al., 2002, Krabbe, 1916). However, 
before reaching the clinical end stage, OPCs are present and capable of proliferating in 
twitcher mice (Taniike and Suzuki, 1995). Additionally, glial fibrillary acidic protein 
(GFAP)-positive astrocytes are found throughout the brain and the spinal cord of twitcher 
mice (Itoh et al., 2002, Krabbe, 1916) (Figure 2-1).  
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Figure 2-1 Astrocytosis in the brains of twitcher mice. Representative 
immunohistochemical images show that glial fibrillary acidic protein (GFAP)-positive 
astrocytes (red) are found throughout the brains (cortex, corpus callosum, and 
cerebellum) of twitcher mice at postnatal day (P)10-40. Note that GFAP+ astrocytes are 
observed in cerebellum and corpus callosum, as early as P10. Scale bar= 500um. (Ijichi 
& Crocker, unpublished data) 
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Figure 2-2 Globoid cells in the brains of twitcher mice. Globoid cells were identified 
in the corpus callosum and cerebellum of twitcher mice at P30 by immunohistochemistry 
using Iba-1 (red, microglial marker), MHCII (green, monocyte marker), DAPI (nuclear 
marker). Note that all globoid cells were positive for Iba-1 with multiple DAPI positive 
nuclei, but only some show MHCII immunoreactivity. Scare bar= 30µm. (Ijichi & Crocker, 
unpublished data) 
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Multinucleated globoid cells are also present in demyelinated sites throughout the GLD 
brain (Itoh et al., 2002, Krabbe, 1916) (Figure 2-2). T cells are also found in areas close to 
vasculature, identified by their expression of cluster of differentiation (CD)45 and CD3 cell 
surface marker (Itoh et al., 2002). However, the infiltration of hematopoietic-origin cells, 
including T cells and macrophages, occurs only after clinical onset, suggesting a later 
pathogenic contribution to GLD (Wu et al., 2000). In the sciatic nerves of twitcher mice, 
axonal damage can be found well before the onset of symptoms and overt demyelination 
(Castelvetri et al., 2011, Smith et al., 2011). This axonopathy in twitcher mice may be 
attributed to an inhibition of neurofilament phosphorylation in axons by the accumulation 
of psychosine during development (Cantuti-Castelvetri et al., 2012). Schwann cells, the 
myelinating cells of the PNS, show a significantly lower proliferative rate in GLD and fail 
to respond normally to growth factors, including basic fibroblast growth factor (bFGF) 
(Yamada et al., 1996). These phenomena may be mediated by dysfunctions of protein 
kinase C (PKC) signaling resulting from exposure to excessive levels of psychosine 
(Yamada et al., 1996). 
The cellular pathology of GLD is also evident outside of the nervous systems. 
For instance, twitcher splenic natural killer (NK) cells have been found to be apoptotic, 
which agrees with findings of an in vitro study reporting that psychosine treatment can 
induce apoptosis in cultured NK cells (Al-Falahi et al., 2009). Stromal/stem cells derived 
from twitcher adipose cells have also been reported to have less proliferation with 
impaired osteogenic differentiation capacity. These defects could underlie femur 
maldevelopment in the twitcher mouse model of GLD (Contreras et al., 2010, Zhang et al., 
2013). A recent study has also revealed that the endothelial architecture in 
microvasculature in twitcher mice are also altered (Belleri et al., 2013). This is likely a 
result of accumulated psychosine inducing rearrangement of the actin cytoskeleton 
and/or inhibition of proliferation, migration, and responsiveness of endothelial cells to 
growth factors (Belleri et al., 2013). In the liver of twitcher mice, hepatocytic pexisomes 
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are also known to have irregular membrane structure, resulting in reduced catalase 
activity (by 43% compared to age-matched wildtype controls) (Contreras et al., 2008). 
Spermatozoa in twitcher mouse testes were reported to have a swollen acrosome, which 
is a cap-like structure in the head portion of a sperm cell, due to the production of 
excessive membrane (Luddi et al., 2005). Overall, GLD has multiple cellular malfunctions 
in various organs. Clearly, a better understanding of disease mechanisms, what cell 
types are most responsible, and how these changes contribute to the pathogenesis of 
GLD, requires further study. 
 
II-2.2 Globoid Cells 
Globoid cells, or multinucleated phagocytes, are a hallmark of GLD pathology. 
From the initial postmortem microscopic analysis of the GLD brain performed by Krabbe, 
these globoid cells were notable due to their large size (Krabbe, 1916). Other studies 
have shown that globoid cells are typically 15µm in diameter (Duchen et al., 1980, 
Norman et al., 1961), can contain up to 20 nuclei, and have fatty filamentous inclusions 
that are frequently positive for PAS (Martin et al., 1981, Suzuki, 1971, Yunis and Lee, 
1970). These fatty substances in globoid cells are thought to be phagocytized myelin 
debris (Itoh et al., 2002, Yunis and Lee, 1970). Multinucleated globoid cells in GLD are 
often found in the corpus callosum and cerebellar peduncles, sites where demyelination 
is prominent (Itoh et al., 2002).  
Globoid cells are thought to originate from CNS resident microglia and/or 
infiltrating peripheral macrophages. This is based on their immunoreactivity to MAC-1 
(alpha M integrin chain-1), ferrin, and KP-1 (CD68), markers of phagocytes (Itoh et al., 
2002, Kobayashi et al., 1985). Currently, there are no reliable means by which to 
distinguish between these two types of phagocytes (Kondo et al., 2011). Some studies 
have suggested that globoid cells can be found in the PNS, where microglia do not reside, 
but only at the later stages of the disease (Kobayashi et al., 1985). This observation 
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might suggest a potential macrophage-origin of globoid cells, or indicate migration of 
microglia-originated globoid cells from the CNS into the PNS. On the other hand, others 
have reported a total absence of globoid cells within the PNS (Wenger et al., 1999). 
Additionally, one study demonstrated that ablation of a key factor of macrophage 
infiltration, keratinocyte chemoattractant factor or its receptor CXCR2 (CXC chemokine 
receptor 2), in twitcher mice did not eradicate globoid cell formation, suggesting that 
globoid cells are of microglial origin (Reddy et al., 2013). Overall, the origin of globoid 
cells has remained elusive. 
Multinucleated phagocytes, also known as giant cells, are observed in several 
neurological diseases, including human immunodeficient virus (HIV)-encephalopathy and 
CNS sarcoidosis (Masliah et al., 1996, Trombley et al., 1981). In general, the presence of 
giant cells is believed to be a secondary response of phagocytes to prolonged 
inflammation (McNally and Anderson, 2011). Globoid cell formation in GLD, therefore, 
has been thought to be a result of chronic demyelination and inflammation (Reddy et al., 
2013). However, globoid cells can be found in the fetal spinal cord of GLD considerably 
earlier than demyelination and/or damage-associated inflammation (Ida et al., 1994, 
Martin et al., 1981), suggesting that globoid cell formation precedes demyelination and 
inflammation.  
Globoid cells can be induced by psychosine in vitro in immortal cell lines, such 
as the monocyte cell line, U937, or the cervical cancer line, HeLa cells (Kanazawa et al., 
2000). Additionally, Im and colleagues demonstrated that psychosine could induce 
multinucleation of human embryonic kidney (HEK)293 or RH7777 hepatoma cells in 
culture (Im et al., 2001). They also determined that this action of psychosine was 
mediated, in part, by a receptor protein called T cell death associated gene 8 (TDAG8) 
(Im et al., 2001). Time-relapse microscopic analyses revealed that psychosine induced 
multinucleation via cytokinesis failure of U937 cells (Kanazawa et al., 2000). This 
mechanism underlying multinucleation in response to psychosine is in contrast to the 
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mechanism of giant cell formation reported in other disaeses, where cellular fusion of 
macrophages is thought to mediate the development of syncytia (Huerta et al., 2009). 
Thus, globoid cells found in GLD may be a different multinucleated cell type from the 
giant cells found in other neurodegenerative diseases. 
 
II-3 Galactosylceramidase (GALC) and Psychosine 
 
II-3.1 GALC 
 Galactosylceramidase, galactosylcerebrosidase, or GALC, is a galactolipid 
hydrase that resides in the lysosome. GALC is known to hydrolyze galactolipids, such as 
psychosine and galactosylceramide, into galactose and lipids. One of GALC substrates, 
galactosylceramide, also known as cerebroside, is abundant in myelin; thus, expression 
of GALC was initially thought to be exclusive to myelinating cells in the nervous systems 
(Suzuki and Suzuki, 1970). However, accumulating evidence now suggests that GALC is 
also expressed in other tissues, including the placenta, kidney, intestines, thymus, skin, 
and the hematopoietic stem cell population (Beier and Gorogh, 2005, Chen et al., 1993, 
Chen and Wenger, 1993, Galbiati et al., 2007, Martino et al., 2009, Visigalli et al., 2010).  
 
II-3.1.1 GALC gene: 
The GALC gene is located on the long arm of chromosome 14 (q31) in humans 
(Cannizzaro et al., 1994, Oehlmann et al., 1993). The human GALC gene is 
approximately 58 kilobases (Kb) containing 17 exons and 16 introns (Figure 2-3) (Luzi et 
al., 1995, Wenger et al., 1997). The initiation codon follows 200 nucleotides of a 5' UTR 
(Luzi et al., 1995). The 5’ end of intron 1 contains a GC- rich sequence with 13 copies of 
GGC (Luzi et al., 1995, Wenger et al., 1997).  
 
 
24 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3 Schematic gene structure of human GALC gene. Schematic drawing 
represents human GALC gene consists of 17 exons (Ex). Cross-hatched box represents 
leading sequence. Open boxes represent coding region of 50kb fragment, and lined 
boxes are coding region for 30kb fragment. Black boxes are untranslated regions (UTR). 
Mutation nomenclatures are based on cDNA sequence except some large deletions. 
Figure adapted from (Wenger et al., 1997). 
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The 5’ flanking region contains a YY1 element (Yin Yang 1: transcription factor binding 
site) and one potential SP1 (Specificity Protein 1: transcription factor) binding region (Luzi 
et al., 1995), which are widely found in other genes. Also, four GC boxes, which are 
known as general transcription factor binding sites, and two AP-2 (Activator Protein-2: 
transcription factor) binding sites have been identified at the beginning of intron 1 (Luzi et 
al., 1995). There is no thymine (T)ATA box (TATAAA) or CAAT box (GGCCAATCT) found 
within 800 nucleotides preceding the initiation codon, ATG (Luzi et al., 1995). There is a 
high promoter activity at nucleotide -172 to -24 (Luzi et al., 1995). Also there is another 
potential initiation sequence found 48 base pairs (bp) upstream of exon 1; however, there 
is no evidence that this alternate start site is used (Luzi et al., 1995). These analyses of 
transcription factor binding sites in the GALC gene have not provided any evidence for 
tissue-specific expression (Matsuda, 2007, Schug et al., 2005). 
 
II-3.1.2 GALC Protein and Functions:  
Chen and colleagues successfully cloned and characterized the cDNA of 
human GALC from brain and urine samples of GLD patients (Chen et al., 1993, Sakai et 
al., 1994). They determined that the full length GALC cDNA consisted of 3795 bp, 
resulting in the full GALC protein with 669 amino acids (Chen et al., 1993). GALC is an 
80kD protein that undergoes glycosylation in endoplasmic reticulum-Golgi complex 
(Nagano et al., 1998). GALC is then transported into a lysosome via a 
mannose-6-phosphate receptor-mediated process and functions as a lysosomal hydrase 
for sphingolipid degradation (Nagano et al., 1998).  
GALC consists of a signaling peptide sequence, triosephosphate isomerase 
(TIM) barrel, !-sandwich domain, and lectin domain (Deane et al., 2011). N-linked 
glycosylation has been implicated as a critical modulation of GALC trafficking to 
lysosomes (Deane et al., 2011). Both the galactose-specific recognition site [threonine 
(T)93] and catalytic sites [glutamic acid (E)182 and E258] reside in TIM barrel (Deane et 
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al., 2011). Based on these structural studies, GALC does not have a lipid-tail binding site; 
thus, GALC recognizes its substrates by a galactose moiety of the galactolipid (Deane et 
al., 2011). GALC protein has been thought to have several isoforms due to the proteolytic 
cleavage of the “precursor” (80kD) into two subunits (50 kD of N terminus and 30kD C 
terminus) by a yet-to-be-identified enzyme (Chen et al., 1993, Nagano et al., 1998, Sakai 
et al., 1994, Wenger et al., 2000) (Figure 2-3). This event is thought to occur in 
lysosomes (Hasilik, 1992, Nagano et al., 1998). However, a recent structural analysis of 
GALC has indicated that there may be a possible molecular cleavage site located within 
the !-sandwich domain, which unlikely causes a physical segregation of GALC into two 
fragments; thus, cleavage may not influence the catalytic activity of GALC (Deane et al., 
2011). 
It has been suggested that GALC may require a co-activator, saposin, when 
GALC catalyzes a glycolipid that resides within a membrane (Sandhoff, 2012, Schulze et 
al., 2009). Saposin, a lysosomal lipid-binding protein, either obtains the galactolipid from 
the membrane bilayer or distorts the bilayer to expose galactolipids, which enables GALC 
to access its enzymatic substrates, such as galactosylceramide (Deane et al., 2011, 
Sandhoff, 2012). Thus, both GALC and saposin may be important to allow for the proper 
function and maintenance of membrane homeostasis.  
 
II-3.1.3 GALC in GLD -Gene Mutations-: 
The most common mutation identified among cases of infantile GLD in the 
United States and Europe is a 30Kb deletion at position 502 (502/del) within intron 10 
(Figure 2-3) (Luzi et al., 1995, Rafi et al., 1995). In fact, this allele is found in nearly 75% 
of all GLD patients in Sweden and Europe (Kleijer et al., 1997). Interestingly, point 
mutations including C1538T and A1652C are more common among Japanese 
populations (Furuya et al., 1997, Kukita et al., 1997, Satoh et al., 1997, Tatsumi et al., 
1995, Xu et al., 2006), whereas the Israeli population tend to have different point 
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mutations, such as G1582A (Rafi et al., 1996, Wenger et al., 2000). While some 
mutations are limited to certain GLD populations, polymorphisms at other loci, such as 
C502T and A865G, are common to all GLD populations (Kleijer et al., 1997, Luzi et al., 
1995, Rafi et al., 1995, Rafi et al., 1996, Tatsumi et al., 1995, Wenger et al., 2000). 
Interestingly, there have been no mutations identified in exon 12 where proteolytic 
cleavage of the GALC precursor occurs (Tappino et al., 2010, Wenger et al., 2000). To 
date, over 70 mutations in the GALC gene have been identified in human GLD (Tappino 
et al., 2010, Wenger, 2000, Wenger, 2001, Wenger et al., 2000). These mutations 
represent several possible mechanisms of dieases, including protein misprocessing and 
alterations in GALC secretion or GALC reuptake (Lee et al., 2010). These findings also 
point to a variety of modes through which mutations(s) can lead to a loss of GALC 
function. Regardless of the type of mutations, all individuals with GLD have considerably 
lower levels of functionally active GALC. If GALC activity in blood samples, for example, 
is lower than 0.5nmol/hr/mg of protein, the individual is considered “at risk” for developing 
GLD. In patients with the infantile variant of GLD, GALC activity is often below 
0.15nmol/hr/mg, which is considered to be the threshold value for a HSCT candidate 
(Jalal et al., 2012). Interestingly, the level of GALC activity does not always correlate with 
disease severity, but it does correlate with the age of onset of GLD (Jalal et al., 2012). 
Overall, functional loss of GALC is an important and pathogenic characteristic of GLD 
that underlies the etiology of GLD itself. 
 
II-3.2 Psychosine 
II-3.2.1 Synthesis of Psychosine: 
Psychosine is a galactolipid also known as galactosylsphingosine. As the name 
denotes, psychosine is composed of a galactose moiety and a sphingosine backbone 
comprised of 18 carbons (Figure 2-4). Psychosine was first described in 1876 and named 
by Johann L. W. Thudichum, a German chemist (Rosenheim, 1907, Thudichum, 1876).  
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Figure 2-4 Structure of psychosine and its degradation by GALC. Schematic 
chemical structure shows that psychosine consists of 18-carbon sphingosine backbone 
with a galactose moiety. Galactosylcerebrosidase (GALC) hydrolyzes psychosine into 
galactose and sphingosine.  
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Psychosine was first isolated from an analytical process of phrenosine, a 
non-phosphorous fraction of human brain matter and a mixture of galactose, cerebronic 
acid and sphingosine (Thudichum, 1876). Thudichum obtained a lipid substance 
composed of C23H45NO7 and called it “psychosine” (Thudichum, 1876); though his 
rationale for this name remains unclear. Thudichum also demonstrated that psychosine 
can be further degraded into galactose and sphingosine by acid treatment (Thudichum, 
1876). Sphingosine is an important lipid serving as a precursor for ceramide, an essential 
component of lipid membranes; thus, psychosine is synthesized during the process of 
lipid membrane synthesis.  
It is now known that psychosine (C24H47NO7) is produced within a cell by the 
binding of uridine diphosphate (UDP)-galactose to sphingosine (Cleland and Kennedy, 
1960). This binding process may be catalyzed by an enzyme, UDP-galactose:ceramide 
galactosyltransferase (CGT). This binding is also known as the Cleland and Kennedy 
reaction (Cleland and Kennedy, 1960). The importance of CGT in the production of 
psychosine is supported by studies on the effects of genetic ablation of CGT in twitcher 
mice (Ezoe et al., 2000). Cross-breeding of CGT knockout (KO) mice, which lack the 
synthetic enzyme for psychosine, with twitcher mice resulted in a significant reduction in 
psychosine accumulation (Ezoe et al., 2000). This result suggested that CGT is a major 
contributor to psychosine production in vivo.  
Expression of CGT is higher in myelinating cells and other cells of the CNS, 
including oligodendrocytes, astrocytes, and neurons, than cells in other organ systems; 
therefore, the nervous system is more liable to accumulate psychosine in GLD 
(Schaeren-Wiemers et al., 1995, Zoller et al., 2005). However, it should be noted that 
accumulation of psychosine in GLD has been identified in other organs outside of the 
nervous system, including the kidneys, lever, adipose cells, thymus and also blood 
(Galbiati et al., 2007, Ichioka et al., 1987, Stahl et al., 1994, Whitfield et al., 2001, Zhang 
et al., 2013, Zhu et al., 2012).  
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These data suggest that psychosine may be efficiently synthesized in CGT-independent 
manner. 
 
II-3.2.2 Function of Psychosine: 
Psychosine is considered as a natural byproduct during membrane lipid 
synthesis (Miyatake and Suzuki, 1972, Vanier, 1976). A recent study has also proposed a 
potential natural physiological function for psychosine in oligodendrocyte development, 
albeit at low concentrations (<100nM) (Zhu, 2013). In general, psychosine is known as a 
lipid that is cytotoxic to many cell types (Castelvetri et al., 2011, Cho et al., 1997, Galbiati 
et al., 2007, Sugama et al., 1990, Taketomi and Nishimura, 1964, Whitfield et al., 2001, 
Zaka and Wenger, 2004, Zhang et al., 2013, Zhu et al., 2012). The naturally occurring 
level of psychosine in healthy individuals is extremely low (less than 10pmol/mg wet 
tissue) (Miyatake and Suzuki, 1972).  
Interestingly, TDAG8, an orphan receptor, has been identified as a potential 
extracellular binding target of psychosine (Im et al., 2001, Wang et al., 2004). However, 
this receptor-mediated pathway is not widely accepted as the toxic mechanism of 
psychosine since other glycolipids can also act as ligands of this G-protein coupled 
receptor (Tomura et al., 2005). Overall, the natural physiological function of psychosine in 
homeostasis is not well studied, perhaps due to the conventional belief that it is potently 
cytotoxic and produced at very low levels only as a natural byproduct of metabolism. 
However, when considered together, regulation of the physiological levels of psychosine 
and normal GALC activity are critical for healthful development. 
 
II-3.2.3 Psychosine in GLD: 
Psychosine is a major pathogenic player of GLD, as it significantly accumulates 
in the cells and tissues of GLD. In the healthy CNS, the level of psychosine is extremely 
low (less than 10pmol/mg wet tissue) (Miyatake and Suzuki, 1972). In GLD brain, 
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however, more than 100 fold increase of psychosine concentration has been detected in 
the CNS tissue (White et al., 2009). The psychosine level is increased in other organs, 
such as the kidney, liver, blood, and thymus of GLD (Galbiati et al., 2007, Zhu et al., 
2012); thus, psychosine may have a pathogenic effect in multiple organ systems. This 
accumulation has also been evidenced in prenatal tissues of GLD (Ida et al., 1994).  
At higher concentrations (>1µM, in vitro), psychosine becomes cytotoxic for 
oligodendrocytes and neurons (Castelvetri et al., 2011, Cho et al., 1997, Zaka and 
Wenger, 2004). It is estimated that the in vivo concentration of psychosine in the GLD 
tissue is much higher (>120µM) than experimentally used in vitro (Shinoda et al., 1987, 
Svennerholm et al., 1980). Therefore, psychosine may have a broader impact on cells 
than observed in vitro. It is thought that in GLD psychosine accumulates in lipid rafts, a 
membrane domain that is responsible for many signaling pathways (White et al., 2009). It 
has also been suggested that psychosine can accumulate both intracellularly and 
extracellularly, which can result in both cell-autonomous and non-cell autonomous effects 
(White et al., 2009). As mentioned above, psychosine has cytotoxic effects on multiple 
cell types, including red blood cells, thymocytes, stromal stem cells, and CNS cells 
(Castelvetri et al., 2011, Cho et al., 1997, Galbiati et al., 2007, Sugama et al., 1990, 
Taketomi and Nishimura, 1964, Whitfield et al., 2001, Zaka and Wenger, 2004, Zhang et 
al., 2013, Zhu et al., 2012). However, the precise mechanism by which accumulated 
psychosine contributes to the pathology of GLD remains unclear.  
 
II-4 The Psychosine Hypothesis 
The psychosine hypothesis was first proposed by Miyatake and Suzuki in 1972 
(Miyatake and Suzuki, 1972). In 1970, Suzuki and his colleagues had discovered that 
there was a deficiency of GALC in patients with GLD. GALC, as mentioned above, is an 
important lysosomal enzyme that regulates a myelin lipid, called galactosylceramide. 
Surprisingly, however, detailed biochemical analyses revealed that there was not a 
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significant accumulation of galactosylceramide in GLD. Miyatake and Suzuki then 
determined that there was an exceptionally high level of another galactolipid, called 
psychosine, present in the CNS tissues from GLD patients. Thus, they hypothesized that 
this abnormal accumulation of psychosine in GLD was the likely candidate toxin for GLD 
pathophysiology.  
The psychosine hypothesis has become the primary focus of GLD research, 
with particular attention to the direct effect of psychosine on the death of 
oligodendrocytes as its primary pathological action leading to demyelination (Miyatake 
and Suzuki, 1972). Indeed, many studies have now confirmed that psychosine can elicit 
cytotoxic effects on oligodendrocytes by inducing apoptosis in vitro (Cho et al., 1997, Giri 
et al., 2008, Giri et al., 2006, Haq et al., 2003, Zaka and Wenger, 2004). Thus, the 
psychosine hypothesis has become the tenet of GLD pathogenesis. 
Although psychosine is an enzymatic substrate of GALC, other substrates can 
also be hydrolyzed by GALC, including the myelin lipid, galactosylceramide. However, in 
GLD, the level of galactosylceramide is unchanged, suggesting an alternate pathway for 
degrading this myelin lipid and for the maintenance of myelin homeostasis (Eto and 
Suzuki, 1970). Recently, it had been reported that only the carbon (C)-18 short chain 
isoform of galactosylceramide accumulates in the brains of twitcher mice, but this C-18 
form does not accumulate to the same extent as psychosine (Esch et al., 2003). The 
levels of long chain galactosylceramides, including the C-22 and C-24 isotypes, are 
similar in both twitcher and wildtype tissue samples (Esch et al., 2003). Changes in these 
isotypes have not been confirmed in human GLD tissues. Despite these reports, a 
potential connection between accumulated short chain galactosylceramides and 
demyelination in GLD has not been identified. On the other hand, the accumulation of 
psychosine and its toxicity in GLD are well documented by numerous studies across 
multiple species and cellular models (Castelvetri et al., 2011, Cho et al., 1997, Galbiati et 
al., 2007, Taketomi and Nishimura, 1964, Whitfield et al., 2001, Zaka and Wenger, 2004, 
33 
Zhang et al., 2013, Zhu et al., 2012). To date, psychosine accumulation remains the most 
plausible primary driving force underlying GLD pathogenesis. Although it has been over 
40 years since the psychosine hypothesis was first proposed (Suzuki, 1998), the exact 
mechanism by which psychosine accumulation accounts for all aspects of GLD pathology 
remains an area of intensive study. 
 
II-5 A Microglial Hypothesis of GLD Pathogenesis 
 
II-5.1 Shortcomings of the Psychosine Hypothesis 
 The psychosine hypothesis, as mentioned above, has garnered the reputation 
as a dogma for the pathogenesis of GLD. Indeed, multiple in vitro studies have 
determined that psychosine is cytotoxic to oligodendrocytes (Cho et al., 1997, Giri et al., 
2006, Haq et al., 2003, Zaka and Wenger, 2004). However, there are many pathological 
aspects of GLD that are not explained by this hypothesis. For example, psychosine also 
has direct cytotoxic effects on neurons in vitro (Castelvetri et al., 2011, Sugama et al., 
1990). This finding agrees with axonal swelling observed prior to demyelination in the 
twitcher mouse (Castelvetri et al., 2011). Psychosine also induces apoptosis of human 
lymphocytes obtained from blood samples (Formichi et al., 2007). In addition, psychosine 
application in non-CNS cell line cultures, such as U937 and HeLa cells, has also been 
reported to induce multinucleation - a cardinal feature of globoid cells (Kanazawa et al., 
2000). Thus, it is likely that the pathogenic effects of psychosine are not limited to 
oligodendrocytes, and that psychosine impacts multiple cell types that together culminate 
in the pathology of GLD. 
 Oligodendrocyte death in GLD has been attributed to the intracellular 
accumulation of psychosine that induces cellular apoptosis (Giri et al., 2008). This 
cell-autonomous theory contradicts observations from the study by Kondo and 
colleagues where they examined the myelinating potential of oligodendrocytes isolated 
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from twitcher mice by transplanting them into the shiverer mouse CNS (Kondo et al., 
2005).  Shiverer mice are a mutant mouse line in which myelination is absent because of 
a lack of myelin basic protein (MBP)(Gumpel et al., 1989). The Kondo study 
demonstrated that transplanted oligodendrocytes from twitcher mice survived and were 
able to appropriately myelinate axons in the shiverer mouse CNS (Kondo et al., 2005). 
Thus, the notion that intracellular accumulation of psychosine is soley responsible for the 
loss of oligodendrocytes in GLD does not explain why twitcher mouse oligodendrocytes 
can myelinate in the shiverer brain. When considered from another perspective, these 
findings also suggest that the extracellular environment may be an important contributor 
to the survivial and function of oligodendrocytes in GLD. In fact, this disease does not 
start with demyelination, but rather, the presence of multinucleated globoid cells can be 
found in the fetal spinal cord at a time well before overt myelin pathology is even 
observed in GLD (Martin et al., 1981). Thus, GLD is likely a multifactorial disease with a 
complex pathophysiology involving many cell types. Moreover, in light of these findings, 
the current oligodendrocyte-centered psychosine hypothesis may require revision. 
 
II-5.2 Importance of Microglia in GLD 
Microglia are CNS-resident phagocytes. Microglia constitute about 5% and 
12% of CNS cell population in the white matter and grey matter, respectively (Lawson et 
al., 1990). Microglia originate from primitive macrophage precursors, entering the 
developing neuroepithelia from the circulation around embryonic day (E)8.5-9.5 in mice 
(Ginhoux et al., 2010). From the time of this CNS colonization by precursors, microglia 
and peripheral macrophages reside in distinct tissue compartments without contact 
(Ginhoux et al., 2013). The primary role of microglia is surveillance since they function as 
a first line of defense against pathogen invasion, and are primary responders to traumatic 
CNS injuries (Nimmerjahn et al., 2005). Additionally, microglia facilitate maintenance of 
CNS tissue homeostasis where they contribute to the development of CNS by 
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contributing to the differentiation and proliferation of neuronal precursors (Cunningham et 
al., 2013). Microglia have also been associated with synapse formation and synaptic 
plasticity mediated by physical contact with pre- and post-synaptic neurons and 
peri-synaptic astrocytes (Schafer et al., 2013, Tremblay et al., 2010). Thus, tight 
regulation of microglial activity is a necessary component of health and aberrant 
microglial activity has many recognized negative consequences for tissue repair and 
disease. 
Microglia have not been a primary focus of pathology in GLD. This may be due 
to the severe demyelination in GLD, which is the most prominent pathological finding of 
this disease. However, several studies have shown strong evidence that microglia may 
play an important role in the pathogenesis of GLD. For example, it was reported that sites 
of demyelination almost always co-exist with astrogliosis and highly activated microglia in 
the twitcher CNS (Ohno et al., 1993). Also, the CNS of twitcher mice expresses high 
levels of proinflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor 
(TNF)-", macrophage inflammatory protein (MIP)-1", MIP-1!, monocyte chemoattractant 
protein-1, and regulated on activation normal T cell expressed and secreted (RANTES), 
all of which are associated with activated microglia (LeVine and Brown, 1997, Wu et al., 
2000). Additionally, Mohri and colleagues demonstrated that microglia can communicate 
with astrocytes via prostaglandin (PG)D2 production during the pathogenesis of GLD, 
and inhibition of PGD2 synthesis in twitcher mice resulted in a substantial reduction in 
astrogliosis and demyelination (Mohri et al., 2006). This report supports microglial 
activation as an early and therefore upstream event, which triggers astrocyte activation 
and precedes demyelination. Also, globoid cells, the aberrant form of activated microglia 
in GLD, have been observed in fetal tissues from genetically determined GLD cases 
(Martin et al., 1981). This is particularly relevant because the presence of these globoid 
cells occurs before initial myelination of the CNS (Martin et al., 1981). Finally, it has been 
previously proposed that uncontrolled activation of microglia may limit the long-term 
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efficacy of HSCT for treating GLD (Pellegatta et al., 2006).  
Despite the ample evidence for microglial involvement in GLD pathogenesis, 
the contribution of microglia toward GLD pathology has not been studied in detail. We 
hypothesized that microglia may be primary mediators of GLD pathogenesis. Our studies 
on the role of microglia in the context of GLD may provide impetus to revise the 
psychosine hypothesis. Toward this objective, we have studied the role of matrix 
metalloproteinases (MMPs,), a family of extracellular proteases implicated in CNS 
demyelination and microglial activation in the context of GLD pathology and 
pathogenesis (Kim et al., 2010, Kouwenhoven et al., 2001, Ozenci et al., 1999). 
 
II-5.3 Matrix Metalloproteinase (MMP)-3 
II-5.3.1 MMP Family: 
MMPs are extracellular endopeptidases that play important roles in tissue 
remodeling, regeneration, and homeostasis (Candelario-Jalil et al. , 2009). MMPs cleave 
all known components of the extracellular matrix (ECM) and tightly regulate extracellular 
environment (Rodriguez et al., 2010). MMPs are zinc (Zn)-dependent extracellular 
proteases that are synthesized as a zymogen that contains a ‘cysteine switch’, an 
interaction between a cysteine residue and Zn2+ within the catalytic domain of the 
enzyme (Van Wart and Birkedal-Hansen, 1990). Disruption of this bond by 
organomercurial agents, heavy metals, oxidants, or proteases, results in conformational 
changes, which expose the catalytic site leading to enzyme activation (Lijnen et al., 1998, 
Van Wart and Birkedal-Hansen, 1990). To date, there are over 100 human MMPs 
identified (Overall, 2002) and seven different subclasses of MMPs based on their 
domains; collagenases, gelatinases, matrilysins, stromelysins, membrane-type MMPs, 
metalloelastases, and enamelysins (Kim and Hwang, 2011). The activity of MMPs is also 
tightly regulated by small endogenous inhibitor proteins called tissue inhibitor of 
metalloproteinases (TIMPs). There are four mammalian TIMP proteins that largely share 
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structural and functional domains. TIMPs non-covalently bind MMPs in a 1:1 
stoichiometry ratio. Imbalance of MMP/TIMP ratios or elevated activation or expression of 
MMPs has been implicated in a wide range of CNS diseases including Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, stroke, amyotrophic lateral sclerosis 
(ALS) and multiple sclerosis (MS) (Kim et al., 2010, Lim et al., 2011, Lorenzl et al., 2003, 
Mandler et al., 2001, Miller et al., 2010, Moore and Crocker, 2012, Mun-Bryce and 
Rosenberg, 1998, Niebroj-Dobosz et al., 2010). Thus, MMPs are important regulators of 
tissue homeostasis in the CNS. 
 
II-5.3.2 MMP-3: 
MMP-3, also known as stromelysin-1, is a member of the stromelysin MMP family, 
which has a relatively simple structure containing a catalytic domain, hemepexin domain, 
and furin recognition site (Cao et al., 2005, Lijnen et al., 1998, Van Wart and 
Birkedal-Hansen, 1990). Like other MMPs, MMP-3 is produced as a zymogen with a 
pro-peptide domain that contains the cysteine switch that masks the catalytic site. Upon 
breakage of this cysteine-zinc bond by activators such as plasminogen and serine 
proteases, the catalytic domain is then exposed and the pro-peptide region is removed by 
auto-cleavage (Lijnen et al., 1998, Van Wart and Birkedal-Hansen, 1990). Activation of 
MMP-3 is believed to be an intracellular event (Kim et al., 2005); however, the exact 
mechanism by which MMP-3 is secreted by cells is still a topic of intense study (Kim and 
Hwang, 2011).  
In the healthy CNS, basal levels of MMP-3 are very low (Kim and Hwang, 2011, 
Maeda and Sobel, 1996). However, in response to injury or inflammation, MMP-3 is 
dramatically upregulated by multiple cell types (Sole et al., 2004).  
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Table 2-2 Catalytic targets of MMP-3 in the CNS 
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Major cellular sources of MMP-3 in the CNS include the astrocyte (Crocker et al., 2008, 
Deb and Gottschall, 1996, Keene et al., 2009, Kim et al., 2008, Savarin et al., 2011), 
stressed neurons (Kim et al., 2005, Nishida et al., 2008) and microglia (Rosenberg et al., 
2001).  
Proteolytic substrates of MMP-3 include many constituents of the extracellular 
matrix (ECM), such as proteoglycans, gelatin, collagen, laminin, fibronectin (Okada et al., 
1986), and tenascins (Imai et al., 1994, Siri et al., 1995, Stegemann et al., 2013) (Table 
2-2). Accumulating evidence suggests that MMP-3 has additional non-ECM substrates 
that can include the protelytic activation of other MMPs (Kim and Hwang, 2011, Ogata et 
al., 1992, Ramos-DeSimone et al., 1999), which activates signaling molecules such as 
tumor growth factor (TGF)-!1 (Maeda et al., 2002), and even prevents cell death by 
shedding the surface molecule Fas-L (Matsuno et al., 2001) (Table 2-2). Overall, MMP-3 
has diverse functions in intracellular, intercellular, and extracellular regulations within the 
CNS. MMP-3 gene expression can be induced by a variety of factors, including cytokines 
(Bond et al., 1999, Crocker et al., 2006, Fleenor et al., 2003), growth factors (Kirstein et 
al., 1996, Witek-Zawada and Koj, 2003), and cellular interactions with the ECM (Werb et 
al., 1989). Aberrant MMP-3 expression has been implicated in the pathogenesis of many 
CNS diseases, including Parkinson’s disease (Choi et al., 2008, Kim et al., 2010), 
Alzheimer’s disease (Deb and Gottschall, 1996, Horstmann et al., 2010, Yoshiyama et al., 
2000), traumatic brain injury (Grossetete et al., 2009, Kim et al., 2005), stroke 
(Rosenberg et al., 1996) and MS (Kouwenhoven et al., 2001, Ozenci et al., 1999).  
 
II-5.3.3 MMP-3 and Neuroinflammation: 
While the functions of MMP-3 are known to be important for CNS homeostasis, its 
dysregulation has also been linked to many aforementioned neurodegenerative diseases. 
Accumulating evidence points to an important role for MMP-3 in regulating 
neuroinflammation (Kim and Hwang, 2011). Specifically, an important aspect of MMP-3 
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has been its expression from activated glia in association with neurodegeneration in the 
CNS (Bonneh-Barkay and Wiley, 2009, Kim and Hwang, 2011). Recent evidence 
suggests that MMP-3 is released from stressed neurons, and then activates microglia. 
This proteolytic activation of microglia can then initiate an inflammatory cascade that can 
culminate in neuronal death (Kim et al., 2007, Kim et al., 2005).  
One aspect of MMP-3 pathophysiology relevant to this thesis is its association 
with demyelination. Indeed, elevated levels of MMP-3 in the CNS were reported in 
several demyelinating disease models, including the mice, which develop spontaneous 
demyelination resulting from overexpression of the proteolipid protein (PLP) isoform 
DM20, infection with Theiler’s murine encephalomyelitis virus (TMEV), and secondary 
demyelination resulting from stroke (D'Souza et al., 2002, Jalal et al., 2012, Kumnok et al., 
2008, Rosenberg et al., 2001, Ulrich et al., 2006). These data suggest an association 
between MMP-3 and CNS demyelination.  
MMP-3 has also been described as an inducer of microglial cytokine release in 
response to cellular stress (Mun-Bryce et al., 2002, Woo et al., 2008). In addition to 
MMP-3 proteolytically targeting inflammatory cytokines, such as TNF-" and IL-1! (Black 
et al., 1996, Ito et al., 1996), MMP-3 has been implicated to directly cleave MBP, a critical 
myelin protein (D'Souza and Moscarello, 2006). Moreover, activated microglia can induce 
apoptosis of oligodendrocytes via reactive oxygen species production (Yeo et al., 2012). 
As mentioned above, MMP-3 is also capable of activating microglia; thus, MMP-3 may 
play an important role in the demyelinating process of GLD via activation of microglia. 
Overall, there are many lines of evidence to suggest MMP-3 may play a role in 
demyelination in GLD.  
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MMPs have not been previously implicated in the pathogenesis of any 
leukodystrophy. MMP-3 was of particular interest to us because it had a strong 
association with demyelination. Many features of GLD, including the robust activation of 
microglia, also suggested a potential role for MMP-3 in this disease. Therefore, one focus 
of this thesis was to investigate the role of MMP-3 in GLD. 
 
II-5.4 Tenascin-C (TnC) 
II-5.4.1 Extracellular Matrix (ECM) in the CNS: 
The extracellular matrix (ECM) is an intricate macromolecular network that 
occupies the extracellular space. It provides cells direct structural support and also 
mediates intercellular signaling. Furthermore, the ECM has been implicated in cellular 
differentiation, lineage fate, and growth (Goetz et al., 2006). The main constituents of the 
ECM in the CNS include laminin, fibronectin, vitronectin, and proteoglycans, which 
include agrins, aggrecans, brevicans, neurocans, perlecans and tenascins (Bandtlow and 
Zimmermann, 2000, Franco and Muller, 2011, Liesi and Silver, 1988, Rogers et al., 1987, 
Welser-Alves et al., 2011). All proteoglycans found in the ECM of the CNS contain either 
heparin sulfate or chondroitin sulfate chains, which are important glycosaminoglycan 
domains for binding to a wide array of interacting proteins (Bandtlow and Zimmermann, 
2000). ECM constituents bind to each other to produce an intricate mesh-like structure 
occupying the extracellular space. The ECM can also bind to the cell surface and/or 
cellular membranes by means of transmembrane domains that can mediate cellular 
development and migration through signaling (Bandtlow and Zimmermann, 2000). 
Indeed, ECM molecules such as laminin, fibronectin, and proteoglycans containing 
glycosaminoglycan domains, have been implicated in neurite outgrowth, axon sprouting, 
neuronal and glial migration, and oligodendrocyte differentiation (Alvarado and Castejon, 
1986, Ard and Bunge, 1988, Calof et al., 1994, Czopka et al., 2010, Gates et al., 1995, 
Giftochristos and David, 1988, Gil et al., 2009). Additionally, the ECM is capable of 
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binding to multiple secreted extracellular molecules to influence their biological signaling 
properties (Bandtlow and Zimmermann, 2000, Bonneh-Barkay and Wiley, 2009, Dityatev 
and Schachner, 2003, Yamaguchi, 2000). For instance, fibronectin binds to 
heparin-binding growth factor-1 to promote growth of endothelial cells (Kan and Shi, 
1990). Also, tenascin-C (TnC) has been reported to bind to multiple growth factors, 
including epidermal growth factor (EFG), FGFs, and platelet-derived growth factors 
(PDGFs), all of which have diverse effects on cellular growth and differentiation in the 
CNS (De Laporte et al., 2013, Garcez et al., 2009, McKinnon et al., 1990). Laminin can 
also bind to brain-derived neurotrophic factor (BDNF), which participates in 
neuroprotection during ischemic injury (Han et al., 2011). This latter study also 
emphasized the importance of laminin binding to BDNF as a mechanism to prolong the 
neuroprotective effect of BDNF (Han et al., 2011). Thus, the biological activity of growth 
factors may rely on binding to ECM molecules (Bandtlow and Zimmermann, 2000).  
The distribution and expression of ECM constituents are tightly regulated, not only 
at the transcriptional and the translational levels, but also by many extracellular 
modulators, including the MMP family of extracellular proteases (Cahoy et al., 2008, 
Ethell and Ethell, 2007, Galtrey et al., 2008). Imbalance or dysregulation of ECM 
components has been observed in many diseases, including Alzheimer’s disease, stroke, 
HIV encephalopathy, and MS (Bonneh-Barkay and Wiley, 2009). Especially in the MS 
brain, the levels of different ECM constituents have been reported to be dramatically 
altered at sites of myelin injury. For example, in acutely demyelinated lesions, TnC levels 
are strikingly decreased relative to unlesioned or healthy tissues, whereas in chronically 
demyelinated areas, levels of TnC are elevated (Back et al., 2005, Gutowski et al., 1999). 
Also, several ECM molecules have been suggested to modulate the responses of 
immune cells and glia at lesion sites within the MS brain (Mohan et al., 2010). Thus, 
changes in the composition of the ECM may contribute to disease pathology.  
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II-5.4.2 Tenascin-C (TnC): 
Tenascin-C (TnC) is a large matrix glycoprotein that forms a mono- or 
hetero-hexamer by disulfide bonding that connects N-termini of six subunits (Erickson 
and Bourdon, 1989, Taylor et al., 1989). Each subunit consists of four domains; an 
assembly domain, an EGF-like repeats domain, a fibronectin-type III like repeats (FNIII) 
domain, and a C-terminal fibrinogen-like globe domain (Taylor et al., 1989). Each domain 
can be alternatively spliced, resulting in a wide range of potential isoforms (Nies et al., 
1991, Spring et al., 1989). Thus, it is not surprising that TnC is known to have a wide 
variety of interacting proteins, including ECM receptors, integrins (Yokosaki et al., 1998, 
Yokoyama et al., 2000), signaling receptors including EGF receptor and toll-like receptor 
4 (TLR4) (Midwood et al., 2009, Swindle et al., 2001), growth factors such as EGF, FGF, 
PDGF (De Laporte et al., 2013), and other ECM molecules, such as fibronectin and 
aggrecan (Day et al., 2004, Ingham et al., 2004). Among many molecules of the ECM, 
TnC is an interesting matrix protein because it has paradoxical functions on cellular 
adhesion by promoting cell growth/maturation while also having the potential to evoke 
local cellular detachment (Jones and Jones, 2000, Spring et al., 1989). Indeed, TnC is 
capable of binding to cell adhesion molecules (CAMs) and annexins, which are known 
components involved in both cell adhesion and detachment (Chung and Erickson, 1994, 
Chung et al., 1996, Hasan et al., 1998, Mai et al., 2000). The dual functionality of TnC 
has been thought to arise from its multidomain structure (Jakovcevski et al., 2013), 
although the precise mechanism regulating its diverse effects on cellular behavior are still 
unknown. 
 Tenascin-C is widely expressed in many organs, including the thymus, liver, 
pancreas, kidney, bladder, muscle, skin, placenta, and the CNS (Borsi et al., 1993, Saga 
et al., 1991). It was hypothesized that genetic ablation of TnC in mice would have had a 
significant impact on their development (Mackie and Tucker, 1999). However, the first 
TnC KO mouse line exhibited normal weight, fertility, and tissue architecture (Saga et al., 
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1992). This finding was unexpected and was subsequently determined to be due to the 
failure to completely ablate TnC messenger ribonucleic acid (mRNA) (Mitrovic and 
Schachner, 1995). It is important to note that there are likely compensatory mechanisms 
resulting from expression of other tenascins, such as tenascin-R, -X, and –W, that may 
have also provided a degree of functional redundancy in the TnC KO mice (Mackie and 
Tucker, 1999). Interestingly, other studies revealed that while the TnC KO mice did not 
have a remarkable basal phenotype, they did exhibit abnormal behaviors, including 
hyperactivity throughout the circadian cycle (Fukamauchi et al., 1996). In the PNS, TnC 
KO mice were also found to have significantly more unmyelinated axons in their sciatic 
nerves than in age-matched wildtype mice (Cifuentes-Diaz et al., 1998). Additional 
physiological differences have since been identified in TnC KO mice, particularly in their 
responses to pathological challenges. For instance, glial scarring in the cerebral cortex of 
TnC KO mice has been reported to contain more astrocytes in response to a cortical stab 
wound than was observed in wildtype mice (Steindler et al., 1995). Also, wound healing 
following a corneal incision has been reported to be delayed in TnC KO mice as a result 
of altered gene expression in the local fibroblasts (Sumioka et al., 2013). TnC deficiency 
also resulted in impaired regeneration of hematopoietic stem cells following bone marrow 
ablation in vivo, although TnC KO mice exhibited developmentally normal hematopoiesis 
(Nakamura-Ishizu et al., 2012). These studies on TnC KO mice have now identified many 
pathological functions of TnC; however, the effect of TnC ablation was not as profound as 
may have been expected at the outset of these studies (Mackie and Tucker, 1999).  
 
II-5.4.3 TnC in the CNS: 
Several salient functions of TnC in the CNS have been revealed by studies on 
TnC KO mice. Recent studies have also identified severe deficits in neuronal activity and 
plasticity both in vivo and in vitro from ablation of TnC (Geissler et al., 2013, Sekeljic and 
Andjus, 2012). Detailed histological analyses of TnC KO mice have also determined that 
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these mice have a significantly higher density of cortical neurons than in wildtype animals 
(Irintchev et al., 2005). Also, oligodendrocytes isolated from TnC deficient mice exhibit 
lower rates of proliferation, likely due to their lack of integrin-mediated signaling (Garcion 
et al., 2001). This reduced oligodendrocyte proliferation is though to underlie the lower 
ratio of oligodendrocytes to neurons also observed in the TnC KO mice (Irintchev et al., 
2005).  
The expression of TnC is also dynamically resgulated by CNS injury and 
inflammation. For instnace, TnC accumulates in the demyelinated lesions of mice 
infected with TMEV, a virus that evokes immune-mediated CNS demyelination (Haist et 
al., 2012). Elevated TnC expression has also been identified as a feature of demyelinated 
lesions in MS (Gutowski et al., 1999). However, based on the variety of potential 
functions of TnC, the impact of TnC on demyelinating lesions could be reasonably 
interpreted to either promote or hamper the remyelination process. For instance, at lesion 
sites, increased level of TnC could benefit cell growth based on the cell adherence 
properties of TnC. Conversely, it is also possible that elevated TnC may hamper the 
migration of progenitor cells, which would be promoting cellular detachment necessary 
for mediating myelin repair (Frost et al., 1996, Garcion et al., 2001). Thus, increased TnC 
within myelin lesions may be an important factor limiting the process(es) of endogenous 
regeneration needed for tissue repair. Also, TnC is known to modulate glial responses. It 
was reported that TnC deficiency leads to astrogliosis in vivo, although the potential 
mechanisms by which aberrant increases in the density of GFAP+ astrocytes in 
unchallenged TnC KO brain remain unclear (Irintchev et al., 2005). The presence of TnC 
is also known to modify the behavior of astrocytes, which can result in a dominating 
inhibitory effect on oligodendrocyte growth and differentiation (Nash et al., 2011). 
Activated astrocytes are recognized as a prominent source of TnC during development 
and in response to demyelination in the adult CNS (Cahoy et al., 2008, Grierson et al., 
1990, McKeon et al., 1991).  
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It has also been reported that astrocytic tenascin expression can be regulated 
by microglia, although the mechanisms by which astrocytic tenascin-c may regulate 
microglia remain elusive (Smith and Hale, 1997). Deposition of TnC has been implicated 
as a potential inducer of MMP-3 expression in non-glial cell types (Thomasset et al., 1998, 
Tremble et al., 1994, Yang et al., 2004). Yet, prior to my thesis experiments, changes in 
ECM constituents had not been previously explored as an aspect of GLD 
neuropathology.  
 
II-6 Specific Aims 
 
II-6.1 Goal and Rationale 
The goal of this thesis was to characterize the non-myelinating glial 
contributions to the pathogenesis of GLD and to determine whether MMP-3 was a 
regulator of glial activation in this disease. As outlined in the preceeding discussion, 
MMP-3 is a potent activator of microglia that has been associated with several 
demyelinating conditions and diseases, including MS (Kouwenhoven et al., 2001, Ozenci 
et al., 1999). However, the potential involvement of MMPs had not been previously 
studied in any leukodystrophy. As well, we explored the potential role of ECM changes in 
GLD as potential mediators of pathological glial functions. 
 
Hypothesis: MMP-3 induces microglial activation that contributes to the 
pathogenesis of GLD. 
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II-6.2 Specific Aim 1: To examine the effect of psychosine in glial cells and 
expression of MMP-3 (Chapter 3) 
Accumulating evidence supports a role for MMP-3 in neuroinflammation and 
demyelination in the CNS. First, MMP-3 expression and activity are elevated in multiple 
demyelinating conditions (D'Souza et al., 2002, Jalal et al., 2012, Kumnok et al., 2008, 
Rosenberg et al., 2001, Ulrich et al., 2006). Secondly, proteolytic targets of MMP-3 
include inflammatory cytokines and ECM proteins (Table 2-2). Third, MMP-3 has been 
implicated in the pathogenesis of myelin lesions. Lastly, MMP-3 is known to activate 
microglia, which are also present in GLD. Thus, we hypothesized that the GLD toxin, 
psychosine, would induce globoid cells from microglia that would be mediated by MMP-3. 
This hypothesis was tested by addressing the following questions: 
Aim1.1) Is MMP-3 expression elevated in GLD? This part of aim 1 examined if the level of 
MMP-3 was elevated during the disease course of GLD. Using brain tissues from twitcher 
mice at different postnatal ages, the level of MMP-3 expression was determined using 
quantitative real-time-polymerase chain reaction (qRT-PCR). Additionally, the source of 
MMP-3 in vivo was examined using immunohistochemical analyses. We also examined 
whether psychosine transcriptionally induced MMP-3 expression in glial cultures, as 
astrocytes have been implicated as a major source of MMP-3 in the CNS. The cellular 
source of MMP-3 in vitro was also determined by immunocytochemistry. 
Aim1.2) Does psychosine induce globoid cells from microglia in vitro?: In this set of 
experiments, we determined whether psychosine induced globoid-like cells from 
microglia. Using a primary glial culture system, we employed immunocytochemistry to 
visualize, identify, and quantify the degree of multinucleation among psychosine-treated 
microglia in culture. The number of "globoid cells" was determined using manual counting, 
while the function of psychosine-induced globoid cells was also characterized using a 
phagocytic activity assay. 
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Aim1.3) Does MMP-3 mediate psychosine-induced globoid cells?: The experiments in 
this sub-aim examined whether MMP-3 mediates psychosine-induced "globoid cell" 
formation in vitro. This was tested using the same quantitative approach in Aim 1.2 but 
using mixed glial cultures derived from MMP-3 KO mice and wildtype mixed glial cultures 
that were also treated with chemical inhibitors specific to MMPs or MMP-3 [e.g. 
N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycylhydroxamic acid (NNGH)].  
 
II-6.3 Specific Aim 2: To examine how changes in ECM influence glial responses to 
psychosine (Chapter 4) 
A factor limiting the long-term efficacy of BMT to treat GLD patients may be the 
persistent presence of reactive microglia in the CNS (Pellegatta et al., 2006). Importantly, 
the extracellular environment surrounding glial cells can significantly contribute to glial 
reactivity in disease. In GLD, there have not, as yet, been any reports investigating 
changes in ECM expression and composition. Thus, we hypothesized that changes in 
ECM components in the GLD brain may contribute to glial activation in this disease and 
microglial activity in particular. Specifically, we hypothesized that signals from ECM 
molecules differentially produced in the GLD brain could modulate psychosine-induced 
glial behaviors. Lastly, we examined whether globoid cells were toxic to oligodendrocytes, 
and tested the influence of ECM on this potential toxicity. The following questions were 
addressed:   
Aim2.1) Are levels of ECM components different in the GLD brains?: The level of several 
ECM constituent macromolecules was measured. ECM components examined were 
laminin, fibronectin, vitronectin, and TnC. Expression of these components were 
examined using immunohistochemsitry on twitcher mouse brain tissues at different 
postnatal ages and human brain tissue samples from individuals who had GLD. 
Age-matched wildtype littermates and age-matched human control samples were used 
as a basis for comparison.  
49 
Aim2.2) How does altered ECM composition influence glial responses to psychosine?: 
We prepared mixed glial cultures on different ECM substrates and then treated these 
cultures with psychosine to determine how changes in the ECM impacted the glial 
responses; as measured by MMP-3 expression, globoid cell formation and phenotype 
(M1/M2) marker expression profiles. 
Aim2.3) Are psychosine-induced globoid cells toxic to oligodendrocytes?: In this aim, we 
tested the potential toxicity of globoid cells to oligodendrocytes in vitro using a co-culture 
system of psychosine-activated microglia/globoid cells that were then placed in culture 
with primary oligodendrocytes. Microglia were grown on either laminin or TnC substrates, 
exposed to psychosine, and then co-cultured with oligodendrocytes. The effect of various 
microglial conditions was then evaluated on the number and survival of oligodendrocytes 
and OPCs, as determined by immunocytochemistry and a lactose dehydrogenase (LDH) 
assay to measure cell death. 
 
II-7 Significance 
GLD is a rare, yet fatal pediatric disease with a rapid progression of 
demyelination and neurodegeneration. More than 90% of GLD cases are of an infantile 
type, in which the patients die by the age of two. Presently, the only effective therapy for 
GLD patients is a HSCT such as umbilical cord blood transplantation and BMT. However, 
the efficacy of HSCT in GLD is limited by the high-risk nature of this procedure and its 
narrow therapeutic window, where this treatment is effective only when applied during 
pre-symptomatic period. Thus, a discovery of alternative or additional therapeutic 
target(s) for GLD is essential for the development of new treatment for GLD. Our current 
knowledge of the precise mechanisms of pathophysiology and cellular pathogenesis in 
GLD are limited by a lack of understanding on the sequence of cellular events. Therefore, 
in this thesis, I focused on the microglial contribution toward GLD pathogenesis. Results 
described in this dissertation provide novel insights into the overall understanding of GLD 
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pathogenesis, which may lead us to novel therapeutic targets and treatment strategies for 
this devastating disease. 
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Chapter Three 
 
Matrix Metalloproteinase (MMP)-3 Mediates Psychosine-induced 
Globoid Cell Formation 
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III-1 Summary 
 
Globoid cell leukodystrophy (GLD), or Krabbe disease, is a fatal demyelinating disease 
attributed to mutations in the galactocerebrosidase (GALC) gene.  Loss-of-function 
mutations in GALC result in accumulation of the glycolipid intermediate, 
galactosylsphingosine (psychosine). Due to the cytotoxicity of psychosine, it has been 
hypothesized that accumulated psychosine underlie the pathophysiology of GLD. 
However, the cellular mechanisms of GLD pathophysiology remain unclear. Globoid cells, 
multinucleated microglia/macrophages in the central nervous system (CNS), are a 
defining characteristic of GLD. Here we report that an exposure of primary glial cultures 
to psychosine induces the expression and the production of matrix metalloproteinase 
(MMP)-3 that mediated a morphological transformation of microglia into a multinucleated 
globoid cell type. Additionally, psychosine-induced globoid cell formation from microglia 
was prevented by either genetic ablation or chemical inhibition of MMP-3. These effects 
are microglia-specific as peripheral macrophages exposed to psychosine did not become 
activated or express increased levels of MMP-3. In the brain from twitcher mice, a murine 
model of human GLD, elevated MMP-3 expression relative to wildtype littermates was 
contemporaneous with disease onset and further increased with disease progression. 
Further, bone marrow transplantation (BMT), currently the only therapeutically beneficial 
treatment for GLD, did not mitigate the elevated expression of MMP-3 in twitcher mice. 
Hence, elevated expression of MMP-3 in GLD may promote microglial responses to 
psychosine that may represent an important pathophysiological process in this disease 
and its treatment. 
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III-2 Introduction 
Leukodystrophies are rare genetic diseases affecting CNS white matter. 
Globoid Cell Leukodystrophy (GLD), also known as Krabbe disease (Krabbe, 1916), is a 
commonly-pediatric de/dysmyelinating disease with an incidence of about 1 in 100,000 
(Duffner et al., 2009). GLD has been attributed to a deficiency of the lysosomal enzyme, 
galactocerebrosidase (GALC), resulting from loss of function mutations in the GALC gene 
(Wenger, 2001). These loss of function mutations in GALC result in a metabolic defect 
and an accumulation of a sphingolipid intermediate, galactosylsphingosine (psychosine) 
(Suzuki and Suzuki, 1970). The excessive accumulation of psychosine in 
oligodendrocytes coupled with the toxicity of this metabolite has led to the “psychosine 
hypothesis” of GLD (Miyatake and Suzuki, 1972, Suzuki, 1998). This hypothesis 
proposes that elevated levels of psychosine cause the death of oligodendrocytes, which 
results in the prominent white matter pathology of GLD. However, when oligodendrocytes 
from the twitcher mouse model of this disease are transplanted into dysmyelinating 
shiverer mice, these oligodendrocytes differentiate and myelinate (Kondo et al., 2005). 
Thus, oligodendrocyte cell death and demyelination in GLD are not a cell-autonomous 
process.  
 Microgliosis and infiltration of peripheral macrophages into the CNS 
parenchyma are notable pathologic changes in GLD. Robust microglial activation in the 
brains of GLD patients provide a unique and defining feature of this disease: they 
transform into highly active, multinucleated phagocytes referred to as 'globoid cells'. 
These globoid cells are also observed in animal models of this disease (Kobayashi et al., 
1985). Globoid cells are known to develop from phagocytes during the course of this 
disease; however, it is not clear whether these giant multi-nucleated cells arise from 
resident CNS microglia and/or infiltrating macrophages. Discerning which cell types 
contribute to the formation and activation of these highly activated phagocytes is 
expected to provide new insights into the pathogenesis of GLD. 
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In a variety of demyelinating diseases, there is a well-established role for matrix 
metalloproteinases (MMPs), a family of extracellular endopeptidases that play significant 
roles in tissue remodeling and regeneration (Yong et al., 2001). MMPs are known to 
cleave all components of the extracellular matrix (ECM) and thereby serve important 
homeostatic functions. Particularly relevant to a potential role in GLD, dysregulated 
activities of MMPs have been associated with a wide variety of neurodegenerative and 
demyelinating diseases, including multiple sclerosis. A role for MMPs in a leukodystrophy 
has not been previously reported. In multiple sclerosis, elevated expression of MMPs by 
leukocytes facilitates the extravasation of autoreactive T cells into the CNS parenchyma 
(Gijbels et al., 1994). Increased expression of MMPs within the CNS is also thought to 
promote tissue degeneration (Pagenstecher et al., 1998). In an animal model of 
Parkinson's disease, for instance, MMP-3 in particular, has been shown to be a potent 
activator of microglia leading to neurodegeneration (Kim et al., 2005). Since microgliosis 
and invasion of peripheral macrophages into the CNS represents a primary pathology in 
GLD, we hypothesized a role for MMP-3 in GLD. 
Herein, we report that psychosine-induced expression of MMP-3 is responsible for 
microglial activation and development of multi-nucleated globoid-like cells in primary 
murine glial cultures. Elevated expression of MMP-3 in the CNS of twitcher mice, which 
was not mitigated by bone marrow transplantation (BMT), the only therapeutically 
beneficial treatment for GLD, suggests a role for MMP-3 in the pathology of GLD. 
Together these data provide the first demonstration of MMP involvement in a 
leukodystrophy. 
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III-3 Materials and Methods 
III-3.1 Mice  
All protocols were performed in accordance with animal use and care protocol 
approved by Institutional Animal Care and Use Committees (IACUC). For cell culture 
experiments, all procedures using wildtype C57BL/6 and MMP-3 knockout (KO) neonates 
were performed at the University of Connecticut Health Center. Bone marrow transplant 
experiments were performed at the University of Illinois at Chicago. 
 
III-3.2 Preparation of Primary Mixed Glial Cultures  
Cultures were prepared from postnatal day (P) 0-3 wild-type C57BL/6 or 
MMP-3 KO mouse pups. Briefly, forebrains were stripped of meninges, chopped into fine 
pieces and dissociated using a neural tissue dissociation kit (papain) according to the 
manufacturer’s protocol (Miltenyi Biotec, Auburn, CA). The single cell suspension was 
then cultured in T75 tissue culture flasks (Grenier Bio-One, Germany) in Dulbecco’s 
modified eagle media (DMEM, Gibco, Carlsbad, CA) supplemented with 10% fetal calf 
serum (FBS; Atlanta Biologicals, Lawrenceville, GA), penicillin (100U/mL: Sigma Aldrich, 
St. Louis, MO) and streptomycin (100mg/mL, Sigma Aldrich). After 12-16 hours, all 
non-adherent cells were removed and fresh media was added to the adherent cells. 
Mixed glial cultures were utilized experimentally when the confluent astrocytic monolayer 
was established.  
 
III-3.3 Purified Glial Cultures  
Primary mixed glial cultures were established, as described above. For purified 
microglial cultures, confluent mixed glial cultures were shaken using orbital shaker at 
110rpm at 37oC 3-4 hrs to allow the loosely adhered microglia to detach from the 
astrocytic monolayer. Media was supplied with 25mM 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES, Invitrogen, Grand Island, 
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NY) and 25mM sodium bicarbonate (Invitrogen) to buffer pH changes in the absence of 
CO2. Following the shaking, media containing detached microglia was collected and 
manually counted using a hemacytometer. Cells were re-plated into 6-well plates in 
mixed glial conditioned media, and used experimentally as a purified microglial culture 
after 2-3 days of incubation at 37oC. Enriched astrocyte cultures were acquired by 
culturing the remaining adherent cells following 3-4 hrs shaking and collection of 
detached microglia, as described above. Fresh media was added to these cultures and 
incubated for 3-5 days at 37oC prior to any experimental manipulation.  
 
III-3.4 Psychosine Treatment & Characterization of Globoid Cells in Culture  
Mixed glial cell cultures were established from P0-P3 C57BL/6 or MMP-3 KO 
mice, as described above. When confluent, culture media was removed and cells were 
washed once in 1x phosphate buffer solution (PBS), then detached using a 0.25% 
Trypsin solution (Invitrogen). Cells were spun, washed with 1X PBS, then re-suspended 
in culture media, counted and plated at a density of 5.0 x 104/ml on circular glass 
cover-slips (Fisher Scientific, Pittsburgh, PA) coated in 5µg/ml laminin (Sigma Aldrich). 
Six replicates were performed per treatment. Cells were allowed to adhere for 4-5 days at 
37oC with 5% CO2, and treated with either culture media (untreated control); psychosine 
(10#M, Sigma Aldrich) (Im et al., 2001); psychosine + the broad-spectrum MMP inhibitor, 
GM6001 (12.5#M, Calbiochem, Billerica, MA); psychosine + GM6001i (inactive GM6001 
analogue: 12.5#M, Calbiochem); or vehicle control (0.13% of DMSO, Sigma Aldrich; and 
0.02% ethanol, Sigma Aldrich). For study using MMP-3 specific inhibitor, NNGH (0.1µM, 
Enzo Life Sciences, Farmingdale, NY) was used in the same paradigm of GM6001. 
Treatments were supplemented every 48hrs, at the same concentrations, over seven 
days of the experiment. We defined globoid cell by immunocytochemistry (see below) as 
Iba-1+ with a rounded amoeboid-like morphology and multi-nucleated. Representative 
images were taken using an Olympus IX71 fluorescent microscope and Eclipse imaging 
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software (empix.com). Numbers of globoid cells were quantified by counting the number 
of Iba-1+ cells in four separate areas per coverslip (n=3 replicates totaling 12 images per 
treatment group were counted).  
 
III-3.5 Immunocytochemistry (ICC) 
Cells were fixed on laminin-coated circular glass cover-slips in freshly prepared 
4% paraformaldehyde (PFA, Sigma Aldrich) for 10 min. at room temperature for 15min., 
then blocked and permeabilized with 0.2% Triton X-100 (Sigma Aldrich) in PBS with 5% 
normal goat serum (Invitrogen) for 1hr.  Fixed cells were incubated at 37oC using the 
microglial marker Iba-1 (1:500; Wako, Richmond, VA), glial fibrillary acidic protein 
(GFAP)-Cy3 (1:1000; Sigma Aldrich) or GFAP (1:1000; Dako, Carpinteria, CA), and 
MMP-3 (Calbiochem; 1:500) primary antibodies in 5% normal goat serum for 1hr. 
Following incubation, cells were washed three times in PBS for 10min. each. Cover-slips 
were then incubated at 37oC with 1:500 Alexa Fluor® 594 and/or 488 (Invitrogen) and 
1:1000 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) for 45min followed by three 
washes in 1x PBS for 10min. each. Finally, coverslips were mounted in Fluoromount-G™ 
(SouthernBiotech, Birmingham, AL). 
 
III-3.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)  
Total RNA was isolated from cultured cells, as described previously (Moore et 
al., 2011), and reverse transcribed into complementary DNA (cDNA) (iScript cDNA 
synthesis kit, Bio-Rad, Hurcules, CA) according to the manufacturer’s protocol. 
Synthesized cDNA samples were amplified using PCR primers specific to mmp-3 and 
TNF mRNA (Integrated DNA Technologies, Coralville, IA), as employed previously (Chen 
et al. , 2009); [MMP-3: forward 5' - GGA AAT CAG TTC TGG GCT ATA CGA-3', reverse, 
5'- TAG AAA TGG CAG CAT CGA TCT TC-3'; TNF: forward 5' - GAC CCT CAC ACT 
CAG ATC ATC TTC T -3', reverse 5' - CCT CCA CTT GGT GGT TTG CT -3'] and 
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SsoFastTMEvaGreen® Supermix (Bio-Rad), according to the manufacturer’s protocol. 
Amplification of target cDNA was analyzed by a Mastercycler® ep realplex (Eppendorf, 
Hauppauge, NY). Primers for GAPDH were used to assess general expression level of 
housekeeping gene among samples; Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH): forward 5' -ACC ACC ATG GAG AAG GC-3', reverse, 5' GGC ATG GAC TGT 
GGT CAT GA-3'. For peripheral blood and macrophage sample, ribosomal unit 18S was 
targeted as a housekeeping gene (18S: forward: 5’- AGT TGG TGG AGC GAT TTG-3', 
reverse: 5’ - TTG CTC AAT CTC GGG TG - 3'). Relative expression of mRNA was 
calculated using the comparative cycle threshold analysis (!!CT), as previously 
described (Livak and Schmittgen, 2001). Briefly, the difference of cycle threshold (CT) 
values between target and housekeeping genes within each sample (!CT) was calculated, 
and then the difference of !CT between control or wildtype and experimental groups 
(!!CT) was derived by substraction. Finally, relative quantification values (RQ) for each 
sample were calculated using the following equation: RQ = 2-!!CT (Livak and Schmittgen, 
2001). The RQ reflects the normalized values of target mRNA expression (i.e. MMP-3) in 
fold change with reference to control or wildtype samples, which are expressed as 1 fold 
change in graphs, within the same experiment.  
 
III-3.7 Microglial Phagocytosis Assay  
Primary mixed glial cultures were prepared, as described above, from 
P0-P3 wild-type C57BL/6 mice. Cultures were plated at a density of 1 x 105 cells/mL on 
laminin-coated glass coverslips and treated for 7 consecutive days with PBS, psychosine 
(10#M), or psychosine and GM6001 (12.5#M). At 48hrs prior to fixation, fluorescein 
isothiocyanate (FITC)-labeled latex beads (Cayman Chemical Company; Ann Arbor, MI) 
were added to all treatment groups. Cells were then incubated at 37oC for the duration of 
the experiment and then fixed using 4% PFA in PBS. Immunocytochemistry was then 
performed for Iba-1 and numbers of Iba-1+/FITC+ labeled cells were counted to 
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determine the numbers of microglia that took up the beads for each treatment group 
(n=3/group; replicates of 9). 
 
III-3.8 Peripheral Blood Cell Assay  
Peripheral blood was collected from wildtype mice by intracardial needle 
puncture and treated for 4 hrs (37˚C, 5% CO2) with either psychosine (10µM) or 
lipopolysaccharide (LPS; 100µg/ml; Sigma Aldrich). To lyse the red blood cells, the 
treated samples were immediately incubated on ice with ammonium chloride (0.72%, pH 
7.2; STEMCELL technologies) for 10min. Samples were spun at 1000Xg for 10min., 
followed by aspiration of ammonium chloride. The pellet was washed with 1mL of Roswell 
Park Memorial Institute media (RPMI; Gibco), spun at 1000Xg for 5min, and supernatant 
was aspirated. The pellet was re-suspended in TRIzol (invitrogen) and total RNA from 
peripheral blood white cells was isolated, as previously described (Moore et al., 2011).  
 
III-3.9 Peripheral Macrophage Collection   
Peripheral macrophages were collected from the peritoneal cavity of adult mice, 
as described previously (Ray and Dittel, 2010) with slight modifications. Briefly, adult 
wildtype C57BL/6 mice were anesthetized and 4-5mL of ice cold PBS with 3% FBS was 
injected intraperitoneally to each animal. Filled peritoneum was massaged well to detach 
the tissue-adhered macrophages into the cavity, followed by collection of injected PBS 
through 25G needle inserted into the peritoneal cavity. Collected cell suspension was 
centrifuged at 1500rpm for 7min, and collected cell pellet was resuspended in RPMI with 
5% FBS. Cells were plated in the plastic dish overnight (37˚C, 5% CO2) to allow 
macrophages to adhere at the bottom of dish. Media was then removed and adhered 
macrophages were plated at 5x106 cells/ml. The purity of differentially adhered 
macrophages was enumerated by flow cytometry (Supplemental Figure 1). Plated 
macrophages were then treated with psychosine or LPS in the same regimen as 
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described in peripheral blood cells assay (see above). 
 
III-3.10 Twitcher Mice  
Twitcher mice (GALCtwi Mice) are a well-characterized murine model of GLD, 
which is caused by a spontaneous mutation in the GALC gene. Mice were housed and 
bred at the Sanford-Burnham Institute (La Jolla, CA) where tissues were collected from 
homozygous GALCtwi/GALCtwi mice and wildtype littermates at different time points 
following birth P0, 10, 20, 31, and 40, as previously described (Taylor et al., 2006). 
Twitcher mice for BMT experiment were housed and bred at the University of Illinois at 
Chicago (Chicago, IL). 
 
III-3.11 Immunohistochemistry (IHC) 
Twitcher mice and age-matched littermate control mice were transcardially 
perfused with PBS and 4% PFA, and their brain was removed. Collected brains were 
immersed in 4% PFA overnight and then in 30% sucrose solution. Brain tissue was 
paraffin-embedded and sectioned 15µm in thickness. Tissue sections mounted on slide 
glass were deparaffinized and dehydrated by series of xylene and ethanol, 
antigen-retrieved by heated citric acid buffer (0.01M, pH6.0), and blocked with 5% normal 
goat serum in PBS for 1 hour. Immunohistochemistry was then performed using primary 
antibodies against GFAP (1:1000, Dako), ionized calcium-binding adapter molecule 1 
(Iba-1; 1:2000, Wako), and MMP-3 (1:100, CalBioChem), diluted in PBS with 2% normal 
goat serum and incubated tissues in antibodies overnight at 4˚C, followed by PBS wash.  
Immunoreactivity for each target was visualized by using fluorescent secondary 
antibodies, including Alexa Fluor® 594 and 488 (1:500; Invitrogen), followed by PBS wash. 
The tissues were then coversliped using FluoroMount G (SouthernBiotech). 
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III-3.12 Bone marrow transplantation (BMT) in Twitcher mice 
Bone marrow cells were obtained from C57BL/6J CD45.1 (8-12 weeks) as 
previously described (Galbiati et al., 2009). Briefly, tibiae and femora were flushed with 
0.9% saline and the cells filtered (44-#m strainer; BD, San Diego, CA). The cellular eluent 
was then centrifuged at 1,500 rpm (5 min) and cell pellets incubated in lysis buffer to 
eliminate all red blood cells (10 min at 48oC; 155 mM ammonium chloride, 10 mM 
potassium bicarbonate, 0.1 mM ethylenediaminetetraacetic acid, EDTA, pH 8). 
Mononuclear cells were washed in saline and counted using a hemocytometer and then 
re-suspended (30 X 106 cells/20 #l saline) for intravenously infusion. Cells were injected 
in newborn Twitcher pups (1-2 days after birth) through the parietal vein, as previously 
described (Billingham et al., 1956, Sands and Barker, 1999). Transplanted mice were 
returned to their mothers without any other treatment.  
 
III-3.13 Statistical Analyses  
Data are presented as mean ± standard error of mean (SEM). A one-way 
analysis of variance (ANOVA) with Tukey's post hoc tests or unpaired Student's t test was 
used to determine group differences. For all tests, p < 0.05 was considered significant.  
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III-4 Results 
III-4.1 Age-dependent increase in the CNS expression of MMP-3 in twitcher mice  
Spontaneous mutations in GALC in C57/BL6 mice have been found to limit 
lifespan and produce neuropathology resembling human GLD. These 'twitcher' mice are 
now established as an authentic model of GLD. To determine whether expression of 
MMP-3 was altered during the lifespan of twitcher mice, total RNA was isolated from 
whole brains of twitcher mice and wildtype littermates from time of birth (P0) through P40, 
at which >95% mortality was observed among homozygous mutant mice. qRT-PCR 
evaluation of mmp-3 mRNA revealed a significant increase in expression in twitcher mice 
compared to wildtype counterparts (Figure 3-1A). This increase of MMP-3 expression 
coincided with the onset of clinical disease in twitcher mice, which is approximately P20 
(Figure 3-1A). Additionally, the increase of MMP-3 expression in twitcher mice showed a 
temporal correlation (Figure 3-1A). The increase in MMP-3 expression in twitcher mouse 
brain relative to wildtype age-matched controls was 7.5 fold by P40. To identify the 
cellular source of increased MMP-3 in the twitcher mouse brain, we performed 
immunohistochemistry for MMP-3 on brain tissue sections from P40 twitcher mice, a time 
point with the highest MMP-3 expression. Immunoreactivity of MMP-3 in twitcher mouse 
brain at P40 was frequently co-localized with GFAP+ astrocytes (Figure 1B-D). Only a 
small portion of Iba-1+ microglia in twitcher mouse brain was co-localized with MMP-3 
immunostaining (data not shown). Although neurons have also been implicated as a 
source of MMP-3 in other neurodegenerative disease models (Kim et al., 2005), our data 
support glia as a prominent source of MMP-3 production in GLD.  
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Figure 3-1 Elevated astrocytic MMP-3 expression in twitcher mouse brain. (A) 
MMP-3 expression level in the brain of wildtype (WT) and twitcher (TWI) mice at various 
ages was quantified by qRT-PCR. (B-D) MMP-3 protein expression (red) was visualized 
by immunohistochemistry from the brain section of P30 twitcher mouse. Note that MMP-3 
immunoreactivity is co-localized (white arrows) with the astrocyte-specific marker, glial 
fibrillary acidic protein (GFAP; green). Data represent mean ± SEM. N=3/age/genotype, 
scale bar = 50µm 
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III-4.2 Psychosine regulates MMP-3 expression from glia, but not peripheral 
immune cells.   
The increase of MMP-3 in twitcher mice and its correlation with disease 
progression prompted us to examine if psychosine is a regulator of this response. To test 
this, mouse primary mixed glial cultures were treated with psychosine (10µM) at a dose 
previously reported to activate a macrophage cell line (Im et al., 2001). qRT-PCR analysis 
of RNA isolated from cultures treated with psychosine for 2, 4 or 20 hours determined that 
there was a time-dependent increase of mmp-3 mRNA expression (Figure 3-2, ANOVA, 
**P<0.01, ***P<0.001). In a second set of experiments, we tested whether the level of 
mmp-3 expression induced by psychosine was concentration-dependent. Psychosine 
concentration less than 10µM did not influence glial cells with respect to MMP-3 
transcription (data not shown). Additionally, analysis of increasing concentrations of 
psychosine (10-100µM) did not uncover a further enhancement of mmp-3 expression 
above that observed with 10µM (data not shown). At the highest concentration of 
psychosine tested (100 µM) we observed significant cytotoxicity in the glial cultures (data 
not shown). Hence, we determined that psychosine transcriptionally induced mmp-3 
expression in primary cultured glia.  
 In a previous study, we determined that MMP-3 is predominantly expressed by 
astrocytes in response to inflammatory stimuli (Crocker et al., 2006). To determine 
whether psychosine-induced mmp-3 expression in glial cultures was derived from 
astrocytes or microglia, or both, we next examined the cellular source of increased 
mmp-3 mRNA expression. Mixed glial cultures, enriched astrocyte cultures, or purified 
microglial cultures were treated with psychosine (10 #M) for 20 hours, and the level of 
mmp-3 mRNA expression was analyzed using qRT-PCR.  
 
 
 
67 
 
 
 
 
 
 
 
 
 
Figure 3-2 Psychosine transcriptionally regulates MMP-3 expression in primary 
glial cultures. Primary mixed glial cultures from wildtype mouse were treated with 
psychosine (10µM) for 2, 4, 24hrs and MMP-3 mRNA expression level was quantified by 
qRT-PCR. Data represent mean ± SEM. N=3-4/treatment/timepoint. ** P<0.01, *** 
P<0.001 
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In our mixed glial cultures, which we have previously characterized, are comprised of 
approximately 95% astrocytes and 5% microglia at 25 days in vitro (Crocker et al., 2006, 
Milner and Campbell, 2002), can be grown and then mechanically sorted to enrich for 
astrocytes and separate purified microglial populations. Importantly, these culture 
conditions are not conducive to oligodendrocyte progenitor cell growth or maturation. 
Psychosine treatment of enriched astrocyte cultures significantly increased mmp-3 
mRNA expression compared to untreated enriched astrocyte cultures (p<0.01, 
psychosine vs. untreated in mixed glia; p<0.05, psychosine vs. enriched astrocytes; 
Figure 3-3a). However, application of psychosine to purified microglial cultures did not 
significantly increase mmp-3 expression when compared with either untreated purified 
microglia cultures or untreated mixed glial cultures (t-test, p=0.247; Figure 3-3c). These 
results indicated that astrocytes were the primary source of mmp-3 expression in our 
cultures.  
 Because macrophages infiltrate the CNS during GLD, and macrophages have 
been implied in the formation of globoid cells in this disease, we next sought to determine 
whether peripheral immune cells, including macrophages specifically, could be induced to 
express MMP-3 in response to psychosine. Whereas psychosine treatment in primary 
purified microglial cultures moderately induced MMP-3 expression, treatment of 
peripheral blood or purified macrophages with equivalent concentrations of psychosine 
did not induce MMP-3 expression (Figure 3-3 b,d,f,h). qRT-PCR analysis of mmp-3 
mRNA expression also revealed that LPS did not induce mmp-3 mRNA expression in 
peripheral blood samples (Figure 3-3e). Since whole blood contains a myriad of cell types 
that may also regulate macrophage responsiveness, and peripheral blood samples 
contain only a small population of macrophages, we also isolated unstimulated peritoneal 
macrophages and challenged these purified cells with either psychosine or LPS. Flow 
cytometry determined that the proportion of macrophages in our preparations from 
peritoneal cavity were over 95% (Figure 3-4).  
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Figure 3-3 Psychosine regulates MMP-3 expression differently in CNS microglia 
and peripheral blood cells/macrophages. Mixed glial culture, purified microglia, whole 
blood white cells, and peritoneal macrophages were treated with psychosine (10µM) or 
LPS (10µg/mL) for 4hrs, and MMP-3 mRNA expression level was analyzed by qRT-PCR 
(a,c,e,g). Also, to ensure the cellular responsiveness to stimulus, TNF mRNA expression 
level was also quantified (b,d,f,h). Note that CNS cells with psychosine treatment had 
increased MMP-3 expression (a,c), but not peripheral cells (e,g), although peripheral cells 
had increased TNF expression in response to LPS (f,h). N=3-4/treatment/cell type. Data 
represent mean ± SEM. *P<0.05, **P<0.01 
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Figure 3-4 Differential adherence highly enriches macrophages from peritoneal 
exudates. Isolated macrophages from peritoneal cavity of adult wildtype mice were 
adhered on plates overnight and yielded higher number of macrophages, determined by 
flow cytometry. CD11b+ cells within the CD45+ live cell population (blue) were >97% in 
adherent cell samples. CD11b positivity was determined by the negative control of mouse 
blood cell sample (red). 
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Treatment of purified peritoneal macrophages for 4 hours with either psychosine or LPS 
revealed that neither psychosine nor LPS induced mmp-3 expression in peritoneal 
macrophages (Figure 3-3g). 
However, analysis of tumor necrosis factor (TNF) expression in these same 
culture preparations determined that TNF expression was robustly induced by LPS 
(Figure 3-3h; ANOVA, P<0.05), suggesting that the peritoneal macrophages were healthy 
and capable of responding to stimulation. These results indicate that microglia and 
peripheral macrophage populations markedly differ in their responses to psychosine and 
regulation of mmp-3 expression. 
 
III-4.3 Psychosine induces 'globoid'-like cells in primary glial cultures.  
A hallmark pathology of GLD is the formation of globoid cells. Based on our 
finding that psychosine regulated MMP-3, an extracellular activator of microglia (Kim and 
Hwang, 2011), and previous work by Im and colleagues reported the development of 
multinucleated cells following psychosine treatment of BV2 and HEK293 cell lines (Im et 
al., 2001), we hypothesized that psychosine may induce a globoid-like phenotype in 
primary cultured glia. We next treated primary mixed glial cultures with 10µM psychosine 
for seven consecutive days. Cultures were then analyzed by immunostaining for the 
microglial marker, Iba-1, the astrocyte marker, GFAP, and nuclear counterstain with DAPI. 
Control, untreated mixed glial cultures exhibited Iba-1+ cells with short-branched 
morphology that is typical of cultured microglia (Figure 3-5A). In contrast, Iba-1+ glia 
exposed to psychosine exhibited an amoeboid-shaped phenotype, which was frequently 
multinucleated (Figure 3-5C). These enlarged multinucleated cells resembled what would 
be referred to as 'globoid' cells in the CNS pathology of GLD specimens. Indeed, the 
number of polynucleated Iba1+ cells in psychosine-treated cultures was increased 5.5 
fold compared to control conditions (p<0.001; Figure 3-5 C&D). 
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Figure 3-5 Psychosine induces globoid cell formation in a primary mixed glial 
culture.  (A-D) Addition of psychosine (10µM) for 7 days significantly increases numbers 
of Iba-1+ (green) multi-nucleated globoid cells compared to both controls [No treatment 
(No/T)] and vehicle in a primary mixed glial culture. Data represent mean ± SEM. 
***p<0.001 relative to No/T. Scale bar= 20µm. 
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III-4.4 Psychosine does not induce globoid-like cells in MMP-3KO glia.  
To determine whether MMP-3 specifically was the mediator of globoid cell 
formation in response to psychosine treatment, we prepared primary mixed glial cultures 
from MMP-3 knockout (KO) mice in addition to wildtype littermates, and applied 
psychosine (10µM) for 7 consecutive days, as outlined above. In MMP-3 KO cultures, 
psychosine did not induce mmp-3 expression, as we expected (data not shown). 
Moreover, globoid cells were not induced in MMP-3KO cultures by psychosine treatment 
(Figure 3-6C,D), but were readily and robustly produced in wildtype cultures (Figure 3-5). 
Microglial morphology in psychosine-treated MMP-3KO cultures was similar to untreated 
cultures (Figure 3-6A,C). Thus, genetic ablation of MMP-3 prevented psychosine-induced 
globoid cell formation in vitro, suggesting that MMP-3 is required for psychosine-induced 
globoid cell formation. 
 
III-4.5 Globoid cell formation in primary glial cultures is blocked by chemical 
inhibition of MMPs.  
To determine whether increased expression of MMP-3 in response to 
psychosine exposure was directly related to the morphological transformation of 
microglia, we treated primary mixed glial cells with the broad-spectrum MMP inhibitor, 
GM6001, in conjunction with psychosine treatment for seven days. Microglial morphology 
was examined using immunostaining with Iba-1 as a microglial marker. Psychosine 
treatment in mixed glial culture induced the morphological change of Iba-1+ cells toward 
globoid-like cells (Figure 3-7B,J). However, this morphological alteration in microglia was 
hampered when an MMP inhibitor was concomitantly added in the treatment (Figure 3-7C, 
J). Next, we sought to determine whether morphological alterations in Iba-1+ microglia 
induced by psychosine were also associated with functional changes in phagocytosis.  
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Figure 3-6 Psychosine-induced “globoid-like cell” formation in vitro requires 
MMP-3. Primary mixed glial cultures were prepared from MMP-3 KO and WT littermates 
and then treated with psychosine (10µM) for 7 days. ICC was performed using Iba-1 
antibody (green) and DAPI (blue) and the number of multi-nucleated microglia were 
quantified. The numbers of Iba-1+ cells did not differ between untreated wt of KO cultures. 
The prevalence of globoid-like cells observed in wt cultures treated with psychosine was 
elevated 6 fold over vehicle treatment (A-D) but were absent from the MMP-3 KO cultures 
(D). Data represent n=8/treatment; **, P<0.01, t-test vs. WT. Scale bar = 20µm.   
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Figure 3-7 Metalloproteinase inhibition impairs psychosine-induced globoid cell 
formation and phagocytic activity of microglia. (A-C) Following a 7d treatment with 
psychosine (10µM), the presence of Iba-1+ globoid cells (green; nuclei-blue) were 
significantly increased (A) compared to control (B), while this effect was reversed with the 
addition of a pan-MMP inhibitor (MMPi; GM6001, 12.5µM) (C,J). Panel B demonstrates 
the large amoeboid shape of Iba-1+ cells treated with psychosine, which was reversed 
with the MMPi. (D-F) Primary mixed glial cultures (Iba-1+ cells-red; FITC+ beads-green; 
nuclei-blue) incubated for last 48hrs of 7d psychosine treatment with latex FITC-labeled 
beads (white arrows) demonstrates that psychosine treatment significantly increased the 
phagocytic activity Iba-1+ cells, which was also significantly decreased by addition of the 
MMPi (K). Primary mixed glial culture from wildtype mouse (G) was treated with 
psychosine (10µM) alone (H), or psychosine and NNGH (0.1µM) concomitantly (I) for 7d. 
Immunocytochemistry study revealed that psychosine induced Iba-1+ (green) globoid 
cells containing multiple nuclei (DAPI, blue) (H), but failed to induce globoid cells when 
NNGH was added together (I). Number of globoid cells was quantified (L). Data represent 
mean ± SEM. ***p<0.001, *p<0.05. Scale bar Top= 30µm; Middle=20µm; Bottom=18µm. 
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To test this, we cultured primary mixed glia, treated them with psychosine for seven days 
but applied fluorescent latex beads to the cultures for the last 48 hours of the experiment. 
Immunostaining for Iba-1+ cells that also contained fluorescent beads was quantified as 
a functional index of phagocytosis in response to psychosine (Figure 3-7D-F,K). 
Psychosine induced a four-fold increase in phagocytosis over basal levels observed in 
untreated, control cultures (ANOVA; p<0.0001). Treatment with the MMP inhibitor, 
GM6001, significantly reduced psychosine-induced phagocytosis (Figure 3-7F,K). These 
data indicate that psychosine-induced activation of microglia in culture was mediated by 
MMPs.  
 
III-4.6 Globoid cell formation in primary glial cultures is blocked by a peptide 
inhibitor of MMP-3.   
Because GM6001 is a non-selective, broad spectrum MMP inhibitor, we wanted 
to ascertain whether selective inhibition of MMP-3 may also attenuate globoid cell 
formation in primary cultures treated with psychosine. To test this, we used the small 
peptide NNGH (Ki=130nM for MMP-3), which exhibits greater specificity for MMP-3 than 
other MMPs. Co-application of NNGH to psychosine-treated cultures resulted in a 
marked reduction in the number of globoid cells compared to cultures treated with 
psychosine alone (Figure 3-7G-I,L). Thus, inhibition of MMPs including specific inhibition 
of MMP-3 attenuated the transformation of primary microglia into the highly activated 
globoid-like cell type.  
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Figure 3-8 Increased mmp-3 mRNA expression in twitcher mouse brain is not 
attenuated by bone marrow transplantation. qRT-PCR was performed on cDNA 
derived from mRNA isolated from whole brain homogenates from P40-50 WT, untreated 
twitcher, and bone marrow transplanted (BMT)-twitcher mice. Data are presented as fold 
change of mmp-3 mRNA relative to the expression of GAPDH within each sample 
(N=3-4/timepoint/genotype). Data represent mean ± SEM.  
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III-4.7 Bone marrow transplantation does not dampen elevated MMP-3 levels in 
twitcher mice. 
Currently, the only treatment option for GLD cases is bone marrow 
transplantation (BMT) (Krivit et al., 1998). Recent clinical follow-up studies have 
determined that although BMT for GLD can alleviate symptoms, it does not prevent 
disease progression and eventually most patients succumb to ongoing progressive 
deterioration (Duffner et al., 2009). The clinical benefit of BMT is also observed in twitcher 
mice (Luzi et al., 2009, Yeager et al., 1984). Indeed, analysis of glial pathology in twitcher 
mice following BMT has reported reduced microgliosis and enhanced numbers of foamy 
macrophages that correlated with improved clinical outcome (Hoogerbrugge et al., 1988). 
We hypothesized that BMT may dampen the elevated mmp-3 expression within the CNS 
in GLD and this may be a contributing factor to the therapeutic benefit of BMT. To 
determine whether elevated mmp-3 expression in the twitcher CNS was affected by BMT, 
we next examined mmp-3 mRNA expression in twitcher mice that received BMT in the 
early postnatal period. A detailed characterization of these transplanted mice has been 
reported (Galbiati et al., 2009). Consistent with our previous analyses, symptomatic 
twitcher mice exhibited higher levels of mmp-3 mRNA than wildtype (control) mice (Figure 
3-8). However, expression of mmp-3 among twitcher mice that had received BMT, 
although exhibiting more inter-subject variability (range: 1.5 - 21 fold over wildtype) did 
not differ from non-BMT treated twitcher mice (Figure 3-8). Hence, the sustained 
expression of mmp-3 in BMT-recipient twitcher mice may reflect a persistent disease 
process within the CNS that is not ameliorated by BMT. 
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III-5 Discussion  
In this study we have determined that psychosine regulates expression of MMP-3, 
which mediates the activation and proliferation of microglia toward a multi-nucleated 
globoid cell phenotype. Psychosine-induced increase in phagocytic activity and globoid 
cell formation were prevented by inhibition of MMP-3. Elevated MMP-3 expression was 
also identified in twitcher mice, an authentic animal model of GLD, and this elevation was 
not reversed by BMT. Hence, elevated MMP-3 expression in GLD may represent an 
important mediator of microglial activation in GLD.  
The roles of microglia and macrophages in GLD are not currently well defined. 
Evidence for beneficial and detrimental functions for both of these phagocytic populations 
in GLD and twitcher mice have been provided in several previous studies by others 
(Kagitani-Shimono et al., 2005, Kondo et al., 2011, Matsushima et al., 1994). We 
hypothesize that sustained induction of MMP-3 by accumulated psychosine in the CNS of 
individuals with GLD promotes microglial activation and globoid cell formation, but not 
macrophage activation, which may promote myelin degeneration through the robust 
phagocytic activity of these microglia-derived cells. Our in vitro experiments would 
indicate that macrophages and microglia are functionally distinct cell types that respond 
in distinctly different ways to psychosine exposure. These results support an ontogenic 
separation of these related yet specialized phagocytic cell types (Ginhoux et al., 2010) 
and our findings provide a potentially unique distinction between microglia and 
macrophages in this disease through their differential propensity to be activated by 
psychosine.  
 While we hypothesize that the highly activated nature of globoid cells in vitro 
may reflect a pathogenic form of microglia that contribute to neuropathology in GLD, it is 
also plausible that highly activated phagocytes could represent an endogenous protective 
response to clear dead or dying cells to foster remyelination (Neumann et al., 2009). For 
instance, remyelination in a chemical lesion model of focal demyelination is impaired 
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when microglia/macrophages are inhibited (Kotter et al., 2005, Li et al., 2005). When 
interpreted in the context of our results, the highly activated microglia in response to 
psychosine could represent a mode of myelin debris clearance that would allow for 
removal of growth inhibiting molecules and promote oligodendrocyte progenitor cell 
proliferation and differentiation (Neumann et al., 2009). Although these previous studies 
were not examined in the context of the twitcher mouse brain, recent work by Kondo et al. 
describes a possible protective function of microglia/macrophages in GLD (Kondo et al., 
2011). Thus, it is plausible that psychosine-induced MMP-3-mediated microglial 
activation could be a robust but ultimately insufficient attempt to foster brain repair in the 
GLD CNS. 
Our results may also indicate that globoid cells in GLD may be exclusively derived 
from resident microglia and provides an explanation for why globoid cells are not 
observed in association with demyelinating peripheral neuropathy in GLD (Siddiqi et al., 
2006, Tanaka et al., 1988). Globoid cell formation in the CNS of human and animal GLD 
is traditionally believed as a secondary consequence followed by a primary 
oligodendrocyte death due to the accumulation of psychosine in oligodendrocytes 
(Takahashi and Suzuki, 1984). Our data demonstrate that microglia transformed toward a 
globoid cell-like morphology in response to psychosine treatment in vitro, however our 
glial culture systems used in this study did not contain oligodendrocytes. Moreover, 
microglial activation and globoid cell formation are effects of psychosine on microglia that 
can occur independently of oligodendrocytes in culture. Thus, based on these data, 
microglial activation and globoid cell formation in GLD, rather than being a secondary 
response to CNS demyelination, may instead be a primary response to psychosine. In 
fact, it was previously reported that globoid cells were observed prior to the onset of 
disease and/or demyelination (Martin et al., 1981).  
Overall, this work indicates that psychosine initiates changes in many cell types; 
including, microglia, astrocytes and oligodendrocytes. In this context, our globoid cell 
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assay using primary glial culture may be a practical model to test and understanding the 
pathological process of microglial activation by psychosine. For instance, identifying the 
proteolytic target(s) of MMP-3 on microglia may provide a novel strategy to better 
understand the specific actions of activated microglia and/or formation of globoid cells in 
GLD. While the pathogenic contribution of microglia can only be inferred from previous 
work, the contribution of MMP-3 toward GLD pathology was not directly addressed in this 
study. Future studies will be required to examine the specific contribution of MMP-3 in 
GLD neuropathology and elucidate whether this process impacts microglial activation, 
inflammatory profiles and globoid cell formation in vivo.  
The proteolytic actions of MMPs are regulated by the tissue inhibitors of 
metalloproteinases (TIMPs) (Crocker et al., 2004). In a course of disease in twitcher mice, 
we examined the expression of TIMP-1, a timp gene that is robustly expressed during 
CNS demyelination that is also well-characterized endogenous inhibitor of MMP-3 
(Gomis-Ruth et al., 1997). Our qRT-PCR analysis determined that expression of TIMP-1 
increased only modestly over the same time frame relative to the robust increase in 
MMP-3 expression (data not shown). Moreover, expression of MMP-2 and -9 in the CNS 
of twitcher mice did not differ from the levels of expression in wildtype littermates 
throughout their postnatal development (data not shown). Hence, in the CNS of twitcher 
mice there is a dysregulation of certain MMPs, namely MMP-3, during the course of 
disease. Elevated expression of MMP-3 has been reported in a variety of CNS white 
matter disorders including multiple sclerosis and experimental models of spontaneous 
demyelination (D'Souza et al., 2002, Pagenstecher et al., 1998, Toft-Hansen et al., 2004). 
On the basis of previous studies, pathological actions of elevated MMP-3 expression in 
GLD could contribute to GLD pathology in two ways. First, we have shown that MMP-3 is 
important for the phenotypic activation of microglia (Kim et al., 2005), as we have also 
demonstrated in response to psychosine. Secondly, previous studies have shown that 
many myelin proteins are proteolytic targets of MMPs (Chandler et al., 1996, Milward et 
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al., 2008), including MMP-3 (Shiryaev et al., 2009). Hence, elevated MMP-3 production in 
the CNS of twitcher mice may contribute to destabilization of CNS myelin and 
oligodendrocyte death as well. 
Currently, the primary therapy for GLD patients is BMT. The effectiveness of this 
stem cell-based therapy in GLD has been reported to be highly variable among human 
cases with limited long-term benefit for some patients (Duffner et al., 2009, 
Hoogerbrugge et al., 1988, Kobayashi et al., 1988). Among twitcher mice, BMT increases 
lifespan and improves neuropathology but these mice still die prematurely 
(Hoogerbrugge et al., 1988, Yagi et al., 2005, Yeager et al., 1984). Previous discussions 
on the limited efficacy of the stem cell transplantation in GLD have indicated that 
microglial activity in twitcher mice remains high, even after neural stem cell 
transplantation (Pellegatta et al., 2006). Our data in this study may shed light on this 
pathology, namely that elevated MMP-3 expression in the CNS of twitcher mice was 
unaltered by BMT, although there is a possibility of delayed induction in MMP-3 
expression by BMT. Thus, sustained induction of MMP-3 may represent an inherent 
limitation of BMT treatment for GLD. Abrogation of microglial activation, perhaps through 
MMP-3-targeted strategies may be a mode for controlling microglial activation that could 
enhance the therapeutic efficacy of BMT in GLD. Hence, persistent expression of MMP-3 
in the GLD brain may represent a limitation of long-term prognosis for this treatment 
approach. In future, experiments designed to address the issue of the limited therapeutic 
window for BMT (Krivit et al., 1998) could potentially include adjunct MMP inhibiting 
therapy to address the excessive production of MMP-3 in the CNS compartment in this 
disease. Nevertheless, whether as a potential therapeutic target for GLD treatment, or as 
a source of basic understanding on MMP-3 regulation of microgliosis in GLD, additional 
study is expected to provide new information on the innate inflammatory response in GLD, 
how it may be regulated by MMP-3, as shown in this study, and potentially provide 
additional insights into MMP-3 in other diseases as well. 
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Formation of multinucleated giant cells are pathological hallmarks of many 
neurological diseases including amyotrophic lateral sclerosis (ALS) (Fendrick et al., 
2007), HIV encephalitis (Budka, 1986), Alzheimer's disease, acute disseminated 
encephalomyelitis, giant cell angiitis [associated with vasculitis in the CNS (Ciappetta et 
al. , 2010)], gliomas and neuroepithelial tumors (Adamek et al., 2008) and other 
leukodystrophies as well (Budka, 1986, Elleder, 1984). Among these other diseases in 
which giant multinucleated microglia are found, elevated expression of MMP-3 has been 
reported in Alzheimer’s disease (Yoshiyama et al., 2000). Although a pathological 
association between MMP-3 and formation of giant cells in these diseases has not been 
previously reported, our study would support this line of future investigation. Moreover, 
the mechanism by which multinucleated microglial cells are formed in response to 
psychosine, and mediated by MMP-3, may have an application toward the pathogenesis 
of these other neurodegenerative diseases. Future studies will explore the actions of 
MMP-3 on microglial cytokinesis, for instance (Kanazawa et al., 2000), in response to 
psychosine and other pathological stimuli that results in formation of multinucleated giant 
cells. The importance in pathogenic contribution of these multi-nucleated phagocytes 
toward neuropathology and disease progression will be required to fully understand the 
mechanism of these disease-associated changes in microglial phenotypes. 
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IV-1 Summary 
Globoid Cell Leukodystrophy (GLD), also known as Krabbe disease, is a rare 
and often fatal genetic demyelinating disease, for which there is no reliable or effective 
long-term treatment. GLD results from mutations in the galactocerebrosidase (galc) gene. 
Reduced or nullified GALC activity results in a pathological accumulation of 
galactosylsphingosine (psychosine) in GLD. The pathological impact of psychosine 
accumulation in GLD is likely manifold; dys/demyelination, lipid raft disruption, perturbed 
neuronal function, microglial activation and formation of globoid cells are all known 
consequences of psychosine toxicity. We recently reported that the extracellular protease, 
matrix metalloproteinase (MMP)-3, was specifically elevated in GLD and is a principal 
regulator of psychosine-induced microglial activation. Well-known substrates of MMP-3 
include many components of the extracellular matrix (ECM), which are increasingly 
recognized for their influence on glial responses in neurodegenerative diseases. Elevated 
production of MMP-3 and its plausible role in GLD led us to examine whether ECM 
components were altered in their expression in the CNS of GLD patients or its animal 
model, the twitcher mouse. Herein, we determined that the ECM glycoprotein tenascin-c 
(TnC) was expressed at significantly higher abundance in GLD than age-matched 
controls. TnC-positive immunostaining displayed a pattern of intensely labeled foci 
resembling plaques that were also frequently thioflavin-S positive. This unique pattern of 
TnC positive staining was evident in brain specimens from both human and the twitcher 
mouse model of GLD. Expression of other ECM components, including vitronectin, 
laminin, and fibronectin were unaltered in these tissues. We then examined the effect of 
TnC on glial function and found that formation of 'globoid-like' cells in psychosine-treated 
primary glial cultures grown on TnC was increased in association with dramatically higher 
MMP-3 mRNA expression. Co-culture of 'globoid-like' cells grown on a TnC substrate 
with primary oligodendrocyte cultures resulted in a marked increase in cytotoxicity when 
compared with cells grown on a laminin substrate. Microglia exposed to psychosine 
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grown on TnC also exhibited increased expression of M1 microglial phenotype markers, 
whereas without TnC exposure grown microglia exhibited predominantly M2 phenotype 
markers. Thus, we hypothesize that the elevated expression of TnC in GLD contributes to 
neuropathology in this disease, at least in part, through the modification of the microglial 
responses to psychosine. These data offer a novel perspective on the role of the ECM 
microenvironment in the pathology of GLD, and provide additional insight into our 
emerging understanding on the microglial contribution to the pathogenesis of this 
disease. 
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IV-2 Introduction 
Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a fatal 
demyelinating disease with an incidence of 1 in 100,000 in the United States (Duffner et 
al., 2009, Wenger et al., 2000). The cause of GLD is attributed to genetic loss-of-function 
mutations in the galactosylceramidase (GALC) gene (Zlotogora et al., 1990). The natural 
function of this lysosomal enzyme, GALC, is to hydrolyze galactolipids, including the toxic 
lipid galactosylsphingosine, ‘psychosine’.  Hydrolysis of psychosine is thought to prevent 
cellular damage (Svennerholm et al., 1980). Thus, its mutation in GLD results in 
supraphysiological accumulation of psychosine (Miyatake and Suzuki, 1972). It is widely 
accepted that abnormal accumulation of psychosine drives GLD pathology through its 
pathophysiological effects on multiple cell types (Miyatake and Suzuki, 1972). However, 
the exact mechanism of action of psychosine and the sequence of events that occur at 
the cellular level culminating in GLD pathology remain unclear.  
 The neuropathological hallmarks of GLD include severe demyelination of the 
central nervous system (CNS), extensive astrogliosis, and the presence of large, 
multinucleated phagocytes called ‘globoid cells’. It had been suggested that formation of 
globoid cells in GLD was a secondary response to profound CNS demyelination; however, 
we recently determined that globoid cells are likely a primary microglial response to 
psychosine (Ijichi et al., 2013). These data support an emerging hypothesis that 
psychosine induces widespread pathological changes in many cell types. Moreover, the 
response of microglia to psychosine provides a new model to study the unique formation 
and specific function(s) of globoid cells found within the CNS in GLD. 
 The extracellular matrix (ECM) is an intricate macromolecular network that 
occupies the extracellular space to provide a structural framework and homeostatic 
signaling environment for tissues. Differential production of ECM components has been 
reported in many CNS diseases, including Alzheimer’s disease (Morawski et al., 2012), 
stroke (Ji and Tsirka, 2012), human immunodeficiency virus encephalitis (Belichenko et 
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al., 1997), and multiple sclerosis (MS) (Bonneh-Barkay and Wiley, 2009). One widely 
studied implication of altered ECM composition includes dysregulation of cellular growth, 
differentiation and cell fate (Eyermann et al., 2012, Goetz et al., 2006, Lathia et al., 2007, 
Lei et al., 2012). For instance, in acutely demyelinated lesions in MS, tenascin-C (TnC) 
levels have been reported to be decreased relative to unlesioned or healthy tissues 
(Gutowski et al., 1999), whereas in chronically demyelinated lesions elevated production 
of TnC from astrocytes has been observed (Back et al., 2005, Gutowski et al., 1999). 
These changes in TnC levels associated with myelin lesions have lead to the suggestion 
that TnC may negatively influence the remyelinating potential of oligodendrocyte 
progenitor cells in and around myelin lesions (Back et al., 2005, Gutowski et al., 1999). 
Increased production of fibronectin in MS has also been reported to pathologically alter 
glial responses. Recently Stoffels et al. reported that astrocyte-derived fibronectin can 
prevent oligodendrocyte differentiation, therein contributing to the chronicity of 
demyelinated lesions in MS (Stoffels et al., 2013). In addition, excessive fibrillar collagen 
production around actively demyelinating lesions in MS has been suggested to impair the 
expression of potentially beneficial chemokines from infiltrating monocytes (Mohan et al., 
2010). Thus, changes in ECM composition are closely associated with the pathology of 
demyelination and may represent important mediators of disease-related cellular 
responses in CNS diseases.  
 The distribution and expression of ECM constituents are tightly regulated, not 
only at the transcriptional and translational level, but also through extracellular proteolysis 
by matrix metalloproteinases (MMPs). Most ECM components are enzymatic substrates 
of MMPs, and degradation of ECM by MMPs can have profound effects on cellular 
signaling (Rodriguez et al., 2010). We had previously determined that MMP-3 
(Stromelysin-1) was highly expressed in human and mouse GLD brain (Ijichi et al., 2013). 
We also determined that MMP-3 mediated psychosine-induced multinucleation of 
microglia with increased phagocytic activity (Ijichi et al., 2013). Since we have determined 
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that psychosine induced MMP-3-dependent formation of multi-nucleated microglia, or 
"globoid cells", this finding led us to hypothesize that changes in ECM may contribute to 
the neuropathology of microglia in GLD. Moreover, as the precise role of globoid cells in 
GLD is currently unclear, we also sought to determine whether 'globoid cells' had a direct 
effect on the survival of oligodendrocytes. In this study, we determined that expression of 
TnC was specifically elevated in GLD and it fostered the pathogenic transformation of 
microglia in response to psychosine by promoting their cytotoxic potential toward 
oligodendrocytes.  
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IV-3 Materials and Methods 
IV-3.1 Animals for primary cultures  
All procedures involving animals were conducted according to the approved 
procedures that comply with guidelines set forth by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Connecticut Health Center. 
 
IV-3.2 Mixed glial cultures  
Primary mixed glial cultures were established from postnatal day (P)0-3 pups of 
C57/BL6 wildtype mice, as previously described (Crocker et al., 2008, Ijichi et al. , 2013). 
Briefly, cortices were manually dissected in cold HBSS, followed by mechanical and 
enzymatic dissociation using a papain-based neural dissociation kit, per manufacture’s 
protocol (Miltenyi Biotec, Auburn, CA). Dissociated cells were plated in DMEM (Gibco, 
Carlsbad, CA) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 
penicillin (100U/mL, Sigma Aldrich, St Louis, MO) and streptomycin (100 mg/mL, Sigma 
Aldrich) in T175 culture flask (Grenier Bio-One, Germany). After 16 hrs, culture media 
was replaced with fresh media to remove non-adherent cells. Adhered cells were 
incubated in the flask at 37oC for 2 to 3 weeks until an astrocytic monolayer was 
established.  
 
IV-3.3 Primary microglial cultures  
Pure microglial cultures were established by detaching microglia from mixed 
glial cultures, as previously described (Ijichi et al., 2013, Welser-Alves et al., 2011). Briefly, 
established mixed glial cultures with 100% confluency were shaken by orbital shaker at 
110 rpm at 37oC for 4 hours to detach microglia from the astrocytic monolayer. 
Supernatants containing detached microglia were spun at 300 Xg for 10 min, followed by 
resuspension of the microglia in astrocyte-conditioned media, and then plated onto 
coverglass coated with either laminin (10 µg/ml, Sigma) or TnC (1 µg/ml, EMD Millipore) 
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or into 6-well UltraLow adherence culture plates (Corning, Tewksbury, MA). Cells were 
acclimated for 2-3 days prior to experiments. Chemical inhibitors used were: GM6001 
(12.5 µM, Calbiochem, Billerica, MA), NNGH (0.1 µM, Enzo Life Sciences, Farmingdale, 
NY), psychosine (10 µM, Sigma), and dimethylsulfoxide (0.13% "DMSO", Sigma Aldrich). 
 
IV-3.4 Primary oligodendrocyte cultures  
Pure oligodendrocytes cultures were established from postnatal (P)0-3 rat pups, 
as described previously (McCarthy and de Vellis, 1980) with modifications. Briefly, brains 
from rat pups were dissected out and meninges were removed. After removal of the 
cerebellum, the brain tissue was mechanically dissociated by mincing with scissors and 
passing through fire-polished Pasteur-pipet. The single cell suspension was then plated 
in T75 flask in maintenance medium composed of DMEM/F12 (Gibco), 10% FBS (Atlanta 
Biologicals), penicillin (100 U/mL, Sigma Aldrich), and streptomycin (100 mg/mL, Sigma 
Aldrich). Cells were incubated at 37oC for 3 weeks or until monolayer was formed. 
Cultures were shaken for 30 min at 37oC at 55 rpm to remove microglia and large debris 
from monolayer. Oligodendrocyte progenitor cells (OPCs) were removed by shaking in an 
orbital shaker at 225 rpm at 37oC for 16 hrs. Medium containing detached cells was 
collected and centrifuged at 300 Xg for 10 min. Cells were resuspended in maintenance 
media and plated in Petri dish for 3 to 4 hours at 37oC to eliminate microglia by differential 
adhesion. Non-adhered cells were collected and plated on poly-ornithine (0.1% Sigma 
Aldrich)-coated coverglass, and incubated for 1 to 2 hrs at 37°C. Media was replaced with 
oligodendrocytes differentiation medium, composed of Neurobasal medium (Gibco), 
L-glutamine (1X, Life Technologies, Grand Island, NY), B-27 supplement (1X, Life 
Technologies), and Triiodothyronine (T3, 10 ng/mL, Sigma Aldrich).  
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IV-3.5 Co-cultures of microglia and oligodendrocytes  
Primary microglial cultures in 6-well UltraLow adherence culture plates and 
oligodendrocytes cultures on poly-ornithine-coated coverslips were established as 
described above. To induce globoid cells in microglia, psychosine, psychosine +TnC, or 
vehicle treatments were applied for consecutive 7 days; then treated microglia were 
collected by gentle pipetting to detach loosely adhered cells at the bottom of wells. 
Collected cells were spun at 300Xg for 10 min, and cells were carefully resuspended in 
oligodendrocytes differentiation media (see above). Number of microglia in single cell 
suspension was counted by hemacytometer and seeded at 0.5-1x105 cells/mL onto 
oligodendrocyte cultures, resulting in approximately 1:1-2 microglia/oligodendrocyte ratio. 
Co-cultures were incubated for 3 days, and media were collected for cytotoxicity assay 
(see below), and cells were fixed for immunocytochemistry (see below). 
 
IV-3.6 Primary neuronal cultures  
Primary cortical or hippocampal neuronal cultures were established from rat 
pups at P1 (Shan et al., 2003). Briefly, brains from rat neonates were dissected out and 
meninges were stripped off. Cortices and hippocampi were isolated in HBSS, followed by 
incubation for 15min at 37°C in trypsin (0.25%). Tissues settled at the bottom of conical 
tubes were washed with HBSS 3 times and triturated 10 times with a fire-polished 
Pasteur pipette in plating media (Neurobasal media with 10% FBS). Single cell 
suspensions were passed through a 70µm filter, and then plated on poly-L-lysine-coated 
plates. Media was replaced with maintaining media A (Neurobasal media, 2% B-27, 2% 
FBS, 0.5mM L-glutamine, 25µM L-glutamic acid, 1X antibiotic/antimycotic solution) 3 
hours after plating. Half of media in cultures was replaced with media B (Neurobasal 
media, 2% B-27, 0.5mM L-glutamine, 1X antibiotic/antimycotic solution) every 3-5 days. 
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IV-3.7 Human brain tissues  
Brain specimens from GLD and age-matched control patients (1-2 years old) 
were obtained from the National Institute of Child Health and Human Development 
(NICHD) Brain and Tissue Bank for Developmental Disorders (Baltimore, MD). Brain 
tissues were paraffin-embedded, cut into 15µm thick sections, and then processed for 
immunostaining (see IHC description, below).  
 
IV-3.8 Mouse brain tissues  
Twitcher mice were bred and housed at the Sanford-Burnham Institute (La Jolla, 
CA), at which the brain specimen from twitcher mice and age-matched littermate control 
mice were collected. Mice were deeply anesthetized in accordance with IACUC-approved 
protocols and transcardial perfusion with phosphate buffer saline (PBS) followed by 4% 
paraformaldehyde (PFA). Brain tissues were collected at the ages of P0, 10, 20, 31, 40, 
as previously described (Taylor et al., 2006). 
 
IV-3.9 Immunohistochemistry (IHC)  
Collected brain and spinal cord tissues were paraffin-embedded, and 15 µm 
sagittal sections were made, as described previously (Crocker et al., 2006, Moore et al., 
2011). Tissue sections were subjected to antigen retrieval using 95°C citric acid buffer 
(0.01 M, pH 6.0), followed by blocking non-specific binding site with 5% normal goat 
serum (NGS; Life Technologies) in PBS-T for 1 hr at room temperature. Sections were 
then incubated with primary antibodies against Tenascin-C (N-19, Santa Cruz 
Biotechnology, Dallas, Tx), Laminin ["-2 (6D580), Santa Cruz], Vitronectin [10/65/75 
(H-202), Santa Cruz], and Fibronectin (C-20, Santa Cruz), followed by PBS wash and 1 
hr incubation with Alexa® 594- or 488- conjugated secondary antibodies (Life 
Technologies) against appropriate species from which primary antibodies were raised. To 
identify nuclei, tissues were counter-stained with 4',6-diamidino-2-phenylindole (DAPI, 
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Life Technologies) and then coverslipped using Fluoromount-GTM (SouthBiotech, 
Birmingham, AL). Immunoreactivity was visualized and analyzed using 
computer-assisted image analysis software (Eclipse, Empix Imaging) on an Olympus 
IX71 microscope. Two to four different specimens were analyzed. 
 
IV-3-10 Thioflavin-s staining  
Following labeling of TnC using primary and secondary antibodies in IHC (see 
IHC section), tissues were then incubated with 0.1% thioflavin-s (Sigma Aldrich) in 
PBS:EtOH (1:1, v:v) for 5 min at room temperature. Tissues were then washed with 80% 
EtOH several times, rehydrated with PBS, and then analyzed. 
 
IV-3.11 Quantitative real-time polymerase chain reaction (q-RT-PCR)  
Total RNA was isolated from cultured cells as described previously (Ijichi et al., 
2013) and converted into complementary DNA (cDNA) via reverse transcription (iScript 
cDNA synthesis kit, BioRad, Hercules, MA), according to the manufacturer’s protocol. 
Synthesized cDNA samples were amplified for q-RT-PCR using primer pairs specific to 
mmp-3 and tenascin-c mRNA (Integrated DNA Technologies, Coralville, IA), as described 
previously (Chen et al., 2009), and SsoFastTMEvaGreen® Supermix (BioRad) according 
to the manufacturer’s protocol. Target cDNA were amplified and analyzed by a 
Mastercycler® ep realplex (Eppendorf, Hauppauge, NY). Primers for GAPDH were used 
to assess the general expression level of the housekeeping gene among samples. 
Relative expression of target RNA was calculated using the comparative cycle threshold 
analysis ($$CT), as previously described (Ijichi et al., 2013). 
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IV-3.12 Immunocytochemistry (ICC)  
Cells plated and grown on laminin-coated or poly-ornithin-coated glass 
coverslips were fixed using 4% PFA and processed for ICC using antibodies against Iba-1 
(Wako, Richmond, VA), CD11b (eBioscience, San Diego, CA), Olig2 (EMD Millipore), 
Myelin Basic Protein (MBP; aa82-87, EMD Millipore), CD206 (C-20, Santa Cruz), and 
major histocompatibility class II (MHCII; Y-Ae, Santa Cruz), following blocking by 5% 
NGS (Life Technologies), as previously described (Moore et al., 2011). Immunoreactivity 
was visualized using fluorescently conjugated secondary antisera against the species of 
the primary antibodies (Alexafluor" 488 or 594, Life Technologies). Positive 
immunostaining results were viewed and analyzed using computer-assisted image 
analysis software on an Olympus IX71 microscope. DAPI staining was used to label 
nuclei in order to determine cellular densities per field and perform multinucleated cell 
analyses, as previously described (Ijichi et al., 2013). Four to six visual fields containing 
50-70 DAPI+ nuclei were randomly chosen per coverslip and number of cells with single 
and/or multiple immunoreactivities were manually counted using ImageJ software (NIH). 
 
IV-3.13 Lactose dehydrogenase (LDH) assay  
Media from cell cultures were collected at the end of treatment time course. 
The level of LDH contained in collected media was measured using a commercial LDH 
assay kit, as per manufacture’s protocol (BioVision, Milpitas, CA).  
 
IV-3.14 Enzyme-linked immunosorbant assay (ELISA)  
Media were collected from cell cultures at the end of experiments. The level of 
tumor necrosis factor alpha (TNF") released into media was analyzed using a 
commercially available TNF" ELISA DuoSet kit per manufacture’s instructions (R&D, 
Minneapolis, MN). 
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IV-3.15 Statistical Analyses  
Data are presented in Mean +/- SEM. Statistical significance was tested by 
one-way analysis of variance (ANOVA) with Tukey’s post hoc analysis, or two-way 
ANOVA with Bonferroni’s post hoc test, using Prism software (Graphpad, San Diego, CA). 
For all comparisons, p<0.05 was considered statistically significant.  
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IV-4 Results 
IV-4.1 TnC expression is elevated in the GLD brain.  
The emerging significance of ECM molecules on glial cell functions led us to 
consider whether differential expression of ECM molecules occurred in GLD. To explore 
this idea, we performed IHC for four prominent ECM molecules; laminin (Lm), fibronectin, 
vitronectin, and TnC on brain tissue sections from human brain from validated GLD cases 
and age-matched control subjects. Expression of the ECM components, Lm, fibronectin, 
or vitronectin, revealed no significant differences between GLD and control brains in 
terms of their expression patterns or staining intensities (Fig. 4-1A). However, there were 
significant TnC-positive deposits in the brain of GLD patients compared to age-matched 
control subjects (Fig. 4-1A). Next, we examined whether TnC was a generalized feature 
of GLD brain pathology across species. To address this question, TnC immunoreactivity 
was analyzed in brain tissues from twitcher mice, an authentic mouse model of GLD 
(Duchen et al., 1980). Similar to the human GLD cases and control brains, there were no 
significant differences in staining for Lm, fibronectin, or vitronectin between the two 
genotypes. However, elevated TnC positive (TnC+) deposits were frequently observed in 
twitcher brains when compared to age-matched controls (Fig. 4-1B). Interestingly, the 
high TnC immunoreactivity in twitcher mouse was frequently observed in plaque-like 
patterns, resembling the staining observed in human GLD. This pattern also exhibited 
similarities to #-amyloid deposits observed in Alzheimer's disease; in fact, TnC+ plaques 
were frequently co-localized with thioflavin-s, a marker for amyloid fibrils [(Kelenyi, 1967), 
Fig. 1C]. Together, these data indicate that the intensity and pattern of TnC was altered in 
the CNS of GLD.  
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Figure 4-1 Tenascin-C is highly expressed in GLD. (A, B) Immunohistochemical 
analysis of the extracellular matrix (ECM) proteins laminin, fibronectin, vitronectin, and 
tenascin-C in the midbrain of human infantile GLD patients (A, bottom row), age-matched 
control human subjects (A, top row). Immunohistochemical analysis of ECM proteins in 
the midbrain of the P30 twitcher mouse model of GLD (B, bottom row), and age-matched 
littermate wildtype control mice (B, top row). Note that intense punctate pattern of 
tenascin-c immunoreactivity in human and murine GLD tissues when compared to control 
subjects. (C) Tenascin-C immunoreactivity co-localizes with Thioflavin-S positive staining 
in the hippocampus of P30 twitcher mouse brain as visualized by immunohistochemistry 
for Tenascin-C and thioflavin-s histological staining. Nuclei are stained with DAPI (blue). 
2-4 specimens were analyzed. Scale bar: A= 250µm, B= 150µm, C= 100µm. 
 103 
 
IV-4.2 TnC enhances glial responses to psychosine in vitro.  
ECM proteins have the potential to potently modulate glial functions. Based on the 
high expression of TnC in GLD brain, and previously reported effects of TnC on glia 
(Battisti et al., 1995, Nash et al., 2011, Smith and Hale, 1997), we next examined whether 
TnC influenced the microglial response to psychosine. We have previously reported that 
psychosine induced globoid cell formation in glial cultures (Ijichi et al., 2013). Using this in 
vitro model system, we prepared primary mixed glial cultures that were grown on either 
TnC or laminin (Fig. 4-2). Cultures were then exposed to psychosine (10 µM) for 7 
consecutive days. Immunocytochemical analyses indicated that globoid cells formed in 
response to psychosine when grown on either ECM substrate (Fig. 4-2A-D). However, in 
glial cultures grown on TnC, there were significantly more psychosine-induced globoid 
cells formed than in glial cultures grown on Lm (Fig. 4-2E). These data suggest that TnC 
enhanced globoid cell formation in response to psychosine in vitro.  
To address how TnC potentiated globoid cell formation, we examined MMP-3 
expression since we had previously determined that induction of globoid cells by 
psychosine required MMP-3 (Ijichi et al., 2013). To determine whether TnC modified 
psychosine-induced MMP-3 expression by glia, we grew mixed glial cultures on either 
TnC or Lm, and treated with psychosine for 4, 24 hours, or 3 days. We then quantified 
MMP-3 mRNA expression by qRT-PCR. At earlier time points, there was no significant 
difference in psychosine-induced MMP-3 expression on either substrate. However, 
MMP-3 mRNA expression by psychosine-treated glia on TnC reached a 92 fold change 
by day 3 of psychosine treatment when compared with controls (Fig. 4-3A). These data 
suggest that microglia grown on TnC exhibit a more robust transcriptional response to 
psychosine.  
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Figure 4-2 Tenascin-C promotes globoid cell formation. Primary glial cell cultures 
(mixture of astrocytes and microglia) grown either on laminin (A, B) or Tenascin-C (TnC; 
C, D) were treated with either vehicle (A, C) or psychosine (B, D) for 7 consecutive days. 
Cells were fixed and immunostained for the microglial marker, Iba-1 (green) and 
counter-stained with DAPI (blue; nuclei). 7-9 visual fields generally containing 50-70 total 
DAPI+ nuclei under 20X magnification were randomly chosen and numbers of 
multinucleated cells were manually counted. Psychosine treatment induced 
multinucleation of Iba-1+ cells regardless of ECM substrate although glia grown on TnC 
produced significantly more "globoid-like" cells when compared to laminin-grown cultures. 
(E). Scale bar= 20µm. Two-way ANOVA; ***, p<0.0001 with N=3/condition. Data are 
provided as mean+/-SEM.   
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Figure 4-3 MMP-3 mediates globoid cell formation in response to psychosine. (A) 
Primary glial cell cultures, which consisted of astrocytes and microglia exclusively, grown 
on either laminin- or TnC-coated plates were challenged with psychosine for 4, 24 hrs, or 
3 days. Total RNA were isolated, reverse-transcribed into cDNA, and MMP-3 mRNA 
expression was analyzed by qRT-PCR. Data represent mean+/-SEM of fold change 
normalized to laminin-treated 4hr samples. (B) Primary glial cultures grown on 
TnC-coated coverslips were treated with either psychosine (Psy; black bar), psychosine 
with the pan-MMP inhibitor, GM6001 (12.5 µM; gray bar) or the MMP-3 specific inhibitor, 
NNGH (0.1 µM; striped bar) for consecutive 7 days. Cells were fixed and immunostained 
for microglial marker, Iba-1 and DAPI for nuclei. 4-6 visual fields under 20X magnification 
were randomly chosen and the number of globoid cells was manually counted. The 
number of globoid cells was significantly decreased when GM6001 or NNGH was applied 
in culture in conjunction with psychosine treatment (Two-way ANOVA; interaction: ** 
p<0.0099; treatment: ***, p<0.0002). Data represent mean+/-SEM. N=3/condition. 
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We next tested whether the enhanced formation of globoid cells grown on TnC 
was also mediated by MMP-3. TnC-grown glial cultures were challenged with psychosine 
in combination with a pan-MMP inhibitor (GM6001), MMP-3-specific inhibitor (NNGH), or 
vehicle (DMSO) for 7 consecutive days. Immunocytochemical analysis determined that 
treatment with either GM6001 or NNGH significantly attenuated the psychosine-induced 
globoid cell formation in TnC-grown microglial cultures (Fig. 4-3B). These data confirmed 
that psychosine-induced globoid cell formation was mediated by MMP-3, but also 
revealed that this process was enhanced by recapitulating the ECM environment of the 
GLD brain (e.g. TnC).   
 
IV-4.3 TnC modifies microglial phenotype in response to psychosine.  
Globoid cells originate from microglia (Ijichi et al., 2013). Our previous study 
had determined that psychosine induced phagocytic activity of microglia, but we had not 
fully characterized the phenotype of these cells. Because microglia can have detrimental 
or beneficial effects, based on their phenotypes, known as M1 and M2, respectively 
(Chhor et al., 2013, Miron et al., 2013), we next determined the phenotypes of both 
mononuclear and polynucleated microglia following treatment with psychosine or 
psychosine and TnC. Microglial phenotypes were determined by ICC using expression of 
MHCII or CD206 on Iba-1+ microglia as indicators of the classic M1 and M2 phenotypes, 
respectively. Mononuclear Iba-1+/MHC+ microglia in co-culture showed relatively similar 
expression levels in all conditions (Fig. 4, A-E), whereas co-cultures with 
psychosine-treated microglia contained significantly more CD206+ mononuclear 
microglia (Fig. 4F). Interestingly, in co-cultures with psychosine- and TnC-treated 
microglia, the number of CD206+ mononuclear microglia was significantly decreased (Fig. 
4F). These data suggest that the presence of TnC during psychosine exposure switches 
the phenotype from beneficial to harmful in mononuclear microglia.  
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Figure 4-4 Tenascin-C changes M1/M2 phenotype in psychosine-treated 
microglia/globoid cells. Isolated microglial culture were treated with psychosine (+Psy 
microglia, black bar), psychosine + TnC (+Psy+TnC microglia, stripe bar), or vehicle 
(+Microglia, white bar) for 7 days, then co-cultured with oligodendrocytes for 3 days. 
(A-D) Cultures were fixed and expression of M1, M2 markers (MHCII, CD206, 
respectively; green) in mononuclear microglia (Iba-1, red) was visualized using 
immunocytochemistry. Pictures are representative images showing that +Psy microglia 
express MHCII (A) and CD206 (C), and +Psy+TnC treated microglia express MHCII (B) 
but not CD206 (D). (E, F) 4-6 visual fields containing 50-70 DAPI+ nuclei were randomly 
chosen and the number of mononuclear Iba-1+ cells was counted. Manual counting of 
Iba-1+ mononuclear cells revealed that microglia treated with Psy alone expressed 
higher proportion of CD206 when compared to psychosine-treated microglia grown on 
TnC or vehicle-treated microglia. Data represent percent of marker positive staining of 
total cell number/field. N=5-8. (G-J) Representative images of psychosine-induced 
polynucleated globoid cells (DAPI; blue/Iba-1; red) that expressed high CD206 (I; green) 
but low MHCII (G; green). In contrast multinucleated "globoid cells" grown on TnC 
expressed high MHCII (H) and low CD206 (J). (K, L) Manual counting of 
psychosine-induced "globoid cells" grown on TnC identified an increase in MHCII cell 
surface staining (K), while CD206 expression was significantly decreased (L), when 
compared with globoid cells induced by psychosine alone. Data represent Mean+/-SEM. 
F: one-way ANOVA; N=3-4/treatment where *** p<0.0001; and L: one-way ANOVA: **, 
p<0.0014; where * P<0.05, ** P<0.01, *** P<0.001 for intergroup comparisons. Scale bar 
=20µm. 
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We then analyzed the phenotype of the polynucleated microglia (globoid cells) 
induced by psychosine when grown either in the presence or absence of TnC (Fig. 
4-4G-J). The number of MHCII+ globoid cells in psychosine-treated microglia grown on 
TnC was slightly higher than those in microglia grown without TnC, albeit without a 
statistically significant difference (Fig. 4-4K). Conversely, the number of CD206+ 'globoid 
cells' from psychosine treated microglia was significantly greater than those from 
psychosine-treated microglia exposed to TnC (Fig. 4-4L). These data provide support for 
a distinct M1-microglial phenotype of microglia in response to psychosine when grown on 
TnC, whereas microglia without TnC tended to exhibit an M2 phenotype. We reasoned 
that this difference in M1/M2 phenotype marker expression may reflect an important 
functional difference of GCs with respect to their potential role in demyelination in GLD. 
 
IV-4.4 TnC determines the cytotoxicity of globoid cells for oligodendrocytes.  
We had previously reported that when microglia were treated with psychosine in 
vitro they transformed into large, highly-phagocytic multinucleated cells (Ijichi et al., 2013). 
Also, globoid cells in the brains of human GLD, twitcher mice, or other animal models of 
GALC deficiency have often been found close to myelin lesion sites and to contain 
tubulous myelin debris (Figols et al., 1992). Thus, we hypothesized that globoid cells 
phagocytize myelin and possibly accelerate disease process(es) of GLD by promoting 
demyelination and oligodendrocyte death. To test this hypothesis, isolated microglia were 
grown on low adherence plates either with or without TnC and then treated with 
psychosine (10 µM) or vehicle. Microglia were then detached, collected and co-cultured 
with primary oligodendrocyte cultures. The impact of psychosine-induced activation of 
microglia grown on TnC was then assessed by lactate dehydrogenase (LDH) assay for 
cell death. Psychosine-treated microglia exhibited less cytotoxicity to oligodendrocytes 
than observed in control-treated microglia (Fig. 4-5A). In contrast, psychosine-treated 
microglia grown on TnC evoked a 2.9 fold increase in cytotoxicity to oligodendrocytes 
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over psychosine-treated microglia without TnC, or compared with control microglia (Fig. 
4-5A).  
We measured TNF$ production in these co-cultures by ELISA to determine 
whether psychosine modulated microglial production of TNF$. Microglia treated with 
psychosine exhibited a measurable reduction in TNF$ production (Fig. 4-5B). Overall, 
psychosine-treated microglia were significantly less cytotoxic to oligodendrocytes than 
non-treated microglia in co-culture, whereas psychosine-treated microglia grown on TnC 
displayed significantly greater toxicity to co-cultured oligodendrocytes and higher TNF" 
production. These data suggest that psychosine can promote a potentially pathogenic 
phenotype of microglia when in the presence of TnC. Also, these data suggest that 
psychosine reduced the native toxicity of microglia to oligodendrocytes, but that the local 
production of TnC in GLD overcomes and promotes psychosine-induced microglial 
cytotoxicity to oligodendrocytes, potentially through modulating TNF" production from 
microglia.  
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Figure 4-5 Globoid cells grown on TnC are toxic to oligodendrocytes. Isolated 
microglia treated with psychosine (+Psy), or grown on TnC and treated with psychosine 
(+Psy+TnC), or vehicle for 7 consecutive days, were then co-cultured with 
oligodendrocyte for 4 subsequent days. Oligodendrocyte cultures were about 50% MBP+ 
at the time of co-culture. (A) Analysis of cell death under each condition was measured by 
LDH assay. Cytotoxicity is expressed as percent of full kill control (0.1% sterile Triton 
X-100). Psychosine-induced globoid cells without TnC (black bar) had minimal toxicity in 
co-culture to oligodendrocytes when compared to untreated microglia (gray bar), 
whereas TnC-grown psychosine-treated microglia exhibited significant toxicity (striped 
bar). (B) Levels of TNF" released from isolated microglia treated with psychosine, 
TnC-grown microglia treated with psychosine, or vehicle control for 7 consecutive days 
were measured by ELISA. Note that psychosine-treated microglia (black bar) exhibited 
the least amount of TNF" release compared to untreated or TnC-exposed 
psychosine-treated microglia (gray, striped bar, respectively). One way ANOVA, p<0.001; 
where, * p<0.05; ** p<0.01; *** p<0.001. N=3/condition. 
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IV-5 Discussion 
In this study, we determined that TnC production was enhanced in twitcher mouse 
and human GLD brain samples. We determined that microglial responses to psychosine 
were enhanced by TnC, as measured by both increased MMP-3 expression and globoid 
cell formation in vitro. These data suggest that localized accumulation of TnC may have 
the potential to modify microglial responses to psychosine. The impact of this TnC 
modulation was revealed by our investigation on the cytotoxicity of globoid cells toward 
oligodendrocytes. We determined that globoid cells plated on TnC evoked a higher level 
of cell death in co-culture with oligodendrocytes than globoid cells without TnC. Strikingly, 
naïve microglia also showed significantly greater toxicity to oligodendrocytes than 
psychosine-treated microglia, which actually reduced the native toxicity of microglia 
toward oligodendrocytes. Together, these data suggest that by recapitulating the ECM 
microenvironment of GLD, we dramatically influenced the cellular phenotype of microglia, 
which may be an important consideration for modeling disease-like responses in cell 
culture systems. Moreover, these findings support a more prominent and primary function 
for microglia and globoid cells as putative direct inducers of myelin pathology in GLD. 
Maladaptive changes in ECM composition have gained increasing interest for 
their correlation and contribution to myelin pathologies. In this study, we determined that 
TnC was differentially expressed in GLD. Tenascin-C has many known functions in 
modulating cellular growth and maturation, and also the repulsion of cells via local 
detachment (Jones and Jones, 2000). We hypothesized that TnC would alter microglial 
responses to psychosine in accordance with these known functions, and determined that 
microglia grown on TnC elicited a more robust increase in psychosine-induced MMP-3 
expression and enhanced 'globoid-like' cell formation. In previous studies on traumatic 
brain injury and Alzheimer’s disease, TnC expression has been closely associated with 
both astrocytes and microglia (Dobbertin et al. , 2010, Nash et al., 2011, Smith and Hale, 
1997, Wiese et al., 2012, Xie et al., 2013). Astrocytes have been identified as the 
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common source of many ECM products including TnC and fibronectin. In our cell culture 
system, the level of TnC was applied as a substrate on which the glial cells were cultured 
since psychosine did not induce endogenous production of TnC from either the 
astrocytes or microglia (Figure 4-6A). Indeed, our immunohistochemical analyses in the 
twitcher brain revealed that TnC immunoreactivity did not always co-localized with 
intensely labeled GFAP positive astrocytes (Figure 4-6C). Neurons have been proposed 
to be a source of TnC in the CNS (Ferhat et al., 1996, Ferhat et al., 1996). Thus, we 
examined whether psychosine induced TnC expression in neurons, using primary 
neuronal culture. Here too, psychosine did not directly induce TnC expression in either 
hippocampal or cortical neuron cultures (Figure 4-6B). However, in the twitcher brain, 
TnC immunolabelling was co-localized with !-III tubulin positive neurons, suggesting a 
possible neuronal relationship with TnC (Figure 4-6D). Thus, data indicate that 
psychosine did not directly regulate TnC transcription by either non-myelinating glia or 
neurons. Together, these point to possible inflammatory regulation of TnC by factors, 
including TNF" and IL-1 (Nakoshi et al., 2008, Noda et al., 2000), which are greatly 
upregulated in GLD brains (Kondo et al., 2011). Nevertheless, heightened TnC levels in 
the CNS during this disease likely contribute to the sensitization of astrocytes and 
microglia to psychosine, as demonstrated by the enhanced production of MMP-3 and 
their toxicity to oligodendrocytes (Fig. 4-3).  
In our previous work, we reported that psychosine transforms microglia into the 
multinucleated phenotype with high phagocytic activity (Ijichi et al., 2013). In this study, 
we extended these previous findings to explore the potential effect of psychosine-induced 
globoid cells on oligodendrocytes. Interestingly, psychosine-induced globoid cells 
exhibited a predominant M2 phenotype with reduced cytotoxicity to oligodendrocytes, 
when compared to untreated microglia.  
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Figure 4-6 Psychosine does not directly regulate TnC expression in glial or 
neuronal cultures. (A) Mixed glial cultures grown on Laminin (Lm) or tenascin-c (TnC) 
and (B) hippocampal (HippoN) or cortical (Cort N) neuronal cultures grown poly-L-lysine 
were treated with psychosine (Psy) at (A)10uM 4hrs-7days or (B) 1 or 10uM 24hrs. Total 
RNA was isolated and reverse-transcribed in cDNA, and TnC expression level was 
analyzed using qRT-PCR. Note that in any of conditions, psychosine treatment did not 
induce TnC expression regardless of concentrations or treatment time in glial or neuronal 
cultures. Data represent Mean+/- SEM. N= 3-4/condition, except for cortical neuron 
conditions (mean of triplicates from N=1). (C, D) TnC protein (green) was visualized using 
immunohistochemistry along with cellular markers for astrocytes (GFAP, red, C) or 
neurons (!III-Tubulin, red, D) in the dentate gyrus of P30 twitcher mice. 3-4 different 
specimens were analyzed. Note that GFAP immunopositive staining did not co-localize 
with TnC immunoreactivity (C). Some TnC+ plaques are co-localized in !III-Tubulin+ 
neurons (arrowheads, D), but not all neurons are co-localized with TnC immunoreactivity. 
Data are representative images. Scale bar = 50µm.  
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This suggests that globoid cells may be benign or potentially beneficial in GLD. However, 
the effect of TnC on the microglial response to psychosine-induced globoid cells and this 
effect on oligodendrocyte co-culture system were dramatic with a shift toward an 
oligotoxic M1 phenotype. Our data also indicated that psychosine modulation of 
microglial function correlated with and may be mediated by the inflammatory cytokine, 
TNF". We hypothesize that TnC accumulation in GLD contributes to white matter 
pathology via altering the microglial response to psychosine-induce demyelination. This 
provides a new perspective on the role of globoid cells and the extracellular environment 
in GLD. The mechanism(s) by which the combination of TnC and psychosine promote 
microglial toxicity to oligodendrocytes is presently unclear. Previous studies in other 
disease models have shown that altered ECM, associated with neuropathology, can 
modify the production of growth factors such as cilliary neurotrophic factor, fibroblast 
growth factor, epidermal growth factor, and tumor growth factor (Dobbertin et al., 2010, 
Nash et al., 2011, Smith and Hale, 1997, Wiese et al., 2012, Xie et al., 2013). Future 
studies are warranted to better understand how TnC-modified microglia, in association 
with aberrant MMP-3 expression in GLD, contribute to the inflammatory environment of 
the CNS in this disease.  
 An important question stemming from this study is: how does TnC alter 
phenotype and response of microglia to psychosine? One possible mechanism is through 
differential expression of ECM receptors on these cells. Several integrins are thought to 
be TnC receptors, including $v, !1, and !2 families (Milner and Campbell, 2002). It was 
reported that TnC binds to "v!3, "v!6, "9!1, and "8!1, which are distinct from the 
integrin receptors for laminin, including "1!1 and "6!1 (Milner and Campbell, 2002). 
Thus, the presence of TnC may stimulate microglia to express more TnC receptors, from 
which downstream signaling may result in functionally different outcomes. Microglia have 
been reported to basally express integrins $v and #1 (Milner and Campbell, 2003). While 
altered integrin expression on microglia in GLD may result from psychosine levels in this 
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disease, the elevated cytokines produced in the CNS during GLD may also contribute to 
the activation of microglia (Kondo et al., 2011). In particular, the cytokines TGF#, TNF, 
and IL-1#, which are known to be elevated in GLD, have also been reported to induce a 
diversity of $ and # integrin expression on microglia (Milner and Campbell, 2003). 
Interestingly, the ECM composition itself can induce changes in microglial integrin 
expression (Milner and Campbell, 2003). Based on our findings in this report, further 
analysis of integrin expression on microglia and their role in mediating the cellular 
responses to psychosine in the presence of TnC would be expected to provide additional 
mechanistic insights into the pathological activation of microglia in GLD. 
 It is important to point out that TnC is a putative substrate of MMP-3. The 
concomitant increase of MMP-3 expression in GLD with the significant modulation of the 
microglial response to psychosine on TnC suggests several potentially important 
associations between TnC and MMP-3. For instance, we have determined that TnC 
dramatically increased mmp-3 mRNA expression in glia (Figure 4-2). Previous work by 
others has been implicated that MMP-3 enzymatically targets TnC and generates several 
cleaved TnC products (Imai et al., 1994, Siri et al., 1995). Although there is no study yet 
to show the binding capacity of cleaved TnC fragments or their signaling potentials, it is 
possible that fragmented TnC may bind to different integrins from ones for full-length TnC, 
or modulate signaling that results in microglial phenotypic changes. Future studies would 
be required to further elucidate the involvement of integrins and possible TnC proteolysis 
on cellular phenotype changes induced by TnC on microglia in response to psychosine. 
Globoid cells found in vivo frequently contain tubulous inclusions and myelin 
debris (Figols et al., 1992, Jesionek-Kupnicka et al., 1997), but their function in GLD had 
been undetermined. Our detailed in vitro analyses and modeling indicate that the local 
presence of TnC dramatically limits any potential beneficial function of globoid cells in 
GLD. Our study now reports that globoid cells behave differently depending on their local 
extracellular environment. Thus, GLD pathophysiology is likely a much more dynamic 
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process than previously recognized. Indeed, cord stem cell and bone marrow 
transplantations, while yielding encouraging but limited effectiveness, may be influenced 
by altered ECM constituents in GLD. In particular, TnC may be a limiting factor for current 
therapeutic strategies, as TnC-mediated effects on microglial cellular phenotype may 
also impact cellular phenotype of transplanted cells. As mentioned above, TnC has 
diverse functions on cellular growth/maturation and repulsion of cells (Jones and Jones, 
2000). At sites of myelin lesions in MS, increased levels of TnC may have a beneficial 
role to promote cell growth; yet it is possible that prolonged elevations of TnC may also 
prevent the migration of progenitor cells necessary for mediating repair (Frost et al., 1996, 
Garcion et al., 2001). It is worthwhile noting that TnC depositions in twitcher brain 
exhibited a unique pattern of patchy clusters in multiple brain regions (data not shown). 
Interestingly, some TnC+ clusters are positive for thioflavin-s, an amyloid marker (Smith 
et al., 2014). Additionally, neuronal source would be consistent with the co-localization of 
TnC foci that also stained for Thioflavin-s in the twitcher mouse brain. These findings are 
also in agreement with our recent report on the development of intraneuronal inclusions 
containing $-synuclein in GLD (Smith et al., 2014). Further analysis of GLD pathology is 
needed to improve our understanding of the cellular source of TnC in GLD, and to further 
characterize the composition of extracellular plaques characterized by TnC staining 
patterns in this disease. 
In summary, we have defined a primary pathogenic function for globoid cells in the 
pathophysiology of GLD. The importance of the ECM microenvironment in GLD was also 
highlighted by the enhanced transformation of microglia in response to psychosine when 
in the presence of TnC. Further detailed analyses on the temporal and spatial functions of 
TnC expression in the CNS are required to further elucidate the stage and full 
significance of TnC to GLD pathology. Future consideration for whether this process 
could be adopted to modify pathogenic microglial functions and how this understanding 
may be therapeutically applied in GLD is necessary.  
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V-1 Summary and Conclusions 
 Globoid cells are a hallmark of GLD pathology. Despite their uniqueness, their 
specific function and contribution to GLD pathogenesis has been largely overlooked. 
Globoid cells have been thought to be a secondary consequence of chronic 
demyelination. However, globoid cells can be observed prior to clinical disease onset and 
demyelination (Martin et al., 1981) (Table 5-1). Additionally, uncontrolled, aberrant 
microglial activity in GLD is thought to be a factor limiting the long-term efficacy of HSCT 
for treating this disease (Pellegatta et al., 2006). Thus, investigating possible functions of 
microglia and globoid cells was expected to provide new insights in the pathogenesis of 
GLD.  
Matrix metalloproteinases have been well characterized for their involvement in 
a variety of neurodegenerative and demyelinating diseases; however, a role for these 
proteases in a leukodystrophy had not been previously examined. We focused on MMP-3, 
because it has been identified as a potent activator of microglia in a model of Parkinson’s 
disease (Kim and Joh, 2006). Elevated MMP-3 has also been reported in multiple models 
of demyelinating and neurodegenerative diseases (D'Souza et al., 2002, Jalal et al., 2012, 
Kumnok et al., 2008, Rosenberg et al., 2001, Ulrich et al., 2006). Therefore, we 
hypothesized that there is a potential association between MMP-3 and microglia/globoid 
cells in the context of GLD pathology. Hence, the primary focus of this dissertation was to 
investigate the contribution of microglia and globoid cells to GLD pathogenesis and to 
examine the specific involvement of MMP-3 in the activation of microglia in GLD. 
 To this end, new models of globoid cell formation were developed to address 
our questions. Using these models, the contribution of MMP-3 to the formation of globoid 
cells (Chapter 3) and their function (Chapter 3 &4) was investigated. Also using this 
model system, the role of the extracellular matrix (ECM) in the function of 
GDL-associated microglia and globoid cells was determined.  
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Table 5-1 Temporal comparisons of GLD abnormalities in the twitcher mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References: 1) (Duchen et al., 1980), 2) (Pollanen and Brody, 1990), 3) (Nagara et al., 
1982), 4) (Takahashi and Suzuki, 1984), 5) (Taniike et al., 1999), 6) (Castelvetri et al., 
2011), 7) (Taniike and Suzuki, 1994), 8) (Ohno et al., 1993), 9) (Wu et al., 2000), 10) 
(Tanaka et al., 1988), 11) (Jacobs et al., 1982)  
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Our study is the first to demonstrate a role for MMPs in a leukodystrophy. Using 
brains from GALC-deficient mice (twitcher mice), we determined that the expression of 
MMP-3 gradually increased within the CNS of twitcher mice as their disease progressed 
(Figure 3-1). Surprisingly, levels of MMP-2 and -9 were not increased in the CNS of 
GLD-affected mice (Figure 5-1), despite their well-estabilshed association with CNS 
inflammation (Benesova et al., 2009, Crocker et al., 2006, Hernandez-Guillamon et al., 
2012). This suggests that the predominant MMP involved in the pathogensis of GLD is 
MMP-3.  
To further characterize this apparent association between MMP-3 and GLD, a 
novel model of globoid cell formation was developed. Globoid cells, the cell type 
pathognomonic to GLD, were produced by exposing mixed glial cultures to psychosine. 
This caused the microglia within the mixed glial cultures to transform into globoid-like 
cells, characterized by multinucleation and a rounded morphology (Figure 3-5). This 
phenomenon was consistent with two previous findings that demonstrated the ability of 
psychosine to transform other cell types into multinucleated cells (Im et al., 2001, 
Kanazawa et al., 2000). Moreover, the globoid-like cells produced from 
psychosine-exposed mixed glial cultures have a higher level of phagocytic activity as 
compared to naïve (non-psychosine exposed) microglia (Figure 3-7). These results 
complement previous reports describing that globoid cells found within the CNS of 
twitcher mice possess a high degree of phagocytic activity as they invariably contain high 
amounts of phagocytized materials (Itoh et al., 2002, Yunis and Lee, 1970).  
Using this new model of globoid-like cell formation, the contribution of MMP-3 
to globoid cell formation was investigated.  First, using a pan-MMP inhibitor (GM6001), it 
was demonstrated that psychosine-induced globoid cell formation was reduced, 
suggesting a role of MMP in their formation (Figure 3-7). Next, the specific role of MMP-3 
in globoid cell formation was investigated by using NNGH, a selective and potent inhibitor 
of MMP-3. Indeed, a significant reduction of globoid cell formation was noted suggesting 
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that the specific action of MMP-3 contribute to globoid cell formation (Figure 3-7). Finally, 
mixed glial cultures were derived from MMP-3 knock out mice. When exposed to 
psychosine, MMP-3 deficient cultures had lower levels of globoid cell formation as 
compared to wild-type cultures (Figure 3-6). Overall, these data strongly suggests that 
MMP-3 activity and globoid cell formation are linked.  
The second part of my thesis studies focused on the role of the ECM as a 
modulator of glial responses to psychosine. Cellular behaviors can be potently modulated 
by the local environment, which consists of various types of ECM (Bandtlow and 
Zimmermann, 2000, Franco and Muller, 2011, Liesi and Silver, 1988, Rogers et al., 1987, 
Welser-Alves et al., 2011). Also, this idea is supported by studies reporting that the 
composition of the ECM is altered in diseases such as multiple sclerosis (MS), 
Alzheimer’s disease, focal cortical dysplasia, tumor, and subarachnoid hemorrhage 
(Gutowski et al., 1999, Soares et al., 2012, Suzuki et al., 2010, Zamecnik et al., 2012, 
Zamecnik et al., 2004). Thus, to better model the cellular environment of the GLD brain in 
our culture systems, we began by investigating the ECM composition of twitcher mouse 
brain. Our examination revealed that Tenascin-C (TnC), among the four ECM 
constituents examined, was strongly expressed in twitcher brains, when compared with 
age-matched wild-type mice (Figure 4-1). To examine the effect of TnC on microglial 
responses to psychosine, glial cultures were established on TnC substrate, and then 
challenged by psychosine treatment. We determined that TnC increased 
psychosine-induced MMP-3 expression (Figure 4-3) and enhanced psychosine-induced 
globoid cell formation (Figure 4-2). Interestingly, exposure of glia to TnC during globoid 
cell induction by psychosine significantly altered the microglial phenotype, as measured 
by oligodendrocyte death in our co-culture system. Overall, this strongly suggests that 
TnC in GLD likely enhances microglial responses to psychosine and ultimately changes 
microglial functionality in GLD toward a pathogenic phenotype.  
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Figure 5-1 Expression levels of MMP-2 and -9 are not significantly elevated in the 
twitcher brains. mRNA expression levels of MMP-2 and -9 in the brains of twitcher mice 
(black bars) and age-matched wild-type controls (white bars) at P0 and P31 were 
analyzed by qRT-PCR. Neither MMP-2 nor MMP-9 levels were significantly increased 
compared to wild-type controls. Note that the increase of MMP-9 expression level in 
twitcher mice at P0 was not statistically significant (P=0.127). N=3/genotype/age. (Ijichi & 
Crocker, unpublished data) 
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In other neurodegenerative and demyelinating disorders, upregulation of TnC has been 
reported (Gutowski et al., 1999, Soares et al., 2012, Suzuki et al., 2010, Zamecnik et al., 
2012, Zamecnik et al., 2004); however, the factors governing TnC expression, as they 
contribute to pathogenesis of these diseases has not been fully elucidated. 
 
V-2 Discussion 
V-2.1 In Vivo vs. In Vitro Globoid Cells 
 Globoid cells are the hallmark feature of GLD pathology, although their role in 
GLD has long been ignored. Interestingly, these cells are among the earliest 
characteristic changes in CNS tissue of GLD (Table 5-1). This lack of knowledge may 
have been due to the assumption that the formation of multinucleated phagocytes, called 
giant cells in other diseases, are typically considered as a consequence of pathology 
rather than an initial pathogenic driving force (McNally and Anderson, 2011). Therefore, 
there have been few studies investigating the mechanism by which globoid cells are 
formed from phagocytes, particularly in the CNS of GLD. This dissertation focused on the 
importance of globoid cell formation in the CNS and demonstrated that 
psychosine-induced multinucleation of microglia in vitro exhibited higher levels of 
phagocytic activity (Chapter 3). Indeed, globoid cells in twitcher brains frequently contain 
PAS-positive debris, suggesting high levels of phagocytic activity. Globoid cells are also 
found to be immunopositive for ferritin (a microglia marker) (Kaneko et al., 1989), 
KP-1/CD68 (a monocyte marker), and some are also positive for vimentin (an 
intermediate filament protein and marker of astrocytes and activated microglia)(Graeber 
et al., 1988), HLA-DRa (an MHCII surface receptor), and TNF-" (Itoh et al., 2002), and 
Iba-1 (a calcium binding protein used to identify microglia) (Kondo et al., 2011). Based on 
the experiments in this dissertation, this collection of markers indicates that globoid cells 
originate from microglia that develop a unique phenotype.  
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 There are several features of globoid cells that differ between in vivo and in 
vitro. The average size of globoid cells found in human and murine GLD tissues range in 
size from approximately 50µm to 200µm in diameter (Duchen et al., 1980, Norman et al., 
1961). However, in vitro globoid cells induced experimentally have an average diameter 
of 15µm to 30µm (unpublished observation). In addition, one globoid cell in CNS tissue 
can contain up to 20 nuclei (Norman et al., 1961); however, we routinely observed about 
4 nuclei per globoid cell in vitro (Figure 3-5, 4-2). These differences between in vivo and 
in vitro globoid cells may be explained by the cellular environment of microglia. Our 
culture system significantly limits the available amount of secreted and cell-contacting 
factors, cell types, dimensional space and time; thus, these limitations may be factors 
underlying these discrepancies in size and complexity of in vivo versus in vitro globoid 
cells.  
In our studies, experimentally induced globoid cells were derived from wild-type 
microglia. Wild-type glial cells express endogenous GALC, unlike cells from twitcher mice, 
which lack functional GALC. Although exogenous psychosine application to wild-type 
microglial cultures did not induce GALC expression (Figure 5-2), normal endogenous 
GALC activity may have attenauted a more dramatic effect of psychosine on microglia. 
This point could be addressed by comparing the number of psychosine-induced globoid 
cells from microglia cultured from wildtype and twitcher mice. Analyses of size change, 
polynucleation, cellular complexities, and even functionalities would serve to address the 
question of whether globoid cell formation if further enhanced by the lack of GALC in the 
culture. Nonetheless, our newly developed model of globoid–like cell production provides 
a new system in which to study the process of globoid cell formation in GLD. 
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V-2.2 MMP-3 and Globoid Cells in the Peripheral Systems 
 Several studies have reported the presence of globoid cells in the PNS, but to a 
lesser extent than in the CNS (Kobayashi et al., 1985). Others reported no evidence of 
globoid cells in peripheral systems (Wenger et al., 1999). These differing reports may 
reflect the fact that there is currently no reliable means by which to distinguish between 
CNS microglia and peripheral macrophages. To address this concern, this dissertation 
studied the potential differences between microglia and macrophages with respect to 
GLD pathology. Isolated microglia from the brain and macrophages from the peritoneal 
cavity of wildtype mice allowed us to examine a possible difference between these types 
of cells with respect to their response to psychosine treatment in vitro. Our study 
demonstrated a clear difference in the response of microglia and macrophages to 
psychosine. Microglia, as mentioned above, responded to psychosine with increased 
MMP-3 expression and globoid cell formation, whereas macrophages exhibited no 
psychosine-induced MMP-3 expression (Chapter 3); although, both populations of cells 
responded robustly to LPS. Additionally, peripheral macrophages did not transform into 
any multinucleated cells in response to psychosine treatment (Figure 5-3). This cellular 
phenotypic difference was also supported by our observation that psychosine did not 
enhance phagocytic activity in macrophages (Figure 5-3). To further examine whether 
MMP-3 mRNA was upregulated in peripheral organs in GLD, as measured in CNS 
tissues (Figure 3-1), MMP-3 expression level was also investigated in the spleen of 
twitcher mice. Our qRT-PCR analysis determined that mRNA levels of MMP-3 did not 
differ, when compared to wildtype spleen tissue (Figure 5-4). These data suggest that: (1) 
microglia are the likely cell of origin for globoid cells in GLD; (2) MMP-3 is required for 
psychosine-induced microglial transformation into globoid cells in response to 
psychosine; and (3) macrophages and microglia are fundamentally distinct cell 
populations in terms of their response to psychosine in GLD. 
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Figure 5-2 Exogenous psychosine does not induce GALC expression in glial 
culture. Wildtype mixed glial cultures were treated with psychosine or vehicle for 2, 4, or 
20 hours and GALC expression levels were analyzed by qRT-PCR. Exogenous 
psychosine application does not induce GALC mRNA expression in mixed glial culture at 
any time point. (Ijichi & Crocker, unpublished data) 
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Figure 5-3 Psychosine does not induce globoid cell formation and phagocytic 
activity in peripheral macrophages. Peripheral macrophages isolated from peritoneal 
cavity of wildtype mice were plated and treated with psychosine for 24 hours. 
Macrophages were visualized and analyzed by immunocytochemistry using antibodies 
against CD11b (red) and DAPI (blue) for multinucleation. Phagocytic activity of 
macrophages was analyzed by FITC-labeled phagocytic bead (green) assay. Psychosine 
treatment does not increase the number of globoid cells or phagocytic activity in 
macrophages. N=3, 5 fields/conditions. Each field contains 50-70 DAPi+ nuclei. Scale 
bars= 20µm (top), 50µm (bottom). (Ijichi & Crocker, unpublished data) 
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Figure 5-4 Splenic tissue from twitcher mice does not have elevated MMP-3 
expression. Splenic tissue was isolated from twitcher mice (Twi), twitcher mice treated 
with bone marrow transplantation (BMT), and age-matched wildtype mice (WT), and 
mRNA levels of MMP-3 were analyzed using qRT-PCR. MMP-3 level was not increased 
in twitcher mice compared to wildtype. Note that BMT did not have an effect on MMP-3 
expression level in the twitcher mouse spleen. (Ijichi & Crocker, unpublished data) 
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The microglial origin of globoid cells is also supported by the observation that globoid 
cells are found in the CNS of both human and murine GLD prior to inflammation and 
macrophage infiltration (Table 5-1)(Martin et al., 1981). Overall, our data indicate that 
globoid cells originate from microglia, and thus, microglia play a prominent role in GLD 
pathology. 
 
V-2.3 Importance of ECM in Modeling Diseases 
 Cellular behavior is tightly regulated by the local microenvironment where cells 
reside. Thus, local ECM molecules can be important mediators of cellular responses to 
stimuli. Consistent with this, our study has demonstrated that TnC exerts a significant 
impact on microglia and globoid cell function in response to psychosine (Chapter 4). The 
enhanced expression of TnC in GLD led us to examine the effect of TnC on globoid cell 
formation and we determined that TnC potently induced globoid cell formation. TnC also 
enhanced cytotoxic effect of microglia toward oligodendrocytes in vitro (Figure 4-5), 
whereas globoid cells formed on laminin were only mildly toxic to oligodendrocytes 
(Figure 4-5). These results complement previous findings demonstrating that activated 
microglia had negative effects on oligodendrocyte survival and proliferation via 
mechanisms mediated by pro-inflammatory cytokines (Pasquini et al., 2007, Taylor et al., 
2010, Vartanian et al., 1995). Indeed, globoid cells in TnC-enriched cultures produced 
significantly higher TNF-" expression than those grown on a laminin substrate (Figure 
4-5). Levels of TNF-" released from microglia were also positively correlated with 
oligodendrocyte death (Figure 4-5). Overall, these data suggest that the local ECM 
microenvironment can markedly influence microglial functions in GLD.  
Our results signify an important role of ECM composition in culture systems 
when developing model for a disease. While pathological changes in secreted molecules, 
including cytokines, chemokines and transmitters, are often reported and given 
consideration in models, disease-specific ECM changes are often overlooked. As we 
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have demonstrated, ECM can be an important modulator of cellular response and 
function. We propose that it is important to carefully consider and attempt to mimic the 
ECM microenvironment in a disease-specific manner when investigating cellular 
responses under any pathological conditions.  
 
V-3 A Microglial Hypothesis of GLD pathogenesis: A working model and its future 
directions 
 Results from this dissertation provide new evidence suggesting that the 
activation of microglia leading to the formation of globoid cells is a primary event in GLD. 
We were also the first to demonstrate a function for globoid cells by determining that 
globoid cells can elicit cytotoxicity toward oligodendrocytes. These results suggest that 
globoid cells in GLD can contribute directly to oligodendrocyte death and demyelination in 
GLD. The psychosine hypothesis, originally described by Suzuki, proposed that GLD 
pathogenesis is a cell-autonomous process driven by an intracellular accumulation of 
psychosine within oligodendrocytes. However, many lines of evidence, from old and even 
more recent studies, support our findings that GLD pathogenesis is a complex, 
multifactorial process, wherein glial and neuronal abnormalities precede demyelination 
and oligodendrocyte loss (Table 5-1). In particular, globoid cells are first observed in the 
CNS of GLD before demyelination (Martin et al., 1981). From the results of this thesis, I 
now hypothesize that aberrant microglial activity and globoid cell formation are primary 
pathological events brought about directly in response to psychosine accumulation in 
GLD. We have named this the “microglial hypothesis” of GLD (Figure 5-5).  
 The results in these studies support our microglial hypothesis by implicating 
pathophysiological mechanisms of aberrant microglial activity in globoid cell formation 
and demonstrating their contribution to demyelination to GLD pathogenesis. Key 
elements of this mechanism include psychosine, microglia, globoid cells, MMP-3, and 
TnC.  
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Figure 5-5 Schematic flowchart of ‘conventional’ and ‘revised’ psychosine 
hypothesis. Schematic drawing illustrates that the conventional psychosine hypothesis 
(top) describes demyelination as a primary event and as an upstream event in GLD 
pathogenesis. Revised psychosine hypothesis (bottom) depicts that psychosine 
influences multiple cell types in the GLD brain and all contribute to demyelination. The 
pathway in which psychosine induces globoid cell formation, leading to demyelination is 
named “microglial hypothesis” (pink). Panels depicting demyelination and neuronal 
damage adapted from www.mayo.edu and www.nature.com, respectively. 
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In the following sections, I will discuss potential molecular mechanisms that could lead to 
future research directions that may provide futher understanding and insights for GLD 
pathogenesis, as outlined in this microglial hypothesis. 
 
V-3.1 Contributions of MMP-3 in GLD Pathogenesis In Vivo 
 In our in vitro system, microglia transformed into multinucleated globoid cells in 
response to psychosine. This phenomenon was blocked by either genetic ablation or 
pharmacological inhibition of MMP-3. However, the mixed glial cultures used in these 
studies were comprised of a limited number of cells, cell types, factors, time and space, 
which may have been insufficient to adequately model the CNS tissue environment in 
GLD. Nevertheless, our examinations of the effects of MMP-3 in GLD pathology provide a 
new avenue to investigate the etiology of this disease.  
One approach to further develop an understanding on the in vivo effect of 
MMP-3 in GLD would be to cross-breed twitcher mice (GALCtwi/twi) with MMP-3 KO mice 
(MMP-3-/-) to generate double-mutant mice. Progeny from these breedings would 
generate twitcher mice that congenitally lack MMP-3 (GALCtwi/twi, MMP-3-/-). As MMP-3 
would be absent throughout development in these double-mutant mice, the number of 
globoid cells during fetal and perinatal period would be expected to be significantly lower 
than MMP-3+/+ twitcher mice. This genetic approach to study MMP-3 in twitcher mice, 
using this cross-breeding strategy, would also allow us to determine whether MMP-3 
contributes to the limited lifespan of mice with GLD. Specifically, ablation of MMP-3 from 
both CNS and non-CNS organs, such as astrocytes, peripheral immune cells and the 
PNS, may reveal a novel global effect of MMP-3, related to improved survival and 
reduced pathology. We recognize that our current limitation is that MMP-3 is not an only 
factor driving the disease. In general, global MMP-3 KO mice also develop compensatory 
changes in gene expression. For this reason, we would ideally target ablation in a specific 
cell type, such as the astrocyte. However, any reduction in either pathology or symptoms 
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in double mutant mice would serve as evidence to support the idea that MMP-3 is an 
important mediator of GLD pathology.  
Another strategy to examine the effect of MMP-3 on GLD pathogenesis in vivo 
would be to administer a pharmacological inhibitor of MMP-3, such as NNGH, to twitcher 
mice. Administration of MMP-3 specific chemical inhibitors into twitcher mice would be 
expected to block MMP-3 and attenuate GLD pathology and disease course. Another 
advantage of this approach would be to test whether symptomatic mice could benefit 
from delayed treatments, modeling the clinical picture of this disease in human GLD. 
Experimentally, MMP-3 inhibitors could also be injected directly into the CNS 
parenchyma, to test whether brain levels of MMP-3 provide benefit. Currently, there are 
broad-spectrum MMP inhibitors, for example batimastat, which are known to cross the 
blood brain barrier (BBB) in animal models (Koutroulis et al., 2008, Mucha et al., 2007), 
which could also be utilized. These pharmacological approaches would provide direct 
translation to a potential clinical application and complement genetic approaches. 
Chemical inhibitors of MMP-3 in twitcher mice would also allow us to examine the efficacy 
of combined therapies, including MMP inhibition with HSCT, for instance. Overall, 
analyses on the effects of MMP-3 inhibition in in vivo models would provide us with more 
detailed insights into the contribution of MMP-3 in GLD pathogenesis, and support this 
approach for potential therapeutic applications to treat this fatal disease. Doxycycline 
hycate is a Food and Drug Administration (FDA)-approved MMP inhibitor that is readily 
used to treat periodontal diseases (Sundararaj et al., 2013) and crosses the BBB. Thus, 
MMP inhibition is a promising therapeutic approach to treat GLD. 
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Figure 5-6 Schematic flowchart of potential molecular mechanisms of MMP-3 
mediated globoid cell formation. Schematic drawing illustrates the potential molecular 
mechanisms by which MMP-3 regulates globoid cell formation; 1) proteolysis of 
substrates by MMP-3, 2) intracellular function of MMP-3, 3) proteolysis of TnC by MMP-3, 
and 4) induction of integrins. 
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V-3.2 Possible Mechanisms of MMP-3-mediated Globoid Cell Formation 
 One principal finding of our study was that MMP-3 mediates 
psychosine-induced globoid cell formation. However, the molecular mechanisms 
underlying how MMP-3 mediates microglial transformation to globoid cells remain elusive. 
MMP-3 enzymatically targets many proteins (Table 2-2). Because of the proteolytic 
nature of MMP-3, elevated expression and activity of MMP-3 by psychosine in GLD 
would be expected to cleave molecular substrate(s), which would then regulate many 
potential processes including multinucleation of microglia (Figure 5-6). Indeed, several 
MMP-3 substrates, including TNF-", MMP-9 and EGF, have been associated with a 
cytokinesis factor, CDK1, in hepatocytes (Serandour et al., 2005). Thus, globoid cell 
formation may be mediated by MMP-3 proteolysis. To investigate this possibility, a 
detailed proteomic profile of molecules expressed by microglia and/or produced during 
globoid cell formation in vitro may be warranted. This examination would be expected to 
reveal not only the MMP-3 substrates involved in the mechanism of globoid cell formation, 
but may also provide novel targets to study their roles in globoid cell formation and 
features. 
 Interestingly, a recent study by Eguchi et al. has suggested a novel intracellular 
function of MMP-3. Their study demonstrated that nuclear MMP-3 protein bound to the 
promoter enhancer sequences of connective tissue growth factor (CTGF) gene and 
activated CTGF transcription in chondrocytes (Eguchi et al., 2008). Thus, it is possible 
that intracellular MMP-3 in microglia may regulate transcription of target genes, which 
may contribute to the failure of cytokinesis, culminating in globoid cell formation 
(Kanazawa et al., 2000). Additionally, it has been proposed that MMP-3, when localized 
to the nucleus, may alter the nuclear matrix, thus potentially contributing to genetic or 
epigenetic defects in disease (Si-Tayeb et al., 2006). It is possible that multinucleation of 
microglia in response to psychosine may be due to an altered nuclear matrix resulting 
from increased intracellular MMP-3 activity (Figure 5-6). Together, increased MMP-3 in 
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GLD may have nuclear localization and intracellular or transcriptional effects that 
contribute to multinucleation of microglia in response to accumulated psychosine. To 
address this possibility, a detailed localization analysis of intracellular MMP-3 within 
microglia, in response to psychosine, would be essential. In addition, examination of the 
changes in the microglial nuclear matrix may also reveal a possible aberrant intracellular 
effect induced by psychosine. Furthermore, transcriptome analyses of 
psychosine-exposed microglia, and psychosine-induced globoid cells, may uncover a 
gene activation profile that could then be used to identify novel key mediators of 
microglial activation and pathology associated with GLD. Overall, examination of the 
molecular and genetic profiles within psychosine-treated microglial and globoid cells 
could provide new insight into GLD pathology. 
 
V-3.3 TnC Contributions to GLD Pathogenesis In Vivo 
 This dissertation identified that local aberrant production of TnC modulates the 
effects of psychosine on microglia in vitro (Chapter 4). Our in vitro studies indicate a need 
to explore the effects of TnC on microglia in GLD using animal models. The genetic 
crossing of twitcher mice (GALCtwi/twi) with TnC KO mice (TnC-/-) (Steindler et al., 1995) to 
produce a double-mutant mouse (GALCtwi/twi, TnC-/-) may be one approach to address this 
question. Cross-breeding of these two genetically modified mouse lines would generate 
not only targeted genotypic mice (double mutant; GALCtwi/twi, TnC-/-) but also various 
littermate controls, wildtype (GALC+/+, TnC+/+), twitcher mice (GALCtwi/twi, TnC+/+) and TnC 
KO mice (GALC+/+, TnC-/-), that would be necessary to properly evaluate the outcomes of 
survival, pathology and globoid cell formation. Genetic ablation of TnC in twitcher mice 
would be expected to determine the effects of TnC on global cellular pathology in GLD 
and an overall impact of TnC on GLD pathogenesis. Based on the data provided by our in 
vitro study, a double mutant mouse would be expected to develop fewer globoid cells and 
less M1 phenotype microglia; thus, less myelin pathology. These effects in double mutant 
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mice would also be expected to improve their mobility and may also significantly extend 
their lifespan. The effects of TnC in peripheral cell infiltration in GLD could also be tested 
by application of HSCT in double mutant mice. As increased TnC has been associated 
with vascular abnormality (Chinoy and Miller, 2006), peripheral cell trafficking in double 
mutant mice treated with HSCT would be less. It is important to note that TnC KO mice 
that lack TnC globally have been reported to develop minor behavioral abnormalities, 
when challenged (Kiernan et al., 1999). If the minor abnormalities associated with global 
TnC ablation significantly interfere with clinical phenotypes in double mutant mice, cell 
type-specific conditional TnC KO mice could be generated, and then crossed with 
twitcher mice. However, the cellular source of TnC in twitcher mouse brain would first 
need to be determined. For instance a cell-specific TnC knockout mice could also be 
produced using Cre-loxP technology. Using a yet to be developed TnC mouse line in 
which a critical regualtory or coding region of TnC is flanked by loxP sites would enable 
cell-specific deletion of TnC. Were these TnCfl/fl mice to then be crossed mice that 
express the Cre-recombinase driven by a cell-specific promoter, such as a GFAP-Cre line, 
the progeny would then have TnC specifically lost from their astrocytes (Garcia et al., 
2004). Cell-specific TnC KO mice could then be cross-bred with twitcher mice to generate 
a triple mutant line for detailed study. Overall, findings from these mutant mice would be 
expected to provide novel mechanistic insights to the contribution of TnC in GLD 
pathogenesis.  
  
V-3.4 TnC as an MMP-3 Proteolytic Target in GLD Pathology 
TnC is a proteolytic substrate of multiple extracellular enzymes, including MMP-3. Thus, it 
is possible that cleavage of TnC occurs during the pathogenesis of GLD. One likely 
candidate for this proteolytic processing is MMP-3, which is known to be upregulated in 
GLD. Several TnC isoforms are known to be cleaved by MMP-3 (Siri et al., 1995). 
Cleavage of TnC and its potential for altered functions have been implicated in other 
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pathological conditions, including periodontitis and Crohn’s disease (Ambort et al., 2010, 
Ruggiero et al., 2013). This dissertation showed that there was an aberrantly high level of 
TnC expression in the CNS of twitcher mice. One aspect of TnC biology that was not 
addressed was whether observed plaques of TnC included cleaved TnC fragments 
(Figure 5-6). To address this question, Western blotting analyses of brain homogenates 
from twitcher mice could be useful. Indeed, our preliminary analysis showed that the CNS 
tissue from twitcher mice contained a higher level of proteins at low molecular weights, 
when compared to wildtype mice (Figure 5-7). However, the reliability and specificity of 
the TnC antibody need to be confirmed using TnCKO brain tissue samples. TnC isoforms 
may also be localized by immunohistochemistry in twitcher CNS tissue, which may lend 
additional support to our ECM hypothesis describing microglial functions in GLD. Overall, 
identification of TnC isoforms and their effects on cellular behaviors may be expected to 
reveal additional pathophysiological mechanisms in GLD. 
 
V-3.5 Integrins: TnC receptors in GLD Pathogenesis 
 A possible mechanism by which TnC may influence microglial 
function is via their nteraction with integrins (Figure 5-6). Integrins comprise a family of 
transmembrane heterodimers expressed by multiple cell types. Integrins are well-known 
ECM receptors that are important for cell-cell contact, cellular migration and signaling 
(Takada et al., 2007). TnC is known to bind to multiple integrins, including "4!1, "5!1, 
"7!1, "9!1, "8!1, and "v!3 (Hauzenberger et al., 1999, Loike et al., 2001, Meiners and 
Mercado, 2003, Milner and Campbell, 2002). It has been reported that microglia express 
"v!3, "4!1 and "5!1 integrin subunits (Milner, 2009). However, levels of integrin 
expression in the GLD brain have not yet been investigated. Future analyses of integrin 
expression, the CNS cell types that express them and their regulation by psychosine may 
provide potential integrin-mediated mechanisms underlying altered signaling leading to 
globoid cell formation in GLD.  
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Figure 5-7 Twitcher brains contain higher levels of small TnC fragments. Total 
protein from brain homogenates of P20 and P31 twitcher mice and age-matched wildtype 
controls were separated in polyacrylamide gel by size, and TnC fragments were 
visualized by Western blot using an antibody against TnC (top). Red arrows indicate the 
higher levels of small (low molecular weight) TnC fragments in the twitcher brains as 
compared to wildtype brains. Bottom gel image shows that loaded amount of protein 
samples between lanes was relatively consistent, determined by !-actin staining. (Ijichi & 
Crocker, unpublished data) 
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TnC can also bind other ECM molecules, like fibronectin, which is also mediated by 
interactions by integrins (Hauzenberger et al., 1999). In this way, altered TnC and/or 
integrin expression may possibly disrupt the homeostatic support by ECM in the GLD 
brain. Overall, identification of integrin involvement would be expected to shed light on 
TnC-mediated pathophysiological mechanisms in GLD. 
 
V-3.6 Contribution of Microglia in GLD Pathogenesis In Vivo 
 We determined that aberrant activity of microglia in response to psychosine 
had a dramatic effect on oligodendrocyte survival. Surprisingly, we determined that 
globoid cells derived on laminin were less toxic to oligodendrocyte than untreated 
microglia, and globoid cells when grown on TnC reversed this beneficial effect. When 
considered in the context of GLD pathology, the activation of microglia and globoid cell 
formation have been found to precede other pathological findings, including 
demyelination and oligodendrocyte death (Table 5-1). Thus, activation of microglia may 
contribute importantly to pathology by driving the innate inflammatory process and even 
contributing to oligodendrocyte death and demyelination. To examine the contribution of 
microglia to GLD pathogenesis, experiments using transgenic mice in which microglia 
can be selectively abolished could be performed. Twitcher mice could be cross-bred with 
a transgenic mouse line that can selectively kill all CD11b+ cells in a ganciclovir-inducible 
manner (CD11b-HSVTK) (Heppner et al., 2005). Treating double-mutant mice (GALCtwi/twi, 
CD11b-HSVTK) with oral ganciclovir would effectively eliminate microglia and 
macrophages in the twitcher mouse background. This strategy would allow us to control 
the timing of microglial ablation by altering the initiation and duration of oral treatment. In 
this way, we could examine how microglia contribute to the pathogenesis of GLD and the 
potential for differential effects at different time points of preclinical and clinical disability in 
twitcher mice. However, prenatal microglial ablation in prenatal or neonatal ganciclovir 
treatment of CD11b-HSVTK mice and the possible impact on development are unknown.  
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 Another way to address the role of microglia in twitcher mice would be to 
administer liposome-encapsulated clodronate (Kohl et al., 2003). Clodronate is an agent 
selectively toxic to phagocytes (i.e., microglian and macrophages) in living animals, which 
has been shown to successfully eliminate microglia in utero (Cunningham et al. , 2013). 
In a previous study on a mouse model of ALS, when microglia were eliminated by 
clodronate followed by HSCT, microglia were replaced with grafted hematopoietic-origin 
cells, which resulted in reduced disease progression (Lee et al., 2012). This approach 
could provide us with temporal control of microglial elimination, when used in conjunction 
with the CD11b-HSVTK mouse and would be expected to establish the role microglia in 
twitcher mice. 
 
V-4 Therapeutic Applications of Our Findings 
A current therapeutic option for GLD, HSCT, is effective only when 
administered during the pre-symptomatic period of GLD (Duffner et al., 2009). The earlier 
HSCT is provided to GLD patients, the more effective it is (Duffner et al., 2011, Wenger et 
al., 2000). This fact strongly suggests that pathological mechanisms that hamper the 
effect of HSCT emerge as the disease progresses. Very early stages of GLD 
pathogenesis, which include astrocytic and microglial activation, may be effectively 
altered by HSCT but timing for this intervention may be crucial. Indeed, aberrant 
microglial activity has been discussed as a potential limiting factor for the efficacy of 
HSCT in GLD (Pellegatta et al., 2006). To date, there are no therapeutic agents that 
selectively target astrocytes and/or microglia. However, it may be possible to selectively 
inhibit key factors in GLD pathogenesis, such as MMP-3, as suggested by our study. 
Indeed, our study demonstrated that the level of MMP-3 in the brain of twitcher mice 
treated with HSCT remained high (Figure 3-7), suggesting that high level of MMP-3 may 
be a factor contributing to the limited efficacy of HSCT. 
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As mentioned above, there are no MMP-3-specific inhibitors that can readily 
cross the BBB. It is interesting to note that minocycline, a FDA-approved 
tetracycline-class antibiotic, has been shown to inhibit MMP-3 in the brain (Garrido-Mesa 
et al., 2013, Masocha et al., 2006). In a trypanosomiasis infection model, it was 
demonstrated that systemic application of minocycline effectively inhibited MMP-3 and 
had the benefit of preventing production of numerous pro-inflammatory cytokines, 
including TNF-", IL-1!, and IL-6 (Masocha et al., 2006). Minocycline also reduced 
numbers of active astrocytes and microglia in this model (Masocha et al., 2006). 
Importantly, minocycline-treated twitcher mice from P5 exhibited significantly lower levels 
of aforementioned pro-inflammatory cytokines and minocycline increased the lifespan of 
twitcher mice by 21% (Luzi et al., 2009). Based on the report that minocycline can inhibit 
MMP-3, it would expected that minocycline-treated twitcher mice would have lower 
MMP-3 levels in their brains compared to untreated twitcher mice, and possibly less 
globoid cell formation. This previous study, however, did not examine the potential of 
minocycline as an adjunct therapy with HSCT in GLD. As minocycline counteracts 
multiple inflammatory elements, including pro-inflammatory cytokine production, reactive 
astrocytosis and microgliosis, it has also been proposed as a neuroprotectant (Chen et al., 
2011). Therapeutic uses of minocycline in GLD may hold promise and may be expected 
to significantly impede the disease progression of GLD. Overall, the findings of this 
dissertation have provided a new level to our understanding of GLD pathogenesis and 
provided new therapeutic targets to treat GLD, a currently fatal and incurable disease. 
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